Anti-transferrin receptor antibodies with tailored affinity

Anti-transferrin receptor antibodies with tailored off-rates are designed to efficiently transport therapeutic entities across the BBB, addressing the inefficiencies of previous delivery methods and enhancing brain uptake for neurological disorder treatments.

JP2024164119AInactive Publication Date: 2024-11-26F HOFFMANN LA ROCHE & CO AG
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024139440
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-07-09
Filing Date
2024-08-21
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing strategies for delivering neuropathic agents across the blood-brain barrier (BBB) are inefficient, leading to limited brain penetration and potential mislocalization to brain endothelial cells, which hampers the therapeutic effectiveness of monoclonal antibodies and other biopharmaceuticals in treating central nervous system pathologies.

Method used

Development of anti-transferrin receptor antibodies with tailored off-rates that specifically bind to human and cynomolgus monkey transferrin receptors, facilitating efficient transport of therapeutic entities across the BBB and into the brain, utilizing a monovalent binding mode to prevent subcellular localization and enhance brain uptake.

Benefits of technology

The antibodies achieve enhanced brain penetration and retention of therapeutic agents, improving treatment efficacy for neurological disorders such as Alzheimer's and Parkinson's diseases by ensuring sustained circulation and reduced vascular saturation, thus overcoming the limitations of traditional high-affinity antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164119000001_ABST
    Figure 2024164119000001_ABST
Patent Text Reader

Abstract

To provide anti-transferrin receptor antibodies that can be used as a blood-brain-barrier shuttle module to deliver a brain effector entity across the blood-brain-barrier into the brain.SOLUTION: Herein is provided an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises a humanized heavy chain variable domain derived from a heavy chain variable domain of a specific sequence and a humanized light chain variable domain derived from a light chain variable domain of another specific sequence, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor.SELECTED DRAWING: Figure 1-1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [Field of the Invention] The present invention relates to anti-transferrin receptor antibodies with designed off-rates against the human transferrin receptor and their use as blood-brain barrier shuttle modules.

[0002] [background] The penetration of neuropathic agents with low brain permeability, such as large biopharmaceuticals or small molecule agents, into the brain is severely restricted by the extensive and impermeable blood-brain barrier (BBB) ​​along with other cellular components in the neurovascular unit (NVU). Many strategies have been tried to overcome this obstacle. One of them is to exploit the transcytosis pathway mediated by endogenous receptors (blood-brain barrier receptors) expressed on brain capillary endothelium. Recombinant proteins, such as monoclonal antibodies or peptides, that enable receptor-mediated delivery of biopharmaceuticals to the brain have been designed against these receptors. However, although strategies to maximize brain uptake minimize mislocalization to brain endothelial cells (BECs), the extent of accumulation in specific organelles in BECs (especially those that lead to degradation of biopharmaceuticals) remains unclear.

[0003] Monoclonal antibodies and other biopharmaceuticals have great therapeutic potential for the treatment of pathologies in the central nervous system (CNS). However, their pathway to the brain is hindered by the BBB. Previous studies have demonstrated that only a very small percentage (approximately 0.1%) of IgG injected into the bloodstream is able to penetrate into the CNS compartment (Felgenhauer, Klin. Wschr. 52 (1974) 1158-1164). This would undoubtedly limit any pharmacological action due to the low concentration of antibodies in the CNS.

[0004] It has previously been found that the proportion of antibodies that are distributed within the CNS can be improved by exploiting BBB receptors (i.e., transferrin receptors, insulin receptors, etc.) (see, e.g., WO 95 / 02421).

[0005] Thus, there is a need for a delivery system for neuropathic drugs that efficiently transports the drugs across the BBB and into the brain.

[0006] WO 2014 / 033074 reports a blood-brain barrier shuttle.

[0007] WO 2014 / 189973 reports anti-transferrin receptor antibodies and methods of use. It has further been reported that targeting BBB receptors with traditional specific high affinity antibodies results in limited increases in BBB transport. The magnitude of antibody uptake into the CNS and distribution in the CNS was later found to be inversely correlated to its binding affinity to the BBB receptor among the anti-BBB antibodies studied. For example, low affinity antibodies against transferrin receptor (TfR) administered at therapeutic dose levels significantly improve the BBB transport and CNS retention of anti-TfR antibodies relative to high affinity anti-TfR antibodies, making it easier to maintain therapeutic concentrations in the CNS (Atwal et al., Sci. Transl. Med. 3 (2011) 84ra43). Such evidence of BBB transport was achieved using a bispecific antibody that binds both TfR and the amyloid precursor protein (APP) cleaving enzyme β-secretase (BACE1). A single systemic administration of a bispecific anti-TfR / BACE1 antibody engineered with a low affinity antibody not only resulted in significant antibody uptake in the brain, but also dramatically reduced brain Aβ1-40 levels compared to monospecific anti-BACE1 alone, suggesting that BBB penetration is influenced by the ability of anti-BACE1 (Atwal et al., Sci. Transl. Med. 3 (2011) 84ra43;Yu et al., Sci. Transl. Med. 3 (2011) 84ra44).

[0008] Furthermore, thorough nonclinical safety evaluation of monoclonal antibodies (mAbs) intended for therapeutic use is of great importance due to the increased variability induced by the complexity of antibody engineering and the diversity of recombinant production cell lines for antibody production. Furthermore, compared to traditional small molecule drugs, the complex structure, unique biological functions, and longer half-life of mAbs add to the safety considerations in addition to concerns due to the long clinical use of mAbs for the treatment of chronic diseases (Lynch, CM, et al., mAbs 1 (2009) 2-11; Kim, SJ, et al., Mol. Cells 20 (2005) 17-29).

[0009] The overall objective of nonclinical studies on mAbs is to define the toxicological properties of the mAb of interest and provide information for product development. The primary objectives of nonclinical evaluation are to (1) identify the target organ for toxicity and determine whether the toxicity is reversible with treatment, (2) identify a safe starting dose and subsequent dose escalation scheme for human Phase I clinical trials, (3) provide information to monitor safety parameters in clinical trials, and (4) provide safety data to support product labeling claims. To achieve these objectives, both in vitro and in vivo nonclinical studies are conducted that help define and understand the pharmacological properties of antibodies (Lynch, CM, et al., mAbs 1 (2009) 2-11; Cavagnaro, JA, In: Cavagnaro, JA (Ed.) "Preclinical safety evaluation of biopharmaceuticals"; Hoboken, NJ: Wiley 2008; 45-65).

[0010] For successful nonclinical safety evaluation of mAbs, the most relevant animal species needs to be selected for toxicity studies (Lynch, CM, et al., mAbs 1 (2009) 2-11; Chapman, K., et al., Nat. Rev. Drug Discov. 6 (2007) 120-126). The relevant species is one in which the antibody is pharmacologically active, in which the target antigen must be present or expressed, and in which the tissue cross-reactivity profile must resemble that of humans (Lynch, CM, et al., mAbs 1 (2009) 2-11; Chapman, K., et al., Nat. Rev. Drug Discov. 6 (2007) 120-126; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240). Immunochemical and functional assays can be used to identify relevant animal species that express the desired epitope and describe tissue cross-reactivity profiles similar to human tissues (Lynch, CM, et al., mAbs 1 (2009) 2-11; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240).Species cross-reactivity studies are useful in this process and include immunohistochemical investigations of tissues from a variety of species using commercially available multi-species tissue microarrays (Lynch, CM, et al., mAbs 1 (2009) 2-11; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240). Alternatively, assessment of antibody binding to cells from these animals by fluorescence activated cell sorting (FACS) is typically more sensitive than immunohistological analysis of cell sections (Lynch, CM, et al., mAbs 1 (2009) 2-11; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205). The DNA and amino acid sequences of the target antigen need to be compared between species and the homology between species needs to be determined (Lynch, CM, et al., mAbs 1 (2009) 2-11; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205).

[0011] In addition, the biodistribution, function, and structure of the antigen must be comparable between the relevant animal species and humans to allow the assessment of toxicity resulting from antibody binding of the target antigen, which is called on-target toxicity (Lynch, CM, et al., mAbs 1 (2009) 2-11; 19,20). Furthermore, the strong similarity in target antigen tissue distribution in animal species and humans suggests that toxicity of the target organs identified in animals will predict possible toxicity in humans. The lack of similarity in antigen tissue distribution between animal species and humans does not entirely preclude the use of animal species for toxicity studies, but these differences should be taken into account in the human risk assessment. Similarly, absolute equivalence of antigen density or affinity between animal models and humans is not required. Justification of the relevance of the species selected for toxicity studies needs to be included in regulatory compliance. If only one species is used for the safety assessment, experimental frameworks accounting for the absence of additional related species are warranted (Lynch, CM, et al., mAbs 1 (2009) 2-11).

[0012] If the monoclonal antibody intended for therapeutic use does not have any species cross-reactivity, a different species for the surrogate antibody or its model needs to be used. Thus, surrogate antibodies are a potential solution to the limited safety testing allowed by humanized monoclonal antibodies with limited species cross-reactivity. However, currently, there are no defined evaluation criteria that a potential surrogate antibody needs to be evaluated before its use in determining safety issues for clinical drugs (Regulatory Toxicology and Pharmacology Volume 40, Issue 3, December 2004, Pages 219-226).

[0013] Thus, while the above considerations must be taken into account to identify an animal model for a particular mAb, it is nevertheless necessary that the mAb of interest has cross-reactivity to the target antigen in the test species. In other cases, the most appropriate test species may not be available. Thus, there is a need for mAbs that do not have intra-species cross-reactivity, but do have inter-species cross-reactivity, with their targets in humans and species intended for non-clinical testing.

[0014] EP 2708560 reports antibodies that specifically recognize the transferrin receptor. FR 2953841 reports antibodies directed against the transferrin receptor and their use for immunotherapy of iron-dependent tumors. US 2009 / 162359 reports bivalent, bispecific antibodies.

[0015] [overview] It has been found that the anti-transferrin receptor antibodies reported herein can be used as blood-brain barrier shuttle modules to transport brain effector entities across the blood-brain barrier and into the brain. In certain embodiments, the blood-brain barrier shuttle module is a monovalent binding entity that specifically binds to the transferrin receptor. The anti-transferrin receptor antibodies reported herein, when used as blood-brain barrier shuttle modules, are useful, for example, in the diagnosis or treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and comorbid Alzheimer's disease and Parkinson's disease.

[0016] Reported herein are anti-transferrin receptor antibodies that specifically bind to human transferrin receptor (huTfR) and cynomolgus monkey transferrin receptor (cyTfR). In certain embodiments, the anti-transferrin receptor antibodies are Binds to the human transferrin receptor (huTfR) and cynomolgus monkey transferrin receptor (cyTfR) has an off-rate against the human transferrin receptor that is less than (i.e., at most) the off-rate of anti-transferrin receptor antibody 128.1 against the cynomolgus monkey transferrin receptor, wherein the off-rate is determined by surface plasmon resonance, wherein anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65; It binds to the human transferrin receptor with an off-rate of 0.11 / s to 0.0051 / s.

[0017] One embodiment reported herein specifically binds to the human transferrin receptor and the cynomolgus monkey transferrin receptor, i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO:01; ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO:26, wherein the antibody has an off-rate against the human transferrin receptor that is less than (i.e., at most) the off-rate of anti-transferrin receptor antibody 128.1 against the cynomolgus monkey transferrin receptor; wherein the off-rate is determined by surface plasmon resonance; wherein the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65; It is an anti-transferrin receptor antibody.

[0018] In one embodiment, the off rate for the human transferrin receptor is between 0.11 / s and 0.0051 / s, inclusive.

[0019] In one embodiment, the antibody has a proline amino acid residue (P) at position 80 (numbering according to Kabat) in the light chain variable domain.

[0020] In one embodiment, the antibody has an asparagine amino acid residue (N) at position 91 (numbering according to Kabat) in the light chain variable domain.

[0021] In one embodiment, the antibody has an alanine amino acid residue (A) at position 93 (numbering according to Kabat) in the light chain variable domain.

[0022] In one embodiment, the antibody has a serine amino acid residue (S) at position 100g (numbering according to Kabat) in the heavy chain variable domain.

[0023] In one embodiment, the antibody has a glutamine amino acid residue (Q) at position 100g (numbering according to Kabat) in the heavy chain variable domain.

[0024] In one embodiment, the antibody has a serine amino acid residue (S) at position 65 (numbering according to Kabat) in the heavy chain variable domain.

[0025] In one embodiment, the antibody has a glutamine amino acid residue (Q) at position 105 (numbering according to Kabat) in the heavy chain variable domain.

[0026] In one embodiment, the antibody has a proline amino acid residue (P) at position 80 in the light chain variable domain, an asparagine amino acid residue (N) at position 91 in the light chain variable domain, an alanine amino acid residue (A) at position 93 in the light chain variable domain, a serine amino acid residue (S) at position 100g in the heavy chain variable domain, a serine amino acid residue (S) at position 65 in the heavy chain variable domain, and a glutamine amino acid residue (Q) at position 105 in the heavy chain variable domain (numbering according to Kabat).

[0027] In one embodiment, the antibody has a proline amino acid residue (P) at position 80 in the light chain variable domain, an asparagine amino acid residue (N) at position 91 in the light chain variable domain, an alanine amino acid residue (A) at position 93 in the light chain variable domain, a glutamine amino acid residue (Q) at position 100g in the heavy chain variable domain, a serine amino acid residue (S) at position 65 in the heavy chain variable domain, and a glutamine amino acid residue (Q) at position 105 in the heavy chain variable domain (numbering according to Kabat).

[0028] One embodiment reported herein is an anti-transferrin receptor antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71, 72, or 73; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:78.

[0029] In a preferred embodiment, the anti-transferrin receptor antibody comprises: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:78.

[0030] One embodiment reported herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor (huTfR), i) a heavy chain variable domain (VH) sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 24; ii) a light chain variable domain (VL) sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 37; wherein the antibody is an anti-transferrin receptor antibody that has about the same off-rate as an antibody comprising the heavy chain variable domain (VH) sequence of SEQ ID NO:24 and the light chain variable domain (VL) sequence of SEQ ID NO:37.

[0031] In one embodiment, the off rate for the human transferrin receptor is between 0.11 / s and 0.0051 / s, inclusive.

[0032] A preferred embodiment reported herein is an antibody that specifically binds to the human transferrin receptor (huTfR), i) a heavy chain variable domain (VH) sequence having the amino acid sequence of SEQ ID NO: 24; ii) an anti-transferrin receptor antibody comprising a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 37.

[0033] In one embodiment of all aspects, the antibody is a multispecific antibody having at least one binding specificity for the transferrin receptor and at least one specificity for a therapeutic target. In one embodiment, the antibody comprises a first antigen-binding site that binds to the transferrin receptor and a second antigen-binding site that binds to a brain antigen. In a further embodiment, the brain antigen is selected from the group consisting of human Abeta, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), human alpha-synuclein, human tau phosphorylated at tyrosine or serine residues, human CD20, amyloid precursor protein (APP), and human glucocerebrosidase. In a preferred embodiment, the multispecific antibody is i) both transferrin receptor and Abeta, or ii) both the transferrin receptor and CD20, or iii) both the transferrin receptor and alpha-synuclein, or iv) both transferrin receptor and phosphorylated tau, or v) both transferrin receptor and HER2, or vi) both transferrin receptor and glucocerebrosidase Bind to.

[0034] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a heavy chain variable domain of SEQ ID NO:81 and a light chain variable domain of SEQ ID NO:82 for a binding site for human Abeta.

[0035] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of heavy chain variable domains of SEQ ID NO:24 and light chain variable domains of SEQ ID NO:37 forming a binding site for the transferrin receptor, and at least a pair of heavy chain variable domains of SEQ ID NO:79 and light chain variable domains of SEQ ID NO:80 for a binding site for human CD20. In one embodiment, the heavy chain variable region comprises a substitution of the amino acid residue at Kabat position 11 with any amino acid, except leucine. In one embodiment, the substitution comprises a substitution of the amino acid residue at Kabat position 11 with a non-polar amino acid. In one preferred embodiment, the substitution comprises a substitution of the amino acid residue at Kabat position 11 in the heavy chain variable domain of SEQ ID NO:79 with an amino acid residue selected from the group consisting of valine, leucine, isoleucine, serine, and phenylalanine.

[0036] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a heavy chain variable domain of SEQ ID NO:83 and a light chain variable domain of SEQ ID NO:84 for a binding site for human alpha-synuclein.

[0037] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:85 and a humanized light chain variable domain obtained from SEQ ID NO:86 for a binding site for human alpha-synuclein.

[0038] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:87 and a humanized light chain variable domain obtained from SEQ ID NO:88 for a binding site for human alpha-synuclein.

[0039] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:89 and a humanized light chain variable domain obtained from SEQ ID NO:90 for a binding site for human alpha-synuclein.

[0040] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:91 and a humanized light chain variable domain obtained from SEQ ID NO:92 for a binding site for human alpha-synuclein.

[0041] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:93 and a humanized light chain variable domain obtained from SEQ ID NO:94 for a binding site for human alpha-synuclein.

[0042] In one embodiment, the antibody is a bispecific antibody comprising at least one pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and a binding site for i) a glucocerebosidase having the amino acid sequence of SEQ ID NO:97, or ii) a functional variant of SEQ ID NO:97 having at least 70% sequence identity, or iii) a functional variant of SEQ ID NO:97 having one or more amino acid mutations, deletions or insertions, or iv) a truncated functional variant of SEQ ID NO:97 having at least one amino acid residue at the N-terminus or C-terminus or within the deleted amino acid sequence, or V) a combination of iii) and iv).

[0043] In one embodiment of all aspects, the antibody comprises: i) optionally a homodimeric Fc region of the human IgG1 subclass having the mutations P329G, L234A, and L235A, or ii) optionally a homodimeric Fc region of the human IgG4 subclass having the mutations P329G, S228P, and L235E, or iii) a heterodimeric Fc region, a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, in which one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C; or iv) a heterodimeric Fc region of the human IgG4 subclass, wherein both Fc region polypeptides comprise the mutations P329G, L234A, and L235A; and a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, in which one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C; or v) a heterodimeric Fc region of the human IgG4 subclass, wherein both Fc region polypeptides contain the mutations P329G, S228P, and L235E; and a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, in which one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C. Includes.

[0044] In one embodiment of all aspects, the antibody is a CrossMab.

[0045] One aspect reported herein is i) a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 52, 53, 54, 55, 56, 57, and 58, and a light chain variable domain selected from the group consisting of SEQ ID NOs: 60, 61, 62, and 63, or ii) a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25, and a light chain variable domain selected from the group consisting of SEQ ID NOs: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47. The anti-transferrin receptor antibody is an anti-transferrin receptor antibody comprising:

[0046] One aspect reported herein is a pharmaceutical formulation comprising an antibody reported herein and a pharma- ceutically acceptable carrier.

[0047] One aspect reported herein is an antibody as reported herein for use as a medicament.

[0048] One aspect reported herein is the use of an antibody reported herein in the manufacture of a medicament for treating a neurological disorder.

[0049] In one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative diseases, cancer, eye diseases, seizure disorders, lysosomal storage diseases, amyloidosis, viral or microbial diseases, ischemia, behavioral disorders, CNS inflammation, Alzheimer's disease, Parkinson's disease, multiple sclerosis, CD20 positive cancer with brain metastases, and Her2 positive cancer with brain metastases.

[0050] One aspect reported herein is the use of an antibody reported herein in the manufacture of a medicament for transporting one or more compounds across the blood-brain barrier (BBB). [Brief description of the drawings]

[0051] [Figure 1-1] Scheme of the transcytosis assay. [Figure 1-2] Scheme of the transcytosis assay. [Diagram 2] Off-rates of different anti-transferrin receptor antibodies measured at 25° C. using BIAcore. 1: 128.1; 2: 128.1 fused to anti-pTau antibody mAb86; 3: 567; 4: 932; 5: 567 fused to anti-pTau antibody mAb86; 6: 1026; 7: 1027; squares: binding to cynomolgus monkey transferrin receptor; circles: binding to human transferrin receptor; y-axis: off-rate [1 / s]. [Diagram 3] Off-rates of different anti-transferrin receptor antibodies measured at 37° C. using BIAcore. 1:128.1; 2:932; 3:1026; 4:1027; squares: binding to cynomolgus monkey transferrin receptor; circles: binding to human transferrin receptor; y-axis: off-rate [1 / s].

[0052] Detailed Description of the Preferred Embodiments of the Invention Reported herein is a humanized variant of rabbit antibody 299 that exhibits high transcytosis in the transcytosis assay of Example 8. The antibody is cross-reactive to human and cynomolgus transferrin receptors, i.e., it binds specifically to both orthologues of the transferrin receptor, exhibits good cell staining, and has a half-life (reflected by off-rate) against the human transferrin receptor similar to that of mouse antibody 128.1 against the cynomolgus transferrin receptor.

[0053] One aspect reported herein is a humanized antibody that specifically binds to the human transferrin receptor, comprising: In the heavy chain variable domain, the HVRs of SEQ ID NOs: 66, 68, and 72; In the light chain variable domain, the HVRs of SEQ ID NOs: 75, 76, and 78 are included. It is a humanized antibody.

[0054] In one embodiment, the humanized antibody comprises a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37.

[0055] In one embodiment, the humanized antibody is effector function silent.

[0056] In one embodiment, the humanized antibody specifically binds to the human transferrin receptor and the cynomolgus monkey transferrin receptor.

[0057] In one embodiment, the humanized antibody comprises: a) a full-length antibody of human subclass IgG1, or b) a full-length antibody of human subclass IgG4, or c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) A full-length antibody of human subclass IgG4 having the mutations S228P, L235E, and optionally P329G; e) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain, or f) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E and optionally P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain. It is.

[0058] One aspect reported herein is i) a first binding site comprising a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37; ii) a second binding site, a) a heavy chain variable domain of SEQ ID NO: 81 and a light chain variable domain of SEQ ID NO: 82, or b) a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 84, or c) a heavy chain variable domain of SEQ ID NO: 85 and a light chain variable domain of SEQ ID NO: 86, or d) a heavy chain variable domain of SEQ ID NO: 87 and a light chain variable domain of SEQ ID NO: 88, or e) a heavy chain variable domain of SEQ ID NO: 91 and a light chain variable domain of SEQ ID NO: 92, or f) a heavy chain variable domain of SEQ ID NO: 89 and a light chain variable domain of SEQ ID NO: 90, or g) a heavy chain variable domain of SEQ ID NO: 93 and a light chain variable domain of SEQ ID NO: 94, or h) a heavy chain variable domain of SEQ ID NO: 79 and a light chain variable domain of SEQ ID NO: 80 and a second binding site selected from and wherein the antibody is a bispecific antibody comprising:

[0059] One aspect reported herein is a pharmaceutical formulation comprising an antibody reported herein and, optionally, a pharma- ceutically acceptable carrier.

[0060] One aspect reported herein is an antibody as reported herein for use as a medicament.

[0061] One aspect reported herein is an antibody as reported herein for use in the treatment of a neurological disorder.

[0062] One aspect reported herein is the use of an antibody reported herein in the manufacture of a medicament.

[0063] One aspect reported herein is a method of treatment comprising administering an antibody reported herein to treat a neurological disorder.

[0064] For purposes herein, an "acceptor human framework" is a framework that comprises the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereto, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is an identical sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.

[0065] "Affinity" refers to the total strength of non-covalent interactions between one binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the inherent binding affinity that reflects a 1:1 interaction between binding pair members (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by a dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.

[0066] An "affinity matured" antibody refers to an antibody that has one or more mutations in one or more hypervariable regions (HVRs) compared to a parent antibody that does not possess such mutations. Such mutations result in an improvement in the affinity of the antibody for antigen.

[0067] As used herein, the term "antibody" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0068] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0069] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0070] The "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0071] "Effector functions" refers to those biological activities attributable to the Fc region of an antibody, which varies depending on the antibody class. Examples of antibody effector functions include C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

[0072] An "effective amount" of an agent, e.g., a pharmaceutical formulation, means an amount useful, at dosages and for periods of time necessary to achieve the desired therapeutic or prophylactic result.

[0073] As used herein, the term "Fc region" is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of a constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain, with the exception that the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in an Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

[0074] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain typically consists of four FR domains: FR1, FR2, FR3, and FR4. The HVR and FR sequences are thus typically represented in VH (or VL) as follows: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0075] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to mean an antibody having a heavy chain having substantially the same structure as a native antibody structure or containing an Fc region as defined herein.

[0076] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells." Transformed cells include the original transformed cell and its progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0077] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda MD (1991), NIH Publication 91-3242, Vols. 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I in Kabat et al., supra. In one embodiment, for VH, the subgroup is subgroup III in Kabat et al., supra.

[0078] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody can optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0079] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence ("complementarity determining region" or "CDR"), forms structurally defined loops ("hypervariable loops"), and / or contains antigen contact residues ("antigen contacts"). Generally, antibodies contain six HVRs; three in VH (H1, H2, H3) and three in VL (L1, L2, L3).

[0080] As used herein, HVR means (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia, C. and Lesk, A. M., J. Mol. Biol. 196 (1987) 901-917); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); (d) a combination of (a), (b), and / or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).

[0081] Unless otherwise specified, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kobat et al., supra.

[0082] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates, e.g., monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0083] An "isolated antibody" is one that is separated from a component of its native environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman, S. et al., J. Chromatogr. B 848 (2007) 79-87.

[0084] "Isolated nucleic acid" refers to a nucleic acid molecule that has been separated from a component of its native environment. Isolated nucleic acid includes nucleic acid molecules contained in cells that normally contain the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its native chromosomal location.

[0085] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies. That is, the individual antibodies within the population are identical and / or bind the same epitope, except for variant antibodies that may contain, for example, naturally occurring mutations or arise during production of the monoclonal antibody preparation. Such variants are generally present in small amounts. In contrast to polyclonal antibody preparations that typically contain different antibodies against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed to one determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present invention can be prepared by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin locus. Such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0086] "Native antibodies" refer to naturally occurring immunoglobulin molecules with variable structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called the variable heavy domain or the heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called the variable light domain or the light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0087] The term "package insert" is used to mean instructions customarily included in commercial packaging of a therapeutic product, containing information about the indications, uses, dosage, administration, combination treatments, contraindications, and / or warnings concerning the use of such therapeutic product.

[0088] "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of the art, for example, using commonly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences. These parameters include any algorithm required to achieve maximum alignment over the entire length of the sequences being compared. However, for purposes of this specification, % amino acid sequence identity values ​​are generated using ALING-2, a sequence comparison computer program. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been filed as user documentation with the US Copyright Office, Washington DC, 20559, where it is registered under copyright registration number TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0089] In situations where ALIGN-2 is utilized for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or relative to a given amino acid sequence B (% amino acid sequence identity can alternatively be expressed as a given amino acid sequence A having or containing a particular % amino acid sequence identity to, with, or relative to a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y

[0090] where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in its program alignment of A and B, and Y is the total number of amino acid residues in B. It is understood that the length of amino acid sequence A is not equal to the length of amino acid sequence B, and the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless otherwise stated, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0091] The term "pharmaceutical formulation" means a preparation that is in a form that allows the biological activity of the active ingredient contained therein to be effective, and does not contain additional ingredients that have unacceptable toxicity to a subject to which the formulation will be administered.

[0092] "Pharmaceutically acceptable carrier" means an ingredient in a pharmaceutical formulation, other than an active ingredient, that is not toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0093] As used herein, "treatment" (and grammatical variations thereof, e.g., "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either prophylactically or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or remitigating the disease state, and ameliorating or improving prognosis. In some embodiments, the antibodies of the invention are used to slow the progression of the disease or to slow the progression of the disease.

[0094] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of native antibodies (VH and VL, respectively) generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (see, for example, Kindt, TJ et al. Kuby Immunology, 6th ed., WH Freeman and Co., NY (2007), page 91). One VH or VL domain can be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen can be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628. Numbering of amino acid residues in the variable regions (light and heavy chain variable regions) will be done according to Kabat (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda MD (1991), NIH Publication 91-3242, Vols. 1-3).

[0095] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid constructs and vectors that integrate into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."

[0096] The term "blood-brain barrier (BBB)" refers to the physiological barrier between the surrounding environment and the brain and spinal cord, formed by tight junctions in the brain capillary endothelial plasma membrane, resulting in a tight barrier that limits the transport of molecules, even very small molecules such as urea (60 daltons), into the brain. The BBB in the brain, the blood-spinal cord barrier in the spinal cord, and the blood-retina barrier in the retina are continuous capillary barriers in the CNS, and are collectively referred to herein as the blood-brain barrier or BBB. The BBB also includes the blood-CSF barrier (choroid plexus). In this case, the barrier is contained in ependymal cells rather than capillary endothelial cells.

[0097] The term "central nervous system (CNS)" refers to the complex system of nervous tissue that controls bodily functions and includes the brain and spinal cord.

[0098] The term "blood-brain barrier receptor (BBBR)" refers to an extracellular membrane-bound receptor protein expressed on endothelial cells of the brain that can transport molecules across the BBB or is used to transport exogenously administered molecules. Examples of BBBRs include, but are not limited to, transferrin receptor (TfR), insulin receptor, insulin-like growth factor receptor (IGF-R), low-density lipoprotein receptors, including but not limited to low-density lipoprotein receptor-related protein 1 (LRP1) and low-density lipoprotein receptor-related protein 8 (LRP8), and heparin-binding epidermal growth factor-like growth factor (HB-EGF). An exemplary BBBR is the transferrin receptor (TfR).

[0099] The term "brain effector entity" refers to a molecule that is transported across the BBB to the brain. The effector entity typically has a characteristic therapeutic activity that is desirable to be transported to the brain. Effector entities include neuropathic agents and cytotoxins, such as polypeptides and antibodies, particularly monoclonal antibodies or fragments thereof, directed against brain targets.

[0100] The term "monovalent binding entity" refers to a molecule capable of specifically binding in a monovalent manner to the BBBR. The blood-brain shuttle module and / or conjugate reported herein is characterized by the presence of one unit of monovalent binding entity. That is, the blood-brain shuttle module and / or conjugate of the present invention contains exactly one unit of monovalent binding entity. Monovalent binding entities include, but are not limited to, polypeptides, full-length antibodies, antibody fragments including Fab, Fab', Fv fragments, single-chain antibody molecules, e.g., single-chain Fab, scFv. The monovalent binding entity can be, for example, a scaffold protein engineered using state of the art techniques such as phage display or immunization. The monovalent binding entity can also be a polypeptide. In a particular embodiment, the monovalent binding entity comprises a CH2-CH3 Ig domain and a single-chain Fab (scFab) against a blood-brain barrier receptor. The scFab is linked to the C-terminus of the CH2-CH3 Ig domain by a linker. In a particular embodiment, the scFab is directed to the transferrin receptor.

[0101] The term "monovalent binding mode" refers to a specific binding to BBBR where the interaction between the monovalent binding entity and BBBR is by one single epitope. The monovalent binding mode prevents any dimerization / multimerization of BBBR due to the single epitope interaction point. The monovalent binding mode prevents the intracellular localization of BBBR from changing.

[0102] The term "epitope" refers to any polypeptide determinant capable of specific binding to an antibody. In certain embodiments, epitopic determinants include chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryls, or sulfonyls, and in certain embodiments can have specific three-dimensional structural characteristics and / or specific charge characteristics. An epitope is the region of an antigen that is bound by an antibody.

[0103] "Transferrin receptor" (TfR) is a transmembrane glycoprotein (having a molecular weight of about 180,000 Da) composed of two disulfide-linked subunits (each with an apparent molecular weight of about 90,000 Da) that is involved in iron uptake in vertebrates. In one embodiment, the TfR herein is a human TfR comprising the amino acid sequence reported in Schneider et al. (Nature 311 (1984) 675-678).

[0104] The term "imaging agent" refers to a compound having one or more properties that allow for the detection, either directly or indirectly, of its presence and / or location. Examples of such imaging agents include proteins and small molecule compounds, including labeled entities that allow for detection.

[0105] The terms "CNS antigen" and "brain target" refer to antigens and / or molecules expressed in the CNS, including the brain, that can be targeted with antibodies or small molecules. Examples of such antigens and / or molecules include, but are not limited to, beta-secretase 1 (BACE1), amyloid beta (Abeta), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), Tau, apolipoprotein E4 (ApoE4), alpha-synuclein, CD20, huntingtin, prion protein (PrP), leucine-rich repeat kinase 2 (LRRK2), parkin, presenilin 1, presenilin 2, gamma secretase, death receptor 6 (DR6), amyloid precursor protein (APP), p75 neurotrophin receptor (p75NTR), glucocerebrosidase, and caspase 6.

[0106] The term "specifically binds" refers to an antibody that selectively or preferentially binds to an antigen. Binding affinity is generally determined using standard assays, such as Scatchard analysis or surface plasmon resonance technology (e.g., using BIACORE®).

[0107] As used herein, the term "CH2-CH3 Ig entity" refers to a protein entity derived from an immunoglobulin CH2 or CH3 domain. A "CH2-CH3 Ig entity" comprises two "CH2-CH3" polypeptides forming a dimer. The immunoglobulin can be IgG, IgA, IgD, IgE, or IgM. In one embodiment, a CH2-CH3 Ig entity derived from an IgG immunoglobulin is referred to herein as a "CH2-CH3 IgG entity." This term includes native sequences of the CH2-CH3 domain as well as variant CH2-CH3 domains. In one embodiment, a "CH2-CH3 Ig entity" is derived from a human heavy chain CH2-CH3 IgG domain extending from Cys226 or Pro230 to the carboxyl terminus of the heavy chain, with the proviso that the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the CH2-CH3 domain region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0108] A "conjugate" is a fusion protein of the invention conjugated to one or more heterologous molecules, including, but not limited to, a label, a neurotoxic agent, or a cytotoxic agent.

[0109] The term "linker" refers to a chemical linker or a single-chain peptide linker that covalently connects the various entities of the blood-brain barrier shuttle module and / or fusion polypeptide and / or conjugate reported herein. The linker, for example, connects the brain effector entity to the monovalent binding entity. For example, if the monovalent binding entity comprises a CH2-CH3 Ig entity and a scFab for a blood-brain barrier receptor, the linker conjugates the scFab to the C-terminus of the CH3-CH2 Ig entity. The linker that conjugates the brain effector entity to the monovalent binding entity (first linker) and the linker that connects the scFab to the C-terminus of the CH2-CH3 Ig domain (second linker) can be the same or different.

[0110] A single-stranded peptide linker consisting of 1-20 amino acid residues linked by peptide bonds can be used. In certain embodiments, the amino acids are selected from the 20 naturally occurring amino acids. In certain other embodiments, one or more of the amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. In other embodiments, the linker is a chemical linker. In certain embodiments, the linker is a single-stranded peptide linker of amino acid sequence having a length of at least 25 amino acid residues, in one preferred embodiment having a length of 32-50 amino acid residues. In one embodiment, the peptide linker is a (GxS)n linker, where G=glycine, S=serine, and (x=3, n=8, 9, or 10) or (x=4 and n=6, 7, or 8), in one embodiment x=4, n=6 or 7, in one preferred embodiment x=4, n=7. In one embodiment, the linker is (G4S)4 (SEQ ID NO: 95). In one embodiment, the linker is (G4S)6G2 (SEQ ID NO: 96).

[0111] Conjugation can be carried out using a variety of chemical linkers. For example, monovalent binding entities or fusion polypeptides and brain effector entities can be conjugated using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propanoate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazide compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). The linker can be a "cleavable linker" that facilitates release of the effector entity upon delivery to the brain. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker (Chari et al, Cancer Res. 52 (1992) 127-131; U.S. Patent No. 5,208,020) can be used.

[0112] Covalent conjugation can be either direct or via a linker. In certain embodiments, direct conjugation is by constructing a polypeptide fusion (i.e., by genetic fusion of two genes that code for a monovalent binding entity to BBBR and an effector entity, expressed as one polypeptide (chain). In certain embodiments, direct conjugation is by forming a covalent bond between a reactive group on one of the two parts of the monovalent binding entity to BBBR and a corresponding group or acceptor on the brain effector entity. In certain embodiments, direct conjugation is by modifying (i.e., genetically modifying) one of the two molecules to be conjugated to include a reactive group (non-limiting examples being sulfhydryl or carboxyl groups) that, under appropriate conditions, forms a covalent bond to the other molecule to be conjugated. As one non-limiting example, a molecule (i.e., an amino acid) bearing a desired reactive group (i.e., a cysteine ​​residue) can be introduced into a monovalent binding entity, for example, to a BBBR antibody, and a disulfide bond can be formed with a nerve agent. Methods for covalent conjugation of nucleic acids to proteins are also known in the art (i.e., photocrosslinking, see, e.g., Zatsepin et al. Russ. Chem. Rev. 74 (2005) 77-95). Conjugation can also be performed using a variety of linkers.For example, monovalent binding entities and effector entities can be conjugated using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazide compounds (e.g., bis(p-azidobenzoyl)hexadiamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). Peptide linkers consisting of 1-20 amino acid residues linked by peptide bonds can also be used. In certain such embodiments, the amino acid residues are selected from the 20 naturally occurring amino acids. In certain other such embodiments, one or more of the amino acid residues are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. The linker can be a "cleavable linker" that facilitates release of the effector entity upon delivery to the brain. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers (Chari et al, Cancer Res. 52 (1992) 127-131; U.S. Patent No. 5,208,020) can be used.

[0113] II. Compositions and Methods Equilibrium dissociation constant (K D ) is commonly used to describe intermolecular interactions. The equilibrium dissociation constant is used as a measure of the interaction strength (e.g., affinity) of two molecules for one another. Thus, K D The value is a measure of the strength of the interaction between biomolecules.

[0114] In addition, K D The value does not account for the dynamics of intermolecular interactions, i.e., K D While it is not possible to infer from such K values ​​how quickly two molecules bind to one another (the association rate constant or "on-rate"), it is also possible to infer how quickly these molecules dissociate (the dissociation rate constant or "off-rate"). D Characterizing biomolecular interactions solely by their K values D Since the values ​​are the ratio, the same K D This would ignore the fact that the values ​​may be made up of extremely different (orders of magnitude) on and off rates.

[0115] However, on and off rates are important in characterizing the binding behavior of a molecule. The off rate is particularly important because it characterizes the duration of binding of, for example, an antibody to its antigen. A long off rate correlates with a slow dissociation of the complex formed, whereas a short off rate correlates with a fast dissociation.

[0116] To have a long-lasting (i.e., less frequent administration required) or tailor-made (e.g., depending on the surrounding conditions) interaction, the off-rate must be experimentally determined. This is even more important because the off-rate is hardly predictable. In addition, the correlation between the off-rate and the binding affinity is poor, as outlined above. For example, K D Due to the fact that the value is a ratio of on-rate to off-rate, even weak binders may remain bound to their targets for a long time, while tight binders may dissociate rapidly.

[0117] A typical bottleneck in antibody generation projects is the ranking of many candidates obtained after panning based on antibody binding strength. Ideally, such a method would be performed with crude bacterial lysates without prior labeling of the antigen. In Ylera, F., et al. (Anal. Biochem. 441 (2013) 208-213), a method for screening off-rates to select high affinity anti-drug antibodies in crude Escherichia coli lysates containing monovalent Fab fragments was reported. They have off-rates selected as ranking parameters, among others because off-rates are concentration dependent. The monovalent format is chosen to avoid avidity effects during off-rate ranking and affinity measurements, since they will be observed as full-length IgG. It was found by Ylera et al. that clones with the best k off-rates were identified by the k-off ranking step, but would not have been identified using only ELISA signal strength as selection evaluation criterion.

[0118] Murray, JB, et al. (J. Med. Chem. 57 (2014) 2845-2850) reported surface plasmon resonance off-rate screening (ORS) as an efficient method of kinetic sample hits to generate chemical space from unpurified reaction products. It is outlined that the dissociation rate constant kd (off-rate) is the component of ligand-protein binding that has the most significant potential to improve compound activity. The authors outline that measuring affinity kinetically throughout a drug discovery program is more informative than steady-state affinity equilibrium measurements. For example, a compound with a 10-fold slower on-rate and off-rate would not be recognized as different when evaluated by affinity equilibrium measurements. Furthermore, the authors found that data measured with a BIAcore T200 instrument showed a 19% average difference in kd between crude and pure samples, while data measured with the older BIAcore T100 instrument had a 15% difference. The authors observed that kd varied by an average of only 30% when compared across instruments and time. This demonstrates that carryover contamination, long-term storage, and instrumental differences have little impact on the observed kd. Indeed, these small deviations in kd closely mirror the differences observed in multicenter studies, where the observed variation was reported to be between 14% and 40%, depending on the system (Murray, JB, et al., J. Med. Chem. 57 (2014) 2845-2850; Katsamba, PS, et al., Anal. Biochem. 352 (2006) 208-221).

[0119] WO 2014 / 189973 reports anti-transferrin receptor antibodies and methods of use. It is further reported that targeting BBB receptors with traditional specific high affinity antibodies generally results in limited increases in BBB transport. It was later found that the magnitude of antibody uptake into the CNS and distribution in the CNS is inversely correlated to its binding affinity to the BBB receptor among the anti-BBB antibodies studied. For example, low affinity antibodies against transferrin receptor (TfR) administered at therapeutic dose levels significantly improve the BBB transport and CNS retention of anti-TfR antibodies relative to high affinity anti-TfR antibodies, making it easier to maintain therapeutic concentrations in the CNS (Atwal et al., Sci. Transl. Med. 3 (2011) 84ra43). Such evidence of BBB transport was achieved using a bispecific antibody that binds both TfR and the amyloid precursor protein (APP) cleaving enzyme β-secretase (BACE1). A single systemic administration of a bispecific anti-TfR / BACE1 antibody engineered with a low affinity antibody not only results in significant antibody uptake in the brain, but also dramatically reduces brain Aβ1-40 levels compared to monospecific anti-BACE1 alone, suggesting that BBB penetration is influenced by the ability of anti-BACE1 (Atwal et al., Sci. Transl. Med. 3 (2011) 84ra43;Yu et al., Sci. Transl. Med. 3 (2011) 84ra44).

[0120] Available data and experiments highlight several underlying mechanisms behind increasing antibody uptake into the CNS using lower affinity antibody approaches.

[0121] First, high affinity anti-BBB receptor (BBB-R) antibodies (e.g., anti-TfR antibodies from Atwal et al. and Yu et al., supra) limit brain uptake by quickly saturating the BBB-R in the brain vasculature, thus reducing the total amount of antibody taken up into the brain and limiting its distribution to the vasculature. Notably, lowering the affinity to the BBB-R improves brain uptake and distribution, with a robust shift observed in location from the vasculature to neurons and associated neuropil distributed in the CNS. It has been found that affinity must be below a certain upper level and above a certain lower level.

[0122] Second, the lower affinity of antibodies for the BBB-R has been proposed to impair the ability of antibodies from the CNS side of the membrane back through the BBB-R to the vascular side of the BBB because the overall affinity of antibodies for the BBB-R is low and the local concentration of antibodies on the CNS side of the BBB is not saturated due to rapid diffusion of antibodies within the CNS compartment.

[0123] Third, as observed for the TfR system in vivo, antibodies with little affinity for BBB-R are not as efficiently cleared from this system as antibodies with higher affinity for BBB-R, and therefore remain at higher circulating concentrations than their higher affinity counterparts. This is advantageous because the circulating antibody levels of lower affinity antibodies are sustained at therapeutic levels for a longer period than higher affinity antibodies. As a result, the uptake of the antibody into the brain is improved for a longer period. Furthermore, this improvement in both plasma and brain exposure will allow for less frequent administration in clinics, which will have a significant benefit for patient compliance and convenience, as well as reducing any possible side effects or off-target effects of the antibody and / or the therapeutic compound bound to it.

[0124] These previous studies utilized mouse antibodies that specifically bound to the mouse TfR but did not specifically recognize the primate or human TfR. Thus, provided herein are antibodies and functional portions thereof that specifically recognize both primate, and in particular, cynomolgus monkey and human TfR, to facilitate safety and efficacy studies in primates with the antibodies prior to therapeutic or diagnostic use in humans.

[0125] Thorough nonclinical safety evaluation of monoclonal antibodies (mAbs) intended for therapeutic use is of great importance due to the increased variability induced by the complexity of antibody engineering and the diversity of recombinant production cell lines for antibody production. Furthermore, compared to traditional small molecule drugs, the complex structure, unique biological functions, and longer half-life of mAbs add to the safety considerations in addition to concerns due to the long clinical use of mAbs for the treatment of chronic diseases (Lynch, CM, et al., mAbs 1 (2009) 2-11; Kim, SJ, et al., Mol. Cells 20 (2005) 17-29).

[0126] The overall objective of nonclinical studies on mAbs is to define the toxicological properties of the mAb of interest and provide information for product development. The primary objectives of nonclinical evaluation are to (1) identify the target organ for toxicity and determine whether the toxicity is reversible with treatment, (2) identify a safe starting dose and subsequent dose escalation scheme for human Phase I clinical trials, (3) provide information to monitor safety parameters in clinical trials, and (4) provide safety data to support product labeling claims. To achieve these objectives, both in vitro and in vivo nonclinical studies are conducted that help define and understand the pharmacological properties of antibodies (Lynch, CM, et al., mAbs 1 (2009) 2-11; Cavagnaro, JA, In: Cavagnaro, JA (Ed.) "Preclinical safety evaluation of biopharmaceuticals"; Hoboken, NJ: Wiley 2008; 45-65).

[0127] For successful nonclinical safety evaluation of mAbs, the most relevant animal species needs to be selected for toxicity studies (Lynch, CM, et al., mAbs 1 (2009) 2-11; Chapman, K., et al., Nat. Rev. Drug Discov. 6 (2007) 120-126). The relevant species is one in which the antibody is pharmacologically active, in which the target antigen must be present or expressed, and in which the tissue cross-reactivity profile must resemble that of humans (Lynch, CM, et al., mAbs 1 (2009) 2-11; Chapman, K., et al., Nat. Rev. Drug Discov. 6 (2007) 120-126; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240). Immunochemical and functional assays can be used to identify relevant animal species that express the desired epitope and describe tissue cross-reactivity profiles similar to human tissues (Lynch, CM, et al., mAbs 1 (2009) 2-11; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240).Species cross-reactivity studies are useful in this process and include immunohistochemical investigations of tissues from a variety of species using commercially available multi-species tissue microarrays (Lynch, CM, et al., mAbs 1 (2009) 2-11; Hall, WC, et al., In: Cavagnaro, JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 207-240). Alternatively, assessment of antibody binding to cells from these animals by fluorescence activated cell sorting (FACS) is typically more sensitive than immunohistological analysis of cell sections (Lynch, CM, et al., mAbs 1 (2009) 2-11; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205). The DNA and amino acid sequences of the target antigen need to be compared between species and the homology between species needs to be determined (Lynch, CM, et al., mAbs 1 (2009) 2-11; Subramanyam, M. and Mertsching, E., In: Cavagnaro JA (Ed.); Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiley 2008; 181-205).

[0128] In addition, the biodistribution, function, and structure of the antigen must be comparable between the relevant animal species and humans to allow the assessment of toxicity resulting from antibody binding of the target antigen, which is called on-target toxicity (Lynch, CM, et al., mAbs 1 (2009) 2-11; 19,20). Furthermore, the strong similarity in target antigen tissue distribution in animal species and humans suggests that toxicity of the target organs identified in animals will predict possible toxicity in humans. The lack of similarity in antigen tissue distribution between animal species and humans does not entirely preclude the use of animal species for toxicity studies, but these differences should be taken into account in the human risk assessment. Similarly, absolute equivalence of antigen density or affinity between animal models and humans is not required. Justification of the relevance of the species selected for toxicity studies needs to be included in regulatory compliance. If only one species is used for the safety assessment, experimental frameworks accounting for the absence of additional related species are warranted (Lynch, CM, et al., mAbs 1 (2009) 2-11).

[0129] If the monoclonal antibody intended for therapeutic use does not have any species cross-reactivity, a different species needs to be used for the surrogate antibody or its model. Thus, surrogate antibodies are a potential solution to the limited safety testing allowed by humanized monoclonal antibodies with limited species cross-reactivity. However, currently there are no defined criteria by which potential surrogate antibodies should be evaluated prior to their use to determine safety issues for clinical drugs (Regulatory Toxicology and Pharmacology Volume 40, Issue 3, December 2004, Pages 219-226).

[0130] Thus, while the above considerations must be taken into account to identify an animal model for a particular mAb, it is nevertheless necessary that the mAb of interest has cross-reactivity to the target antigen in the test species. In other cases, the most appropriate test species may not be available. Thus, there is a need for mAbs that do not have intra-species cross-reactivity, but do have inter-species cross-reactivity, with their targets in humans and species intended for non-clinical testing.

[0131] A. Exemplary Anti-Transferrin Antibodies Herein, anti-transferrin receptor antibodies are reported that have off-rates for binding to human transferrin receptor that are within a particular range to ensure proper BBB transport. This range is defined at one end by the off-rate of mouse anti-transferrin receptor antibody 128.1 (variable domain amino acid sequences given in SEQ ID NOs: 64 and 65) measured by surface plasmon resonance for cynomolgus monkey transferrin receptor, and at the other end by 5% of that off-rate (i.e., 20-fold slower dissociation). In one embodiment, the off-rate for human transferrin receptor is between 0.11 / s and 0.0051 / s, inclusive.

[0132] The humanized antibody of clone 299 reported herein was not available by applying standard humanization techniques. It was necessary to introduce non-standard mutations into the amino acid sequence to obtain a humanized antibody with transferrin receptor binding off-rates in the intended range, including 0.11 / s and 0.0051 / s. This is particularly important because the antibody reported herein is being developed to cross the human blood-brain barrier and deliver a therapeutic payload into the brain.

[0133] It was found that to obtain a suitable, developable humanized antibody, two cysteine ​​amino acid residues in the light chain of the parent rabbit antibody had to be replaced by a proline and an asparagine amino acid residue, respectively. In addition to being within the defined off-rate range, a serine residue present in the center of rabbit CDRL3 had to be replaced by an alanine residue.

[0134] It has further been found to be advantageous to change three amino acid residues at positions 65, 100g, and 105 (numbering according to Kabat) of the heavy chain.

[0135] All numbering used herein is based on the Kabat variable domain numbering scheme.

[0136] The rabbit anti-transferrin antibody clone 299 exhibited properties comparable to those of the anti-transferrin receptor antibody 128.1, as can be seen from the table below.

[0137] [Table 1]

[0138] In the table below, the off-rates of humanized variants of the rabbit light chain variable domain of clone 299 in combination with humanized variants of the rabbit heavy chain variable domain of clone 299 are shown. The binding partner was the human transferrin receptor (measured at 25° C.).

[0139] [Table 2] TIFF2024164119000004.tif118164

[0140] The VH23 and VL9 combination was selected as a starting point for further engineering to develop a binding site that mirrors the binding characteristics of antibody 128.1 to the cynomolgus monkey transferrin receptor for closer binding to the human transferrin receptor.

[0141] In the table below, the off-rates of various exemplary mutants of VH23 and VL9, as well as various humanized mutants of other variable domains, against the human transferrin receptor are comparatively shown (measured as in Example 14, at 25° C.).

[0142] [Table 3]

[0143] In the table below, comparative kinetic data for various exemplary mutants of VH23 and VL9 are shown (measured in Example 13).

[0144] [Table 4]

[0145] In the table below, the off-rates of the humanized variant of the murine light chain variable domain of clone 494 in combination with the humanized variant of the murine heavy chain variable domain of clone 494 are shown. The binding partner was the human transferrin receptor.

[0146] [Table 5]

[0147] More particularly, in one aspect, the invention is based in part on the discovery that the anti-transferrin receptor antibodies reported herein can be used as blood-brain barrier shuttle modules to transport brain effector entities across the blood-brain barrier and into the brain. In certain embodiments, the blood-brain barrier shuttle module is a monovalent binding entity that specifically binds to the transferrin receptor. The anti-transferrin receptor antibodies reported herein, when used as blood-brain barrier shuttle modules, are useful, for example, in the diagnosis or treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and comorbid Alzheimer's disease and Parkinson's disease.

[0148] An antibody comprising a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 mirrors the binding characteristics of murine antibody 128.1 for the cynomolgus monkey transferrin receptor for the human transferrin receptor in terms of binding off-rate.

[0149] Thus, one aspect reported herein is an isolated antibody that binds to the human transferrin receptor (huTfR) and the cynomolgus monkey transferrin receptor (cyTfR), wherein the antibody has an off-rate, as measured by surface plasmon resonance, for the human transferrin receptor of between 0.11 / s and 0.0051 / s.

[0150] Another aspect reported herein is the use of an antibody or antibody fragment that binds to the human transferrin receptor (huTfR) and the cynomolgus monkey transferrin receptor (cyTfR), where the antibody has an off-rate, as measured by surface plasmon resonance, for the human transferrin receptor of between 0.11 / s and 0.0051 / s, to transport a therapeutic entity across the blood-brain barrier.

[0151] In one embodiment, the off-rates are measured at 500, 250, 125, 62.5, 31.25, 15.625, and 0 nM.

[0152] In one embodiment, off-rates are measured using a surface plasmon resonance chip with a biotin surface and a running buffer of 1×PBS supplemented with 250 mM sodium chloride at a flow rate of 10 μL / min.

[0153] In one embodiment, association is monitored for 180 seconds and dissociation is monitored for 600 seconds.

[0154] In one embodiment, the off-rates are measured in a BIAcore T200.

[0155] In one embodiment, the off rate is between 0.081 / s and 0.0081 / s.

[0156] In one embodiment of all aspects, the off-rate is measured at 25°C.

[0157] In one embodiment of all aspects, the off-rate is the off-rate measured at 25°C.

[0158] One embodiment reported herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor (huTfR) and the cynomolgus monkey transferrin receptor (cyTfR) and comprises i) a humanized heavy chain variable domain obtained from the heavy chain variable domain of SEQ ID NO:01, and ii) a humanized light chain variable domain obtained from the light chain variable domain of SEQ ID NO:26, wherein the light chain variable domain has a proline amino acid residue (P) at position 80, an asparagine amino acid residue (N) at position 91, and an alanine amino acid residue (A) at position 93 (numbering according to Kabat).

[0159] In one embodiment, the antibody further comprises a serine amino acid residue (S) at position 100g (numbering according to Kabat) in the heavy chain variable domain.

[0160] In one embodiment, the antibody further has a serine amino acid residue at position 65 (S) (numbering according to Kabat) in the heavy chain variable domain.

[0161] In one embodiment, the antibody further has a glutamine amino acid residue (Q) at position 105 (numbering according to Kabat) in the heavy chain variable domain.

[0162] One embodiment reported herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor (huTfR) and the cynomolgus monkey transferrin receptor (cyTfR) and comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO:01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO:26, wherein the antibody has an off-rate (units 1 / s) against the human transferrin receptor that is less than (i.e., at most) the off-rate (units 1 / s) of anti-transferrin receptor antibody 128.1 against the cynomolgus monkey transferrin receptor, wherein the off-rate is measured by surface plasmon resonance, wherein the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65.

[0163] In one embodiment, the antibody has an off-rate (units / s) for the human transferrin receptor that is i) less than (i.e., at most) the off-rate (units / s) of anti-transferrin receptor antibody 128.1 for the cynomolgus monkey transferrin receptor, and ii) less than (i.e., at most) 5% of the off-rate (units / s) of anti-transferrin receptor antibody 128.1 for the cynomolgus monkey transferrin receptor.

[0164] One aspect reported herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor (huTfR) and the cynomolgus monkey transferrin receptor (cyTfR). In a particular embodiment, the anti-transferrin receptor antibody is Binds to the human transferrin receptor (huTfR) and cynomolgus monkey transferrin receptor (cyTfR) has an off-rate (in 1 / s) against the human transferrin receptor that is less than (i.e., at most) the off-rate of anti-transferrin receptor antibody 128.1 against the cynomolgus monkey transferrin receptor, where the off-rate is measured by surface plasmon resonance, and anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65; It binds to the human transferrin receptor with an off-rate of 0.11 / s to 0.0051 / s.

[0165] In one aspect, provided herein is an anti-transferrin receptor antibody comprising at least one, two, three, four, five, or six HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71, 72, or 73; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:78.

[0166] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 71 or 72 or 73. In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 72. In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:73. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:71 or 72 or 73. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:71 or 72 or 73, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:78. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:71 or 72 or 73, HVR-L3 comprising the amino acid sequence of SEQ ID NO:78, and HVR-H2 comprising the amino acid sequence of SEQ ID NO:68. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 72.

[0167] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from: (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:78. In one embodiment, the antibody comprises: (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:78.

[0168] In another aspect, an antibody of the invention comprises: (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 66, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 71 or 72 or 73; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 75, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 76, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78.

[0169] In another aspect, the present invention provides an antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:75; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:76; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO:78.

[0170] In any of the above embodiments, the anti-transferrin receptor antibody is humanized. In one embodiment, the anti-transferrin receptor antibody comprises an HVR in any of the above embodiments and further comprises an acceptor human framework, e.g., a human immunoglobulin framework or a human consensus framework.

[0171] In another aspect, an anti-transferrin receptor antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 24 and has about the same off-rate as an antibody comprising a heavy chain variable domain (VH) sequence of SEQ ID NO: 24. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-transferrin receptor antibody comprising that sequence retains the ability to bind to transferrin receptor with the same off-rate. In certain embodiments, a total of 1-10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO:24. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-transferrin receptor antibody comprises a VH sequence of SEQ ID NO:24, including post-translational modifications of that sequence. In certain embodiments, the VH comprises one, two, or three HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:66, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:68, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72.

[0172] In another aspect, an anti-transferrin receptor antibody is provided, the antibody comprising a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 37, and having about the same off-rate as an antibody comprising the light chain variable domain (VL) sequence of SEQ ID NO: 37. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but the anti-transferrin receptor antibody comprising that sequence retains the ability to bind to transferrin receptor with the same off-rate. In certain embodiments, a total of 1-10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 37. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-transferrin receptor antibody comprises a VL sequence in SEQ ID NO: 37, including post-translational modifications of that sequence. In certain embodiments, the VL comprises one, two, or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 75; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 76; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78.

[0173] In another aspect, an anti-transferrin receptor antibody is provided, the antibody comprising a VH of any of the embodiments provided above and a VL of any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO:24 and SEQ ID NO:37, respectively, including post-translational modifications of those sequences.

[0174] In a further aspect of the invention, the anti-transferrin receptor antibody of any of the above embodiments is a monoclonal antibody, including a chimeric, humanized, or human antibody. In one embodiment, the anti-transferrin receptor antibody is an antibody fragment, e.g., an Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a full-length antibody, e.g., an intact IgG1 antibody, or other antibody class or isotype as defined herein.

[0175] In one embodiment of all aspects, the antibody is conjugated to a therapeutic compound.

[0176] In one embodiment of all aspects, the antibody is conjugated to an imaging agent or label.

[0177] In another embodiment, the antibody is a multispecific antibody, and the therapeutic compound optionally forms part of the multispecific antibody. In one such embodiment, the multispecific antibody comprises a first antigen-binding site that binds to TfR and a second antigen-binding site that binds to a brain antigen. In one such embodiment, the brain antigen is selected from the group consisting of beta-secretase 1 (BACE1), Abeta, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), tau, apolipoprotein E (ApoE), alpha-synuclein, CD20, huntingtin, prion protein (PrP), leucine-rich repeat kinase 2 (LRRK2), parkin, presenilin 1, presenilin 2, gamma secretase, death receptor 6 (DR6), amyloid precursor protein (APP), p75 neurotrophin receptor (p75NTR), glucocerebrosidase, and caspase 6. In another embodiment, the multispecific antibody binds to both TfR and BACE1. In another embodiment, the multispecific antibody binds to both TfR and Abeta. In another embodiment, the multispecific antibody binds to both TfR and alpha-synuclein. In another embodiment, the multispecific antibody binds to both TfR and CD20. In another embodiment, the multispecific antibody binds to both TfR and glucocerebrosidase. In another embodiment, the therapeutic compound is a neuropathic agent.

[0178] In one aspect of the above embodiments, the invention provides a pharmaceutical formulation comprising any of the aforementioned antibodies and a pharma- ceutically acceptable carrier.

[0179] In one aspect of the above embodiments, the invention provides any of the aforementioned antibodies for use as a medicament.

[0180] In another aspect of the above embodiment, the invention provides the use of any of the aforementioned antibodies in the manufacture of a medicament for treating a neurological disorder, hi one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation.

[0181] In another aspect of the above embodiment, the invention provides any of the aforementioned antibodies for use in treating a neurological disorder, hi one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation.

[0182] In another aspect of the above embodiments, the invention provides any of the aforementioned antibodies for use in transporting one or more compounds across the BBB.

[0183] In another aspect of the above embodiment, there is provided the use of any of the aforementioned antibodies in the manufacture of a medicament for transporting one or more compounds across the BBB.

[0184] In one aspect of the above embodiment, a method of transporting a compound through the BBB in a subject is provided, comprising exposing any of the above-mentioned antibodies to the BBB so that the antibody transports the compound bound thereto through the BBB. In one embodiment, the BBB is in a human subject. In one embodiment, the antibody bound to the compound is administered at a therapeutic dose. In one embodiment, the therapeutic dose saturates TfR. In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0185] In another aspect of the above embodiment, a method is provided for increasing the exposure of a subject's CNS to a compound, comprising exposing any of the above-mentioned antibodies to the BBB, so that the antibody transports the compound bound to it through the BBB.In one embodiment, the BBB is in a human subject.In one embodiment, the antibody bound to the compound is administered at a therapeutic dose.In one embodiment, the therapeutic dose saturates TfR.In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0186] In one aspect of the above embodiment, a method is provided for increasing the CNS retention of a compound administered to a subject, comprising exposing any of the above-mentioned antibodies to the BBB so that the CNS retention of the compound is increased.In one embodiment, the antibody bound to the compound is administered at a therapeutic dose.In one embodiment, the therapeutic dose saturates TfR.In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0187] In one aspect of the above embodiment, a method for treating a neurological disorder in a mammal is provided, comprising treating the mammal with any of the above-mentioned antibodies. In one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation. In one embodiment, the neurological disorder is in a human subject. In one embodiment, the antibody bound to the compound is administered at a therapeutic dose. In one embodiment, the therapeutic dose saturates TfR. In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical signs of antibody administration.

[0188] In one embodiment, the antibody is modified in one or more properties selected from effector function of the antibody Fc region, complement activation function of the antibody, and affinity of the antibody for TfR.

[0189] In one embodiment, the property is an effector function of an antibody Fc region.

[0190] In one embodiment, the property is the complement activation function of the antibody.

[0191] In one embodiment, the property is the affinity of the antibody for TfR.

[0192] In one embodiment, effector function or complement activation function is reduced or eliminated relative to a wild-type antibody of the same isotype, hi one embodiment, effector function is reduced or eliminated by a method selected from reducing glycosylation of the antibody, modifying the antibody isotype to an isotype that naturally has reduced or eliminated effector function, and modifying the Fc region.

[0193] In one embodiment, effector function is reduced or eliminated by reducing glycosylation of the antibody, hi one embodiment, glycosylation of the antibody is reduced by a method selected from generating the antibody in an environment that does not allow wild-type glycosylation, removing carbohydrate groups already present on the antibody, and modifying the antibody such that wild-type glycosylation does not occur.

[0194] In one embodiment, glycosylation of the antibody is reduced by production of the antibody in an environment that does not allow for wild-type glycosylation (e.g., production in a non-mammalian cell production system or if the antibody is produced synthetically). In one embodiment, the antibody is produced in a non-mammalian cell production system. In another embodiment, the antibody is produced synthetically.

[0195] In one embodiment, glycosylation of an antibody is reduced by engineering the antibody such that wild-type glycosylation does not occur, for example, where the Fc region of the antibody contains a mutation at position 297, replacing the wild-type asparagine residue at that position with another amino acid that prevents glycosylation at that position.

[0196] In one embodiment, effector function is reduced or eliminated by at least one modification of the Fc region. In one embodiment, effector function or complement activation function is reduced or eliminated by deletion of all or part of the Fc region, or by engineering the antibody so that it does not contain an Fc region or a non-Fc region competent for effector function or complement activation function. In one embodiment, at least one modification of the Fc region is at any of the following positions: 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 297, 298, 301, 303, 322, 324, 327, 329, 333, 30 a point mutation in the Fc region that impairs binding to an Fc receptor selected from one or more of: 335, 338, 340, 373, 376, 382, ​​388, 389, 414, 416, 419, 434, 435, 437, 438, and 439; a point mutation in the Fc region that impairs binding to C1q selected from the following positions: 270, 322, 329, and 321; a deletion of part or all of the Fc region, and a point mutation at position 132 of the CH1 domain. In one embodiment, the modification is a point mutation in the Fc region that impairs binding to C1q selected from the following positions: 270, 322, 329, and 321. In another embodiment, the modification is a deletion of part or all of the Fc region. In another embodiment, the complement trigger function is reduced or eliminated by deleting all or part of the Fc region, or by engineering the antibody to not contain the Fc region involved in the complement pathway. In one embodiment, the antibody is selected from a Fab or single chain antibody. In another embodiment, the non-Fc region of the antibody is modified to reduce or eliminate the activation of the complement pathway by the antibody. In one embodiment, the modification is a point mutation in the CH1 region that impairs binding to C3. In one embodiment, the point mutation is at position 132 (see, e.g., Vidarte et al., J. Biol. Chem. 276 (2001) 38217-38223).

[0197] In another aspect of the above embodiment, the affinity of the antibody for TfR is reduced when measured relative to a wild-type antibody of the same isotype that does not have a lower affinity for TfR. In one such aspect, the antibody has a K for TfR of about 1 pM to about 100 μM. D or IC 50 has.

[0198] In one embodiment, the antibody reported herein is effector function silent.In one embodiment, the antibody has no effector function.In one embodiment, the antibody is of human IgG1 subclass and has the mutations L234A, L235A, and P329G (numbering according to EU index of Kabat) in both heavy chains.

[0199] In one embodiment, the antibody comprises: a) a full-length antibody of human subclass IgG1, or b) a full-length antibody of human subclass IgG4, or c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) A full-length antibody of human subclass IgG4 having the mutations S228P, L235E, and optionally P329G; e) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain, or f) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E and optionally P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain. It is.

[0200] In one aspect of the above embodiments, the invention provides a pharmaceutical formulation comprising any of the aforementioned antibodies and a pharma- ceutically acceptable carrier.

[0201] In one aspect of the above embodiments, the invention provides any of the aforementioned antibodies for use as a medicament.

[0202] In another aspect of the above embodiment, the invention provides the use of any of the aforementioned antibodies in the manufacture of a medicament for treating a neurological disorder, hi one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation.

[0203] In another aspect of the above embodiment, the invention provides any of the aforementioned antibodies for use in treating a neurological disorder, hi one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation.

[0204] In another aspect of the above embodiments, the invention provides any of the aforementioned antibodies for use in transporting one or more compounds across the BBB.

[0205] In another aspect of the above embodiment, there is provided the use of any of the aforementioned antibodies in the manufacture of a medicament for transporting one or more compounds across the BBB.

[0206] In one aspect of the above embodiment, a method of transporting a compound through the BBB in a subject is provided, comprising exposing any of the above-mentioned antibodies to the BBB so that the antibody transports the compound bound thereto through the BBB. In one embodiment, the BBB is in a human subject. In one embodiment, the antibody bound to the compound is administered at a therapeutic dose. In one embodiment, the therapeutic dose saturates TfR. In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0207] In another aspect of the above embodiment, a method is provided for increasing the exposure of a subject's CNS to a compound, comprising exposing any of the above-mentioned antibodies to the BBB, so that the antibody transports the compound bound to it through the BBB.In one embodiment, the BBB is in a human subject.In one embodiment, the antibody bound to the compound is administered at a therapeutic dose.In one embodiment, the therapeutic dose saturates TfR.In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0208] In one aspect of the above embodiment, a method is provided for increasing the CNS retention of a compound administered to a subject, comprising exposing any of the above-mentioned antibodies to the BBB so that the CNS retention of the compound is increased.In one embodiment, the BBB is in a human subject.In one embodiment, the antibody bound to the compound is administered at a therapeutic dose.In one embodiment, the therapeutic dose saturates TfR.In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical symptoms of antibody administration.

[0209] In one aspect of the above embodiment, a method for treating a neurological disorder in a mammal is provided, comprising treating the mammal with any of the above-mentioned antibodies. In one embodiment, the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative disease, cancer, eye disease, seizure disorder, lysosomal storage disease, amyloidosis, viral or microbial disease, ischemia, behavioral disorder, and CNS inflammation. In another such aspect, the neurological disorder is in a human subject. In one embodiment, the antibody bound to the compound is administered at a therapeutic dose. In one embodiment, the therapeutic dose saturates TfR. In another embodiment, the antibody administration is at a dose and / or administration frequency calibrated to minimize acute clinical signs of antibody administration.

[0210] In another embodiment, a method is provided for reducing the clearance of a compound administered to a subject, wherein the compound is conjugated to an antibody that binds with low affinity to TfR, thereby reducing the clearance of the compound.

[0211] In another embodiment, a method is provided for optimizing the pharmacokinetics and / or pharmacodynamics of a compound effective in the CNS in a subject, wherein the compound is conjugated to an antibody that binds with low affinity to TfR, and the antibody is selected such that its affinity for TfR after binding to the compound provides a constant amount of transport across the BBB of the antibody conjugated to the compound that optimizes the pharmacokinetics and / or pharmacodynamics of the compound in the CNS.

[0212] In further aspects, anti-transferrin receptor antibodies according to any of the above aspects and embodiments can include, alone or in combination, any of the features described in Sections 1-5 below.

[0213] 1. Antibody affinity In one embodiment, Kd is measured by radiolabeled antigen binding assay (RIA). In one embodiment, the RIA is performed with a Fab version of the antibody of interest and its antigen. For example, the solution binding affinity of the Fab for the antigen is measured by binding the Fab to a minimum concentration ( 125 I) Equilibration with labeled antigen, followed by capture of bound antigen with anti-Fab antibody-coated plates (see, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881). To establish conditions for the assay, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 μg / mL capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), then blocked with 2% (w / v) bovine serum albumin in PBS for 2-5 hours at room temperature (approximately 23° C.). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125 I] antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of Fab-12, an anti-VEGF antibody, in Presta, LG et al., Cancer Res. 57 (1997) 4593-4599). The Fab of interest is then incubated overnight, although the incubation may continue for a longer period (e.g., about 65 hours) to ensure equilibrium is reached. The mixture is then transferred to a capture plate for incubation at room temperature (e.g., 1 hour). The solution is then removed and the plate is washed 8 times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. Once the plate has dried, 150 μL / well scintillant (MICROSCINT-20™; Packard) is added and the plate is counted for 10 minutes in a TOPCOUNT™ gamma counter (Packard). Concentrations of each Fab that provide 20% or less of maximal binding are selected for use in competitive binding assays.

[0214] In another embodiment, Kd is measured using BIACORE® surface plasmon resonance assay. For example, the assay using BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) is performed at 25°C with immobilized antigen CM5 chip at about 10 response units (RU). In one embodiment, carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted to 5 μg / mL (about 0.2 μM) with 10 mM sodium acetate pH 4.8 and then injected at a flow rate of 5 μL / min to achieve about 10 response units (RU) of linked protein. After injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS containing 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at a flow rate of approximately 25 μL / min at 25° C. Association rates (k on ) and dissociation rate (k オフ The equilibrium dissociation constant (Kd) is calculated by k オフ / k on The on rate is calculated as a ratio of 10 to 10 by the above-mentioned surface plasmon resonance assay method (see, for example, Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881). 6 M -1 s -1If the on rate exceeds 100%, it can be determined by using a fluorescence quenching technique that measures the increase or decrease in the fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, band pass 16 nm) of 20 nM anti-antigen antibody (Fab type) in PBS pH 7.2 at 25°C in the presence of increasing concentrations of antigen when measured in a spectrometer equipped with a stirred cuvette, e.g., a spectrometer equipped with stopped flow (Aviv Instruments) or an 8000-series SLM-AMINCO™ spectrometer (ThermoSpectronic).

[0215] 2. Antibody Fragments In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson, PJ et al., Nat. Med. 9 (2003) 129-134. For a review of scFv fragments, see, e.g., Plueckthun, A., In; The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York (1994), pp. 269-315. See also WO 93 / 16185; U.S. Pat. Nos. 5,571,894, and 5,587,458. See US Pat. No. 5,869,046 for a discussion of Fab and F(ab')2 fragments which contain salvage receptor binding epitope residues and have extended half-lives in vivo.

[0216] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, for example, EP 0404097; WO 1993 / 01161; Hudson, PJ et al., Nat. Med. 9 (2003) 129-134; and Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448. Tribodies and tetrabodies are also described in Hudson, PJ et al., Nat. Med.9 (20039 129-134).

[0217] A single domain antibody is an antibody fragment that contains all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516).

[0218] Antibody fragments can be prepared by a variety of techniques, including, but not limited to, proteolytic digestion of an intact antibody and production by recombinant host cells (e.g., E. coli or phage), as described herein.

[0219] 3. Chimeric and humanized antibodies In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison, SL et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855. In one example, the chimeric antibody comprises a non-human variable region (e.g., a variable region from a mouse, rat, hamster, rabbit, or a non-human primate, such as a monkey) and a human constant region. In a further example, the chimeric antibody is a "class-switched" antibody, in which the class or subclass has been changed from that of the parent antibody. The chimeric antibody includes an antigen-binding fragment thereof.

[0220] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce antigenicity to humans but retain the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which the HVRs, e.g., CDRs (or portions thereof), are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody will also optionally comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are replaced by corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0221] Humanized antibodies and methods for preparing them are reviewed, for example, in Almagro, JC and Fransson, J., Front. Biosci. 13 (2008) 1619-1633, and described, for example, in Riechmann, I. et al., Nature 332 (1988) 323-329 (describing specificity determining region (SDR) grafting); Queen, C. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033; U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri, SV et al., Methods 36 (2005) 25-34; Padlan, EA, Mol. Immunol. 28 (1991) 489-498; (where "FR shuffling" is described) Dall'Acqua, WF et al., Methods 36 (2005) 43-60; and (where "guide selection" approaches to FR shuffling are described) Osbourn, J. et al., Methods 36 (2005) 61-68 and Klimka, A. et al., Br. J. Cancer 83 (2000) 252-260.

[0222] Human framework regions that can be used for humanization include framework regions selected using the "best-fit" method (e.g., Sims, MJ et al., J. Immunol. 151 (1993) 2296-2308); framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Presta, LG et al., J. Immunol. 151 (1993) 2623-2632); human mature (somatically matured) framework regions or human germline framework regions (see, e.g., Almagro, JC and Fransson, J., Front. Biosci. 13 (2008) 1619-1633); and framework regions obtained from screening of FR libraries (see, e.g., Baca, M. et al., J. Biol. Chem. 272 ​​(1997) 10678-10684 and Rosok, MJ et al., J. Biol. Chem. 271 (19969 22611-22618).

[0223] 4. Multispecific antibodies In certain embodiments, the antibodies provided herein are multispecific antibodies, e.g., bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for the transferrin receptor and the other is for any other antigen. Bispecific antibodies can also be used to localize cytotoxins to cells expressing the transferrin receptor. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

[0224] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein, C. and Cuello, A. C., Nature 305 (1983) 537-540; WO 93 / 08829; and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659) and "knobs-in-holes" engineering (e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can be produced by manipulating electrostatic steering effects to prepare antibody Fc heterodimeric molecules (WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny, SA et al., J. Immunol. 148 (1992) 1547-1553); using "diabody" technology to prepare bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448); and using single-chain Fv (scFv) dimers (see, e.g., Gruber, M et al., J. Immunol. 152 (1993) 6444-6448). (1994) 5368-5374); and by preparing trispecific antibodies, e.g., as described in Tutt, A. et al., J. Immunol. 147 (1991) 60-69.

[0225] Engineered antibodies with three or more functional antigen binding sites, including "octopus antibodies," are also included herein (see, e.g., U.S. Patent Application Publication No. 2006 / 0025576).

[0226] The antibodies or fragments herein also include "dual acting Fabs" or "DAFs" that contain an antigen binding site that binds to the transferrin receptor as well as another different antigen (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820).

[0227] The antibodies or fragments herein also include the multispecific antibodies described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792, and WO 2010 / 145793.

[0228] In one embodiment of all aspects reported herein, the anti-transferrin receptor antibody is a bispecific antibody.

[0229] One aspect reported herein is a) a first light chain and a first heavy chain of an antibody that specifically binds to a first antigen; b) a second light chain and a second heavy chain of an antibody that specifically binds to a second antigen, wherein the variable domains VL and VH of the second light chain and the second heavy chain are replaced by each other; Here, it is a bivalent, bispecific antibody in which the first antigen or the second antigen is the human transferrin receptor.

[0230] The antibody based on a) does not contain the modifications reported in b), and the heavy and light chains based on a) are independent chains.

[0231] In an antibody based on b), in the light chain the variable light domain VL is replaced by the variable heavy domain VH of said antibody and in the heavy chain the variable heavy domain VH is replaced by the variable light domain VL of said antibody.

[0232] In one embodiment, i) in the constant domain CL of the first light chain according to a) the amino acid at position 124 (numbering according to Kabat) is substituted by a positively charged amino acid and in the constant domain CH1 of the first heavy chain according to a) the amino acid at position 147 or the amino acid at position 213 (numbering according to Kabat EU index) is substituted by a negatively charged amino acid, or or, ii) in the constant domain CL of the second light chain based on b) the amino acid at position 124 (numbering according to Kabat) is substituted by a positively charged amino acid, and in the constant domain CH1 of the second heavy chain based on b) the amino acid at position 147 or the amino acid at position 213 (numbering according to Kabat EU index) is substituted by a negatively charged amino acid.

[0233] In one preferred embodiment, i) in the constant domain CL of the first light chain according to a) the amino acid at position 124 is independently substituted (in one preferred embodiment independently by lysine (K) or arginine (R)) by a lysine (K), an arginine (R) or a histidine (H) (numbering according to Kabat), and in the constant domain CH1 of the first heavy chain according to a) the amino acid at position 147 or the amino acid at position 213 is independently substituted by a glutamic acid (E) or an aspartic acid (D) (numbering according to Kabat EU index), or, ii) in the constant domain CL of the second light chain based on b) the amino acid at position 124 is independently substituted (in one preferred embodiment independently by lysine (K) or arginine (R)) by a lysine (K), an arginine (R) or a histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the second heavy chain based on b) the amino acid at position 147 or the amino acid at position 213 is independently substituted by a glutamic acid (E) or an aspartic acid (D) (numbering according to Kabat EU index).

[0234] In one embodiment in the constant domain CL of the second heavy chain, the amino acids at positions 124 and 123 are substituted by K (numbering according to Kabat EU index).

[0235] In one embodiment in the constant domain CH1 of the second light chain, the amino acids at positions 147 and 213 are substituted by E (numbering according to Kabat EU index).

[0236] In one preferred embodiment, in the constant domain CL of the first light chain the amino acids at positions 124 and 123 are substituted by K and in the constant domain CH1 of the first heavy chain the amino acids at positions 147 and 213 are substituted by E (numbering according to Kabat EU index).

[0237] In one embodiment in the constant domain CL of the second heavy chain the amino acids at positions 124 and 123 are substituted by K; wherein in the constant domain CH1 of the second light chain the amino acids at positions 147 and 213 are substituted by E; in the variable domain VL of the first light chain the amino acid at position 38 is substituted by K; in the variable domain VH of the first heavy chain the amino acid at position 39 is substituted by E; in the variable domain VL of the second heavy chain the amino acid at position 38 is substituted by K and in the variable domain VH of the second light chain the amino acid at position 39 is substituted by E (numbering according to Kabat EU index).

[0238] One aspect reported herein is a) a first light chain and a first heavy chain of an antibody that specifically binds to a first antigen; b) a second light chain and a second heavy chain of an antibody that specifically binds to a second antigen, wherein the variable domains VL and VH of the second light chain and the second heavy chain are replaced with each other, and wherein the constant domains CL and CH1 of the second light chain and the second heavy chain are replaced with each other; Here, it is a bivalent, bispecific antibody in which the first antigen or the second antigen is the human transferrin receptor.

[0239] The antibody based on a) does not contain the modifications reported in b), and the heavy and light chains based on a) are independent chains.

[0240] In an antibody based on b), in the light chain the variable light domain VL is replaced by the variable heavy domain VH of said antibody and the constant light domain CL is replaced by the constant heavy domain CH1 of said antibody, and in the heavy chain the variable heavy domain VH is replaced by the variable light domain VL of said antibody and the constant heavy domain CH1 is replaced by the constant light domain CL of said antibody.

[0241] One aspect reported herein is a) a first light chain and a first heavy chain of an antibody that specifically binds to a first antigen; b) a second light chain and a second heavy chain of an antibody that specifically binds to a second antigen, wherein the constant domains CL and CH1 of the second light chain and the second heavy chain are replaced by each other; Here, it is a bivalent, bispecific antibody in which the first antigen or the second antigen is the human transferrin receptor.

[0242] The antibody based on a) does not contain the modifications reported in b), and the heavy and light chains based on a) are independent chains.

[0243] In an antibody based on b), in the light chain the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody and in the heavy chain the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody.

[0244] One aspect reported herein is a) a full-length antibody that specifically binds to a first antigen and is composed of two antibody heavy chains and two antibody light chains; b) 1, 2, 3 or 4 single chain Fab fragments which specifically bind to 1 to 4 further antigens (i.e. to the second and / or third and / or fourth and / or fifth antigens, preferably to one further antigen, i.e. the second antigen); wherein the single-chain Fab fragment based on b) is fused to the full-length antibody based on a) via a peptide linker at the C-terminus or N-terminus of the heavy or light chain of the full-length antibody, wherein the first antigen or one of the further antigens is a multispecific antibody, the first antigen being the human transferrin receptor.

[0245] In one embodiment, one or two identical single-chain Fab fragments that bind to a second antigen are fused to said full-length antibody via a peptide linker at the C-terminus of a heavy or light chain in said full-length antibody.

[0246] In one embodiment, one or two identical single-chain Fab fragments that bind to a second antigen are fused to said full-length antibody via a peptide linker at the C-terminus of the heavy chain in said full-length antibody.

[0247] In one embodiment, one or two identical single-chain Fab fragments that bind to a second antigen are fused to said full-length antibody via a peptide linker at the C-terminus of the light chain in said full-length antibody.

[0248] In one embodiment, two identical single-chain Fab fragments that bind to a second antigen are fused to the full-length antibody via a peptide linker at the C-terminus of each of the heavy or light chains of the full-length antibody.

[0249] In one embodiment, two identical single-chain Fab fragments that bind to a second antigen are fused to said full-length antibody via a peptide linker at the C-terminus of each heavy chain of said full-length antibody.

[0250] In one embodiment, two identical single-chain Fab fragments that bind to a second antigen are fused to said full-length antibody via a peptide linker at the C-terminus of each light chain of said full-length antibody.

[0251] One aspect reported herein is a) a full-length antibody that specifically binds to a first antigen and is composed of two antibody heavy chains and two antibody light chains; b) ba) an antibody heavy chain variable domain (VH); or bb) a first polypeptide consisting of an antibody heavy chain variable domain (VH) and an antibody constant domain 1 (CH1), said first polypeptide being fused by the N-terminus of said VH domain to the C-terminus of one of the two heavy chains of said full-length antibody via a peptide linker; c) ca) an antibody light chain variable domain (VL) or cb) a second polypeptide consisting of an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL), said second polypeptide being fused via the N-terminus of the VL domain to the C-terminus of the other of the two heavy chains in said full-length antibody via a peptide linker; wherein an antibody heavy chain variable domain (VH) of the first polypeptide and an antibody light chain variable domain (VL) of the second polypeptide together form an antigen-binding site that specifically binds to a second antigen, Here, it is a trivalent bispecific antibody, in which the first antigen or the second antigen is the human transferrin receptor.

[0252] In one embodiment, the antibody heavy chain variable domain (VH) of the polypeptide based on b) and the antibody light chain variable domain (VL) of the polypeptide based on c) are linked and stabilized via an intrachain disulfide bridge by introduction of a disulfide bond between the following positions: i) position 100 of the light chain variable domain relative to position 44 of the heavy chain variable domain; or ii) position 43 of the light chain variable domain relative to position 105 of the heavy chain variable domain; or iii) position 100 of the light chain variable domain relative to position 101 of the heavy chain variable domain (usually numbered according to the Kabat EU index)

[0253] Techniques for introducing non-natural disulfide bridges for stabilization are described, for example, in WO 94 / 029350, Rajagopal, V., et al., Prot. Eng. (1997) 1453-59; Kobayashi, H., et al., Nuclear Medicine & Biology, Vol. 25, (1998) 387-393; or Schmidt, M., et al., Oncogene (1999) 18 1711-1721. In one embodiment, any disulfide bond between the variable domains of the polypeptides according to b) and c) is between position 44 of the heavy chain variable domain and position 100 of the light chain variable domain. In one embodiment, any disulfide bond between the variable domains of the polypeptides according to b) and c) is between position 105 of the heavy chain variable domain and position 43 of the light chain variable domain (usually numbered according to Kabat). In one embodiment trivalent bispecific antibodies are preferred which do not comprise any disulfide stabilisation between the variable domains VH and VL in the single chain Fab fragment.

[0254] One aspect reported herein is a) a first light chain and a first heavy chain of a full-length antibody that specifically binds to a first antigen; b) a second (modified) light chain and a second (modified) heavy chain of a full-length antibody that specifically binds to a second antigen, in which the variable domains VL and VH are replaced by each other and / or in which the constant domains CL and CH1 are replaced by each other; c) 1 to 4 antigen-binding peptides that specifically bind to one or two further antigens (i.e., a third and / or a fourth antigen) and are fused to the C-terminus or N-terminus of the light chain or heavy chain in a) and / or b) via a peptide linker; wherein the first or second or one of the further antigens is a trispecific or tetraspecific antibody, the trispecific or tetraspecific antibody being the human transferrin receptor.

[0255] The antibody based on a) does not contain the modifications reported in b), and the heavy and light chains based on a) are independent chains.

[0256] In one embodiment, the trispecific or tetraspecific antibody comprises one or two antigen-binding peptides that specifically bind to one or two further antigens according to c).

[0257] In one embodiment, the antigen-binding peptide is selected from the group consisting of an scFv fragment and an scFab fragment.

[0258] In one embodiment, the antigen-binding peptide is an scFv fragment.

[0259] In one embodiment, the antigen-binding peptide is an scFab fragment.

[0260] In one embodiment, the antigen-binding peptide is fused to the C-terminus of the heavy chain in a) and / or b).

[0261] In one embodiment, the trispecific or tetraspecific antibody comprises one or two antigen-binding peptides that specifically bind to one additional antigen according to c).

[0262] In one embodiment, the tria- or tetra-specific antibody comprises two identical antigen-binding peptides that specifically bind to the third antigen according to c). In a preferred embodiment, such two identical antigen-binding peptides are both fused to the C-terminus of the heavy chain in a) and b) via the same peptide linker. In a preferred embodiment, the two identical antigen-binding peptides are either scFv or scFab fragments.

[0263] In one embodiment, the tria or tetraspecific antibody comprises two antigen-binding peptides that specifically bind to the third and fourth antigens according to c). In one embodiment, said two antigen-binding peptides are both fused to the C-terminus of the heavy chain in a) and b) via the same peptide connector. In a preferred embodiment, said two antigen-binding peptides are either scFv or scFab fragments.

[0264] One aspect reported herein is a) two light chains and two heavy chains of an antibody (comprising two Fab fragments) that specifically binds to a first antigen; b) two further Fab fragments of an antibody that specifically binds to a second antigen, said further Fab fragments both being fused to either the C-terminus or the N-terminus of the heavy chain in a) via a peptide linker; In this case, the following modifications were made in the Fab fragment: i) in both Fab fragments of a) or in both Fab fragments of b) the variable domains VL and VH are replaced by each other and / or the constant domains CL and CH1 are replaced by each other, or, ii) in both Fab fragments of a) the variable domains VL and VH are replaced by each other and the constant domains CL and CH1 are replaced by each other; And, b) in both Fab fragments the variable domains VL and VH are replaced by one another or the constant domains CL and CH1 are replaced by one another, or, iii) in both Fab fragments of a) the variable domains VL and VH are replaced by each other or the constant domains CL and CH1 are replaced by each other, And, b) in both Fab fragments the variable domains VL and VH are replaced by each other and the constant domains CL and CH1 are replaced by each other, or, iv) in both Fab fragments of a) the variable domains VL and VH are replaced by each other and in both Fab fragments of b) the constant domains CL and CH1 are replaced by each other, or, v) in both Fab fragments of a) the constant domains CL and CH1 are replaced by each other, and in both Fab fragments of b) the variable domains VL and VH are replaced by each other, wherein the first or second antigen is a human transferrin receptor.

[0265] In one embodiment said further Fab fragments are both fused either to the C-terminus of the heavy chain in a) or to the N-terminus of the heavy chain in a) via a peptide linker.

[0266] In one embodiment, both of said further Fab fragments are fused to either of the C-terminus of the heavy chain in a) via a peptide linker.

[0267] In one embodiment said further Fab fragments are both fused to the N-terminus of the heavy chain in a) via peptide connectors.

[0268] In one embodiment, the following modifications are made in the Fab fragment: i) in both Fab fragments of a) or in both Fab fragments of b) the variable domains VL and VH are replaced by each other and / or the constant domains CL and CH1 are replaced by each other.

[0269] In one embodiment, the following modifications are made in the Fab fragment: i) In both Fab fragments of a), the variable domains VL and VH are replaced by each other and / or the constant domains CL and CH1 are replaced by each other.

[0270] In one embodiment, the following modifications are made in the Fab fragment: i) In both Fab fragments of a) the constant domains CL and CH1 are replaced by each other.

[0271] In one embodiment, the following modifications are made in the Fab fragment: i) In both Fab fragments of b), the variable domains VL and VH are replaced by each other and / or the constant domains CL and CH1 are replaced by each other.

[0272] In one embodiment, the following modifications are made in the Fab fragment: i) In both Fab fragments of b), the constant domains CL and CH1 are replaced by each other.

[0273] One aspect reported herein is a) a (modified) heavy chain of a first antibody that specifically binds to a first antigen and comprises a first VH-CH1 domain pair, wherein the N-terminus of a second VH-CH1 domain pair of the first antibody is fused to the C-terminus of the heavy chain via a peptide linker; b) two light chains of the first antibody in a); c) a (modified) heavy chain of a second antibody that specifically binds to a second antigen and comprises a first VH-CL domain pair, the N-terminus of a second VH-CL domain pair of the second antibody being fused to the C-terminus of the heavy chain via a peptide linker; d) two (modified) light chains of the second antibody according to c), each of which comprises a CL-CH1 domain pair; wherein the first or second antigen is a human transferrin receptor.

[0274] One aspect reported herein is a) heavy and light chains of a first full-length antibody that specifically binds to a first antigen; b) heavy and light chains of a second full-length antibody that specifically binds to a second antigen, wherein the N-terminus of the heavy chain is linked to the C-terminus of the light chain via a peptide linker; Here, it is a bispecific antibody, wherein the first antigen or the second antigen is the human transferrin receptor.

[0275] The antibody based on a) does not contain the modifications reported under b), and the heavy and light chains are independent chains.

[0276] One aspect reported herein is a) a full-length antibody that specifically binds to a first antigen and is composed of two antibody heavy chains and two antibody light chains; b) specifically binds to the second antigen and 2 Domain and VL 2 an Fv fragment comprising domains, both domains being linked to each other via disulfide bridges; Here, VH 2 Domain or VL 2 either one of the domains is fused via a peptide linker to a heavy or light chain of a full-length antibody that specifically binds to a first antigen; Here, it is a bispecific antibody, wherein the first antigen or the second antigen is the human transferrin receptor.

[0277] In a bispecific antibody, the heavy and light chains according to a) are independent chains.

[0278] In one embodiment, the VH 2 Domain or VL 2 The other of the domains is not fused via a peptide linker to a heavy or light chain of a full-length antibody that specifically binds to the first antigen.

[0279] In all embodiments reported herein, the first light chain comprises a VL domain and a CL domain, and the first heavy chain comprises a VH domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain.

[0280] One aspect reported herein is a) two Fab fragments that specifically bind to a first antigen; b) one CrossFab fragment that specifically binds to a second antigen, in which the CH1 and CL domains have been exchanged with each other; c) an Fc region comprising a first Fc region heavy chain and a second Fc region heavy chain; wherein the C-terminus of the CH1 domain of the two Fab fragments is linked to the N-terminus of a heavy chain Fc region polypeptide; wherein the C-terminus of the CL domain of the CrossFab fragment is bound to the N-terminus of the VH domain of one of the Fab fragments; wherein the first antigen and the second antigen are human transferrin receptors; It is a bispecific, trivalent antibody.

[0281] One aspect reported herein is a) two Fab fragments that specifically bind to a first antigen; b) one CrossFab fragment that specifically binds to a second antigen, in which the CH1 and CL domains have been exchanged with each other; c) an Fc region comprising a first Fc region heavy chain and a second Fc region heavy chain; wherein the C-terminus of the CH1 domain in the first Fab fragment is bound to the N-terminus of one heavy chain Fc region polypeptide, and the C-terminus of the CL domain in the CrossFab fragment is bound to the N-terminus of the other heavy chain Fc region polypeptide; wherein the C-terminus of the CH1 domain of the second Fab fragment is bound to the N-terminus of the VH domain of the first Fab fragment or the N-terminus of the VH domain of the CrossFab fragment; Here, it is a bispecific, trivalent antibody in which the first and second antigens are human transferrin receptors.

[0282] One aspect reported herein is a) a full-length antibody that specifically binds to a first antigen and is composed of two antibody heavy chains and two antibody light chains; b) a VH that specifically binds to a second antigen and comprises a heavy chain fragment and a light chain fragment; 2 Domain and VL 2 A Fab fragment comprising a variable light domain, 2 the variable heavy domain VH of said antibody 2 and in the heavy chain fragment the variable heavy domain VH 2 The variable light chain domain VL of the antibody 2 and a Fab fragment, wherein wherein a heavy chain Fab fragment is inserted between the CH1 domain of one heavy chain and each Fc region of the full-length antibody, the N-terminus of the light chain Fab region is conjugated to the C-terminus of the light chain of the full-length antibody, and the light chain is paired with the heavy chain of the full-length antibody into which the heavy chain Fab fragment has been inserted; Here, the first and second antigens are bispecific antibodies, each of which is a human transferrin receptor.

[0283] One aspect reported herein is a) a full-length antibody that specifically binds to a first antigen and is composed of two antibody heavy chains and two antibody light chains; b) a VH that specifically binds to a second antigen and comprises a heavy chain fragment and a light chain fragment; 2 Domain and VL 2 A Fab fragment comprising a variable light domain, 2 the variable heavy domain VH of said antibody 2 and in the heavy chain fragment the variable heavy domain VH 2 The variable light chain domain VL of the antibody2 and a Fab fragment, wherein wherein the C-terminus of the heavy chain fragment of the Fab fragment is conjugated to the N-terminus of one heavy chain of the full-length antibody, the C-terminus of the light chain fragment of the Fab fragment is conjugated to the N-terminus of the light chain of the full-length antibody, and the light chain is paired with the heavy chain of the full-length antibody to which the heavy chain fragment of the Fab fragment is conjugated; Here, the first and second antigens are bispecific antibodies, each of which is a human transferrin receptor.

[0284] In one embodiment of all aspects, the antibodies reported herein are multispecific antibodies, which require heteromultimerization of at least two heavy chain polypeptides, wherein the antibodies specifically bind to the human transferrin receptor and a second non-human transferrin receptor antigen.

[0285] Several approaches to modify CH3 to support heterodimerization have been described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, etc., WO 2012 / 058768, WO 2013 / 157954, WO 2013 / 096291. These documents are incorporated herein by reference. Typically, in approaches known in the art, the CH3 domain of the first heavy chain and the CH3 domain of the second heavy chain are both engineered in a complementary manner such that a heavy chain containing one engineered CH3 domain can no longer homodimerize with another heavy chain of the same structure (e.g., a CH3-engineered first heavy chain can no longer homodimerize with another CH3-engineered first heavy chain, and a CH3-engineered second heavy chain can no longer homodimerize with another CH3-engineered second heavy chain). This allows a heavy chain containing one engineered CH3 domain to heterodimerize with another heavy chain containing a CH3 domain. The same other heavy chains are engineered in a complementary manner. For this embodiment of the invention, the CH3 domain of the first heavy chain and the CH3 domain of the second heavy chain are engineered in a complementary manner by amino acid substitution. This allows the first heavy chain and the second heavy chain to heterodimerize. On the other hand, the first heavy chain and the second heavy chain can no longer homodimerize (e.g., for steric reasons).

[0286] Various approaches to support heavy chain heterodimerization known in the art have been cited and included above and are contemplated as various alternatives for use in the multispecific antibodies according to the present invention, which comprise a "non-crosslinking Fab region" from a first antibody that specifically binds to a first antigen and a "crosslinking Fab region" from a second antibody that specifically binds to a second antigen, in combination with the specific amino acid substitutions described above for the present invention.

[0287] The CH3 domains of the multispecific antibodies reported herein can be mutated by the "knob-into-hole" technique, which has been described in detail with examples in, for example, WO 96 / 027011; Ridgway, JB, et al., Protein Eng. 9 (1996) 617-621; and Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681. In this method, the interaction surfaces of the two CH3 domains are mutated to improve the heterodimerization of both heavy chains containing these two CH3 domains. Each of the two CH3 domains (of the two heavy chains) can be a "knob", while the other one is a "hole". Introduction of disulfide bridges further stabilizes the heterodimer (Merchant, A. M., et al., Nature Biotech. 16 (1998) 677-681; Atwell, S., et al., J. Mol. Biol. 270 (1997) 26-35) and improves yields.

[0288] In a preferred embodiment, the multispecific antibody as reported herein comprises the T366W mutation in the CH3 domain of the "knob chain" and the T366S, L368A, Y407V mutations in the CH3 domain of the "hole chain" (numbering according to the Kabat EU index). Additional interchain disulfide bridges between the CH3 domains can also be used, for example by introducing a Y349C mutation in the CH3 domain of the "knob chain" and an E356C or S354C mutation in the CH3 domain of the "hole chain" (Merchant, AM, et al., Nature Biotech. 16 (1998) 677-681). Thus, in another preferred embodiment, the multispecific antibody as reported herein comprises the Y349C and T366W mutations in one of the two CH3 domains and the E356C, T366S, L368A, and Y407V mutations in the other of the two CH3 domains. Alternatively, the multispecific antibody reported herein comprises the mutations Y349C and T366W in one of the two CH3 domains and the mutations S354C, T366S, L368A and Y407V in the other of the two CH3 domains (the additional mutation Y349C in one CH3 domain and the additional mutations E356C or S354C in the other CH3 domain form an interchain disulfide bridge) (numbering according to Kabat EU index).

[0289] Other knob-in-hole technologies, as described in EP 1 870 459 A1, can alternatively or additionally be used. In one embodiment, the multispecific antibody reported herein comprises the mutations R409D and K370E in the CH3 domain of the "knob chain" and the mutations D399K and E357K in the CH3 domain of the "hole chain" (numbering according to the Kabat EU index).

[0290] In one embodiment the multispecific antibody as reported herein comprises the T366W mutation in the CH3 domain of the "knob chain" and the T366S, L368A and Y407V mutations in the CH3 domain of the "hole chain", and further comprises the R409D and K370E mutations in the CH3 domain of the "knob chain" and the D399K and E357K mutations in the CH3 domain of the "hole chain" (numbering according to Kabat EU index).

[0291] In one embodiment, the multispecific antibody as reported herein comprises the mutations Y349C and T366W in one of the two CH3 domains and the mutations S354C, T366S, L368A and Y407V in the other of the two CH3 domains. Alternatively, the multispecific antibody as reported herein comprises the mutations Y349C and T366W in one of the two CH3 domains and the mutations S354C, T366S, L368A and Y407V in the other of the two CH3 domains, and further comprises the mutations R409D and K370E in the CH3 domain of the "knob strand" and the mutations D399K and E357K in the CH3 domain of the "hole strand" (numbering according to the Kabat EU index).

[0292] Apart from the "knobs-into-holes technique", other techniques for modifying the CH3 domains of heavy chains in multispecific antibodies to heterodimerize are known in the art. These techniques, in particular those described in WO 96 / 27011, WO 98 / 050431, EP 1 870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954 and WO 2013 / 096291, are contemplated herein as alternatives to the "knobs-into-hole technology" in combination with the multispecific antibodies reported herein.

[0293] In one embodiment of the multispecific antibody reported herein, the approach described in EP 1 870 459 is used to support the heterodimerization of the first and second heavy chains of the multispecific antibody. This approach is based on the introduction of charged amino acids with opposite charges at specific amino acid positions in the CH3 / CH3 domain interface between both the first and second heavy chains.

[0294] This embodiment therefore relates to a multispecific antibody as reported herein, wherein in the tertiary structure of the antibody the CH3 domain of the first heavy chain and the CH3 domain of the second heavy chain form an interface located between the respective antibody CH3 domains, and wherein each amino acid sequence of the CH3 domain of the first heavy chain and the CH3 domain of the second heavy chain, respectively, comprises a set of amino acids located within said interface in the tertiary structure of the antibody, wherein a first amino acid from the set of amino acids located at the interface in the CH3 domain of one heavy chain is replaced by a positively charged amino acid and a second amino acid from the set of amino acids located at the interface in the CH3 domain of the other heavy chain is replaced by a negatively charged amino acid. The multispecific antibody of this embodiment is also referred to herein as "CH3(+ / -) engineered multispecific antibody" (wherein the abbreviation "+ / -" refers to the oppositely charged amino acids introduced into each CH3 domain).

[0295] In one embodiment of said CH3(+ / -) engineered multispecific antibody reported herein the positively charged amino acids are selected from K, R and H and the negatively charged amino acids are selected from E or D.

[0296] In one embodiment of said CH3(+ / -) engineered multispecific antibody reported herein the positively charged amino acids are selected from K and R and the negatively charged amino acids are selected from E or D.

[0297] In one embodiment of said CH3(+ / -) engineered multispecific antibody reported herein the positively charged amino acid is K and the negatively charged amino acid is E.

[0298] In one embodiment of said CH3(+ / -) engineered multispecific antibodies reported herein, in the CH3 domain of one heavy chain the amino acid R at position 409 is substituted by D and the amino acid K at position is substituted by E; and in the CH3 domain of the other heavy chain the amino acid D at position 399 is substituted by K and the amino acid E at position 357 is substituted by K (numbering according to Kabat EU index).

[0299] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2013 / 157953 is used to support heterodimerization of the first and second heavy chains in the multispecific antibody. In one embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid T at position 366 is replaced by K and in the CH3 domain of the other heavy chain, the amino acid L at position 351 is replaced by D (numbering according to Kabat EU index). In another embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid T at position 366 is replaced by K and the amino acid L at position 351 is replaced by K and in the CH3 domain of the other heavy chain, the amino acid L at position 351 is replaced by D (numbering according to Kabat EU index).

[0300] In another embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain the amino acid T at position 366 is substituted by K, the amino acid L at position 351 is substituted by K and in the CH3 domain of the other heavy chain the amino acid L at position 351 is substituted by D (numbering according to Kabat EU index). Furthermore, at least one of the following substitutions is contained in the CH3 domain of the other heavy chain: the amino acid Y at position 349 is substituted by E, the amino acid Y at position 349 is substituted by D and the amino acid L at position 368 is substituted by E (numbering according to Kabat EU index). In one embodiment the amino acid L at position 368 is substituted by E (numbering according to Kabat EU index).

[0301] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2012 / 058768 is used to support the heterodimerization of the first and second heavy chains in the multispecific antibody. In one embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid L at position 351 is substituted by Y and the amino acid Y at position 407 is substituted by A, and in the CH3 domain of the other heavy chain, the amino acid T at position 366 is substituted by A and the amino acid K at position 409 is substituted by F (numbering according to the Kabat EU index). In another embodiment, in addition to the substitutions mentioned above, the CH3 domain of the other heavy chain has at least one substitution at amino acid positions 411 (originally T), 399 (originally D), 400 (originally S), 405 (originally F), 390 (originally N) and 392 (originally K) (numbering according to the Kabat EU index). - substitution of the amino acid T at position 411 by an amino acid selected from N, R, Q, K, D, E and W (numbering according to the Kabat EU index), - substitution of the amino acid D at position 399 by an amino acid chosen from R, W, Y and K (numbering according to the Kabat EU index), - substitution of the amino acid S at position 400 by an amino acid chosen from E, D, R and K (numbering according to the Kabat EU index), - a substitution of the amino acid F at position 405 by an amino acid selected from I, M, T, S, V and W (numbering according to the Kabat EU index), - a substitution of the amino acid N at position 390 by an amino acid selected from R, K and D (numbering according to the Kabat EU index), and - substitution of the amino acid K at position 392 by an amino acid selected from V, M, R, L, F and E (numbering according to the Kabat EU index); It is.

[0302] In another embodiment of said multispecific antibody as reported herein (engineered on the basis of WO 2012 / 058768), in the CH3 domain of one heavy chain the amino acid L at position 351 is substituted by Y, the amino acid Y at position 407 is substituted by A and in the CH3 domain of the other heavy chain the amino acid T at position 366 is substituted by V and the amino acid K at position 409 is substituted by F (numbering according to Kabat EU index). In another embodiment of said multispecific antibody as reported herein, in the CH3 domain of one heavy chain the amino acid Y at position 407 is substituted by A and in the CH3 domain of the other heavy chain the amino acid T at position 366 is substituted by A and the amino acid K at position 409 is substituted by F (numbering according to Kabat EU index). In the last aforementioned embodiment, in the CH3 domain of the other heavy chain the amino acid K at position 392 is substituted by E, the amino acid T at position 411 is substituted by E, the amino acid D at position 399 is substituted by R and the amino acid S at position 400 is substituted by R (numbering according to Kabat EU index).

[0303] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2011 / 143545 is used to support heterodimerization of the first and second heavy chains in the multispecific antibody. In one embodiment of said multispecific antibody reported herein, amino acid modifications in the CH3 domains of both heavy chains are introduced at positions 368 and / or 409 (numbering according to the Kabat EU index).

[0304] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2011 / 090762 is used to support heterodimerization of the first and second heavy chains in the multispecific antibody. WO 2011 / 090762 relates to amino acid modifications based on the "knobs-into-holes" technology. In one embodiment of said CH3(KiH) engineered multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid T at position 366 is replaced by W and in the CH3 domain of the other heavy chain, the amino acid Y at position 407 is replaced by A (numbering according to the Kabat EU index). In another embodiment of said CH3(KiH) engineered multispecific antibody reported herein, in the CH3 domain of one heavy chain the amino acid T at position 366 is replaced by Y and in the CH3 domain of the other heavy chain the amino acid Y at position 407 is replaced by T (numbering according to Kabat EU index).

[0305] In one embodiment of the multispecific antibody reported herein, which is of IgG2 isotype, the approach described in WO 2011 / 090762 is used to support heterodimerization of the first and second heavy chains in the multispecific antibody.

[0306] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2009 / 089004 is used to support heterodimerization of the first and second heavy chain in the multispecific antibody. In one embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid K or N at position 392 is replaced by a negatively charged amino acid (in a preferred embodiment by E or D, in a preferred embodiment by D) and in the CH3 domain of the other heavy chain, the amino acid D at position 399, the amino acid E or D at position 356 or the amino acid E at position 357 are replaced by a positively charged amino acid (in a preferred embodiment by K or R, in a preferred embodiment by K, in a preferred embodiment the amino acid at position 399 or 356 is replaced by K) (numbering according to the Kabat EU index). In a further embodiment, in addition to the aforementioned substitutions, in the CH3 domain of one heavy chain, the amino acid K or R at position 409 is substituted by a negatively charged amino acid (in a preferred embodiment by E or D, in a preferred embodiment by D) (numbering according to Kabat EU index). In a further embodiment, in addition to or instead of the aforementioned substitutions, in the CH3 domain of one heavy chain, the amino acid K at position 439 and / or the amino acid K at position 370 are substituted independently of each other by a negatively charged amino acid (in a preferred embodiment by E or D, in a preferred embodiment by D) (numbering according to Kabat EU index).

[0307] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2007 / 147901 is used to support the heterodimerization of the first and second heavy chains in the multispecific antibody. In one embodiment of said multispecific antibody reported herein, in the CH3 domain of one heavy chain, the amino acid K at position 253 is substituted by E, the amino acid D at position 282 is substituted by K and the amino acid K at position 322 is substituted by D, and in the CH3 domain of the other heavy chain, the amino acid D at position 239 is substituted by K, the amino acid E at position 240 is substituted by K and the amino acid K at position 292 is substituted by D (numbering according to Kabat EU index).

[0308] In one embodiment of the multispecific antibody reported herein, the approach described in WO 2007 / 110205 is used to support heterodimerization of the first and second heavy chains in the multispecific antibody.

[0309] In one embodiment of all aspects and in the embodiments reported herein, the multispecific antibody is a bispecific or trispecific antibody. In one preferred embodiment of the invention, the multispecific antibody is a bispecific antibody.

[0310] In one embodiment of all aspects reported herein, the antibody is a bivalent or trivalent antibody. In one embodiment, the antibody is a bivalent antibody.

[0311] In one embodiment of all aspects reported herein, the multispecific antibody has the constant domain structure of an IgG type antibody. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG1 or human subclass IgG1 with the mutations L234A and L235A. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG2. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG3. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG4 or human subclass IgG4 with the further mutation S228P. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG1 or human subclass IgG4. In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG1 with the mutations L234A and L235A (numbering according to Kabat EU index). In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG1 with the mutations L234A, L235A and P329G (numbering according to Kabat EU index). In a further embodiment of all aspects reported herein, the multispecific antibody is characterized in that said multispecific antibody is of human subclass IgG4 with the mutations S228P and L235E (numbering according to Kabat EU index).In a further embodiment of all aspects reported herein the multispecific antibody is characterised in that said multispecific antibody is of human subclass IgG4 with the mutations S228P, L235E and P329G (numbering according to Kabat EU index).

[0312] In one embodiment of all aspects reported herein, an antibody comprising a heavy chain comprising a CH3 domain as specified herein comprises an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to Kabat EU index). In one embodiment of all aspects reported herein, an antibody comprising a heavy chain comprising a CH3 domain as specified herein comprises an additional C-terminal glycine residue (G446, numbering according to Kabat EU index).

[0313] 5. Antibody Variants In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen binding.

[0314] a) Substitution, insertion, and deletion mutants In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "Conservative Substitutions". More substantial changes are provided in Table 1 under the heading of "Exemplary Substitutions" and as further described below with reference to the classification of amino acid side chains. Amino acid substitutions can be introduced into the subject antibody and the products can be screened for the desired activity, e.g., retained / activated antigen binding, reduced immunogenicity, or improved ADCC or CDC. [Table 6]

[0315] Amino acids can be grouped according to common side chain properties. (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues affecting chain orientation: Gly, Pro; (6) Aromaticity: Trp, Tyr, Phe

[0316] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0317] Certain substitutional variants involve the substitution of one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant selected for further study will have an alteration (e.g., improvement) in a particular biological property relative to the parent antibody (e.g., improved affinity, reduced immunogenicity) and / or will have substantially retained a particular biological property of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which can be conveniently generated using, for example, phage display-based affinity maturation techniques, such as those described herein. Briefly, one or more HVR residues are matured and the mutant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0318] Mutations (e.g., substitutions) can be made in the HVRs, for example, to improve antibody affinity. Such mutations can be in HVR "hot spots", i.e., residues encoded by codons that undergo high frequency of mutation during somatic mutation methods (see, e.g., Chowdhury, PS, Methods Mol. Biol. 207 (2008) 179-196), and / or in residues that contact the antigen. The resulting mutated VH or VL are tested for binding affinity. Affinity maturation by constructing a secondary library and reselecting from the secondary library is described, for example, in Hoogenboom, HR et al. in Methods in Molecular Biology 178 (2002) 1-37. In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then prepared. This library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity involves the HVR-directed approach, in which multiple HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or by modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0319] In certain embodiments, substitutions, insertions, or deletions can be made in one or more HVRs, so long as such mutations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative mutations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity can be made in the HVRs. Such mutations can be, for example, outside of the antigen contact residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR is either unmutated or contains two or more, two or three amino acid substitutions.

[0320] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is described in Cunningham, BC and Wells, JA, Science 244 (1989) 1081-1085 and is called "alanine scanning mutagenesis". In this method, target residues or groups (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at amino acid positions that demonstrate functional sensitivity to the initial substitution. Alternatively or additionally, a crystal structure of an antigen-antibody complex identifies contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted as candidates for substitution or can be removed. Mutants can be screened to determine whether they contain the desired properties.

[0321] Amino acid sequence insertions range in length from one residue to polypeptides containing 100 or more residues and include amino- and / or carboxyl-terminal fusions, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to enzymes or polypeptides which increase the serum half-life of the antibody (e.g., for ADEPT).

[0322] b) Glycosylation Mutants In certain embodiments, the antibodies provided herein are mutated to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by mutating the amino acid sequence, thereby creating or removing one or more glycosylation sites.

[0323] If the antibody comprises an Fc region, the carbohydrate attached thereto can be altered. Native antibodies produced by mammalian cells typically comprise biantennary oligosaccharides, which are generally attached by N-linkage to Asn297 of the CH2 domain in the Fc region (see, e.g., Wright, A. and Morrison, SL, TIBTECH 15 (1997) 26-32). The oligosaccharides can comprise a variety of carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose, attached to GlcNAc at the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the invention can be made to form antibody variants with specific improved properties.

[0324] In one embodiment, antibody variants are provided that have carbohydrate structures that lack fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be 1%-80%, 1%-65%, 5%-65%, or 20%-40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycan structures (e.g., complex hybrid high mannose structures) attached to Asn297, as measured, for example, by MALDI-TOF mass spectrometry as described in WO 2008 / 077546. Asn297 refers to an asparagine residue located near position 297 in the Fc region (EU numbering of Fc region residues). However, due to small sequence variations in antibodies, Asn297 may also be located about ±3 amino acids upstream or downstream of position 297, i.e., at positions 294-300. Such fucosylation variants can have improved ADCC function. See, e.g., U.S. Patent Application Publication Nos. 2003 / 0157108; 2004 / 0093621. Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include U.S. Patent Application Publication Nos. 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; U.S. Patent Application Publication Nos. 2003 / 0115614; 2002 / 0164328; 2004 / 0093621; No. 32140; No. 2004 / 0110704; No. 2004 / 0110282; No. 2004 / 0109865; International Publication No. 2003 / 085119; No. 20 03 / 084570; 2005 / 035586; 2005 / 035778; 2005 / 053742; 2002 / 031140; Okazaki, A. et al., J. Mol. Biol. 336 (2004) 1239-1249; Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622.Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka, J. et al., Arch. Biochem. Biophys. 249 (1986) 533-545; U.S. Patent Application Publication No. 2003 / 0157108; and WO 2004 / 056312, especially Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622; Kanda, Y. et al., Biotechnol. Bioeng. 94 (2006) 680-688; and WO 2003 / 085107).

[0325] Further provided are antibody variants having bisected oligosaccharides, for example, in which the biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants can have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003 / 011878; U.S. Pat. No. 6,602,684; and U.S. Pat. Appl. Pub. No. 2005 / 0123546. Also provided are antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants can have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764.

[0326] c) Fc region mutants In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) that contains an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0327] In certain embodiments, the present invention contemplates antibody variants that retain some but not all of the effector functions, making them desirable candidates for applications in which the half-life of the antibody in vivo is important. Certain additional effector functions (e.g., complementation and ADCC) are not essential or are deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / lack of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely lacks ADCC activity) but retains FcRn binding ability. NK cells, the primary cells mediating ADCC, express Fc (RIII only), whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is reviewed in Table 3 on page 464 of Ravetch, JV and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 83 (1986) 7059-7063; and Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 82 (1985) 1499-1502); U.S. Patent No. 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166 (1987) 1351-1361). Alternatively, non-radioactive assays can be utilized (see, e.g., ACTI™ non-radioactive cytotoxic assays for flow cytometry (CellTechnology, Inc. Mountain View, Calif.) and CytoTox 96® non-radioactive cytotoxic assays (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells.Alternatively or additionally, ADCC activity of a molecule of interest can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes, R. et al., Proc. Natl. Acad. Sci. USA 95 (1998) 652-656. A Cq1 binding assay can also be performed to confirm that an antibody is unable to bind C1q and therefore lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, CDC assays can be performed (see, e.g., Gazzano-Santoro, H. et al., J. Immunol. Methods 202 (1996) 163-171; Cragg, MS et al., Blood 101 (2003) 1045-1052; and Cragg, MS and MJ Glennie, Blood 103 (2004) 2738-2743). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int. Immunol. 18 (2006) 1759-1769).

[0328] Antibodies with reduced effector function include those with one or more substitutions at residues 238, 265, 269, 270, 297, 327, and 329 in the Fc region (U.S. Patent No. 6,737,056).Such Fc variants include Fc variants with substitutions at two or more amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant with substitutions of residues 265 and 297 to alanine (U.S. Patent No. 7,332,581).

[0329] Certain antibody variants with improved or diminished binding to FcRs have been described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields, RL et al., J. Biol. Chem. 276 (2001) 6591-6604).

[0330] In certain embodiments, the antibody variant comprises an Fc region having one or more amino acid substitutions that improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 of the Fc region (residues in EU numbering).

[0331] In some embodiments, mutations are made in the Fc region that result in altered (i.e., either improved or decreased) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie, EE et al., J. Immunol. 164 (2000) 4178-4184.

[0332] Antibodies with improved binding to the neonatal Fc receptor (FcRn), which is responsible for extended half-life and maternal IgG transport to the fetus (Guyer, RL et al., J. Immunol. 117 (1976) 587-593 and Kim, JK et al., J. Immunol. 24 (1994) 2429-2434), have been described in U.S. Patent Application Publication No. 2005 / 0014934. These antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those having a substitution at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434, e.g., a substitution at Fc region residue 434 (U.S. Patent No. 7,371,826).

[0333] For other examples of Fc region variants, see also Duncan, AR and Winter, G., Nature 322 (1988) 738-740; U.S. Patent Nos. 5,648,260; 5,624,821; and WO 94 / 29351.

[0334] d) Cysteine ​​Engineered Antibody Variants In certain embodiments, it may be desirable to form cysteine ​​engineered antibodies, e.g., "thioMAbs," in which one or more residues of the antibody are replaced by a cysteine ​​residue. In certain embodiments, the replaced residues occur in accessible sites of the antibody. By replacing those residues with cysteines, reactive thiol groups are located at accessible sites of the antibody that can be used to conjugate the antibody to other moieties, e.g., drug moieties or linker-drug moieties, to form immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues can be replaced by cysteines: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine ​​engineered antibodies can be generated, for example, as described in U.S. Pat. No. 7,521,541.

[0335] e) Antibody derivative In certain embodiments, the antibodies provided herein can be further modified to contain additional non-proteinaceous moieties that are known and readily available in the art. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde can have advantages during manufacturing due to its stability in water. The polymer can be of any molecular weight and can be branched or unbranched. The number of polymers attached to an antibody can vary, and when more than one polymer is attached, they can be the same or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular property or function of the antibody to be improved, such as whether the antibody derivative will be used therapeutically under defined conditions.

[0336] In another embodiment, a conjugate of an antibody and a non-proteinaceous moiety is provided that can be selectively heated by exposure to radiation. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, NW et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation can be of any wavelength, including but not limited to wavelengths that are not harmful to normal cells, and heats the non-proteinaceous moiety to a temperature that kills cells near the antibody-non-proteinaceous moiety.

[0337] B. Blood-brain barrier shuttle module In one embodiment of all aspects, the antibody is a multispecific antibody having at least one binding specificity for the transferrin receptor and at least one binding specificity for a therapeutic target. In one embodiment, the antibody comprises a first antigen-binding site that binds to the human transferrin receptor and a second antigen-binding site that binds to a brain antigen. In a further embodiment, the brain antigen is selected from the group consisting of Abeta, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), alpha-synuclein, CD20, glucocerebrosidase, or amyloid precursor protein (APP). In a preferred embodiment, the multispecific antibody is i) both transferrin receptor and Abeta, or ii) both the transferrin receptor and CD20, or iii) both the transferrin receptor and alpha-synuclein, or iv) both transferrin receptor and phosphorylated tau, or v) both transferrin receptor and HER2, or vi) both transferrin receptor and glucocerebrosidase Bind to.

[0338] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a heavy chain variable domain of SEQ ID NO:81 and a light chain variable domain of SEQ ID NO:82 for a binding site for Abeta.

[0339] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of heavy chain variable domains of SEQ ID NO:24 and light chain variable domains of SEQ ID NO:37 forming a binding site for the transferrin receptor, and at least a pair of heavy chain variable domains of SEQ ID NO:79 and light chain variable domains of SEQ ID NO:80 for a binding site for human CD20. In one embodiment, the heavy chain variable region comprises a substitution of the amino acid residue at Kabat position 11 with any amino acid, except leucine. In one embodiment, the substitution comprises a substitution of the amino acid residue at Kabat position 11 with a non-polar amino acid. In a preferred embodiment, the substitution comprises a substitution of the amino acid residue at Kabat position 11 in the heavy chain variable domain of SEQ ID NO:79 with an amino acid residue selected from the group consisting of valine, leucine, isoleucine, serine, and phenylalanine.

[0340] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a heavy chain variable domain of SEQ ID NO:83 and a light chain variable domain of SEQ ID NO:84 for a binding site for human alpha-synuclein.

[0341] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:85 and a humanized light chain variable domain obtained from SEQ ID NO:86 for a binding site for human alpha-synuclein.

[0342] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:87 and a humanized light chain variable domain obtained from SEQ ID NO:88 for a binding site for human alpha-synuclein.

[0343] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:89 and a humanized light chain variable domain obtained from SEQ ID NO:90 for a binding site for human alpha-synuclein.

[0344] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:91 and a humanized light chain variable domain obtained from SEQ ID NO:92 for a binding site for human alpha-synuclein.

[0345] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:93 and a humanized light chain variable domain obtained from SEQ ID NO:94 for a binding site for human alpha-synuclein.

[0346] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37 which form a binding site for the transferrin receptor, and a binding site for human glucocerebrosidase.

[0347] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO: 7 and a light chain variable domain of SEQ ID NO: 34 which form a binding site for the transferrin receptor, and at least a pair of a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 84 for a binding site for human alpha-synuclein.

[0348] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:85 and a humanized light chain variable domain obtained from SEQ ID NO:86 for a binding site for human alpha-synuclein.

[0349] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:87 and a humanized light chain variable domain obtained from SEQ ID NO:88 for a binding site for human alpha-synuclein.

[0350] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:89 and a humanized light chain variable domain obtained from SEQ ID NO:90 for a binding site for human alpha-synuclein.

[0351] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:91 and a humanized light chain variable domain obtained from SEQ ID NO:92 for a binding site for human alpha-synuclein.

[0352] In one embodiment the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and at least a pair of a humanized heavy chain variable domain obtained from SEQ ID NO:93 and a humanized light chain variable domain obtained from SEQ ID NO:94 for a binding site for human alpha-synuclein.

[0353] In one embodiment, the antibody is a bispecific antibody comprising at least a pair of a heavy chain variable domain of SEQ ID NO:7 and a light chain variable domain of SEQ ID NO:34 which form a binding site for the transferrin receptor, and a binding site for human glucocerebrosidase.

[0354] Monovalent binding entities that specifically bind to blood-brain barrier receptors have the following binding and transcytosis properties: - Efficient cell binding of BBBR-expressing cells as monovalent binding entities - Efficient in vitro transcytosis as a monovalent binding entity - Human-Cynomolgus cross-reactivity (e.g. in BIAcore and FACS experiments) can be characterized in terms of

[0355] Transcytosis screening can be performed in a hCMEC / D3-based assay. The assay can be performed in a pulse-chase format. hCMEC / D3 brain endothelial cells are incubated with monovalent binding entities for 1 hour, then washed, and the following parameters are measured at 0 and 4 hours after washing: i) The amount of monovalent binding entity taken up into the cells during the loading phase ii) Basal amount of monovalent binding entities 4 hours after loading and washing iii) Apical amount of monovalent binding entities 4 hours after loading and washing iv) Amount of monovalent binding entity in cells (by cell lysis) at 0 hours and 4 hours after loading and washing v) Total amount of monovalent binding entities at 0 and 4 hours after loading and washing

[0356] To be suitable as a monovalent binding entity in the blood-brain barrier shuttle module reported herein, an anti-transferrin receptor antibody (e.g., as a monovalent binding entity) must i) be taken up by hCMEC / D3 cells (endocytosis), ii) be transported outside of hCMEC / D3 cells (exocytosis), and iii) be stable within hCMEC / D3 cells (not transported to endosomes for degradation or have low transport).

[0357] Thus, in one embodiment, a monovalent binding entity is characterized in an hCMEC / D3-based assay by: i) (substantial) uptake into hCMEC / D3 cells during a 1 hour loading phase; ii) release into the apical and / or basolateral compartments after the loading period and washing steps within 4 hours; and iii) a low (intracellular) degradation rate.

[0358] In one embodiment, loading is for 1 hour at a concentration of about 2.67 μg / mL monovalent binding entity.

[0359] To be suitable as a monovalent binding entity for the blood-brain barrier shuttle module reported herein, a monovalent binding entity must have a binding affinity of at least one of the following thresholds in the hCMEC / D3-based assay described above: i) the amount of monovalent binding entity taken up into the cells during a loading phase of 400 pg or more; ii) a basal amount of monovalent binding entities 4 hours after loading and washing of 100 pg or more; and iii) Apical amount of monovalent binding entity 4 hours after loading and washing of 150 pg or more It has been found that it is necessary to show

[0360] The mouse anti-human transferrin receptor antibody 128.1 (for variable region sequences see WO 93 / 10819 and SEQ ID NOs: 64 and 65) can be taken as a reference. In this case, to be suitable as a monovalent binding entity of the blood-brain barrier shuttle module reported herein, the monovalent binding entity must meet the following thresholds in the hCMEC / D3-based assay described above: i) the amount of monovalent binding entity internalized into the cells during the loading phase that is 60% or more of the loading of antibody 128.1; ii) a basal amount of monovalent binding entities 4 hours after loading and washing that is greater than or equal to 60% of the basal amount of antibody 128.1; and iii) an apical amount of monovalent binding entities 4 hours after loading and washing that is greater than or equal to 60% of the apical amount of antibody 128.1 must be shown.

[0361] The hCMEC / D3 based assay can be performed as follows (this is one embodiment of all aspects reported herein).

[0362] Culture medium and supplements for hCMEC / D3 (see WO 2006 / 056879 and Weksler, BB, et al., FASEB J. 19 (2005) 1872-1874) can be obtained from Lonza. hCMEC / D3 cells (passages 26-29) can be grown to confluence on collagen-coated coverslips (microscope) or flasks in EBM2 medium containing 2.5% FBS, ¼ of added growth factors, and fully supplemented with added hydrocortisone, gentamicin, and ascorbic acid.

[0363] For all transcytosis assays, high density pores (1 × 10 8 pieces / cm 2) PET membrane filter inserts (pore size 0.4 μm, diameter 12 mm) are / can be used in 12-well cell culture plates. The medium volumes are calculated to be 400 μL and 1600 μL for the apical and basolateral chambers, respectively. The apical chamber of the filter insert is filled with rat tail collagen I (7.5 μg / cm 2 ), and subsequently coated / coated with fibronectin (5 μg / mL). Each incubation lasts for 1 h at RT. hCMEC / D3 cells are cultured in EBM2 medium for 10-12 days to form a confluent monolayer (approximately 2 × 10 5 pieces / cm 2 ) for 1 hour or overnight (o / n). Empty filters can be blocked / blocked in PBS containing 1% BSA for 1 hour or overnight (o / n) and then subsequently calibrated in EBM2 for at least 1 hour prior to the assay.

[0364] The assay (see Figure 1 for a scheme of the assay method) was performed in serum-free EBM2 medium reconstituted as described herein. On the day of the assay, cells were serum-starved for 60 min to deplete the natural ligands of the relevant blood-brain barrier receptors. Filter inserts with or without cells (but blocked overnight in complete medium) were incubated apically with the relevant monoclonal antibodies (monovalent binding entities) for 1 h at 37°C. Monolayers were washed three times for 3-5 min at room temperature (RT) in serum-free medium on the apical side (400 μL) and basolateral sides (1600 μL), respectively. Pre-warmed medium was added to the apical chamber and the filters were transferred to a new 12-well plate (blocked overnight in PBS containing 1% BSA) containing 1600 μL of pre-warmed medium. At this point, the filters with or without cells were dissolved in 500 μL of RIPA buffer to determine the uptake of specific antibodies (monovalent binding entities). The remaining filters were incubated at 37° C. or 4° C. Samples were collected at various time points to determine the apical and / or basolateral release of antibodies (monovalent binding entities). The antibody content in the samples can be quantified using a highly sensitive IgG ELISA (see Example 9). For each time point, data should be generated from two blank filters and three filter-cell cultures.

[0365] C. Recombinant Methods and Compositions Antibodies can be produced using recombinant methods and compositions described, for example, in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid is provided that encodes an anti-transferrin receptor antibody described herein. Such a nucleic acid can encode an amino acid sequence comprising the VL and / or an amino acid sequence comprising the VH of the antibody (e.g., the light chain and / or the heavy chain of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such a nucleic acid are provided. In a further embodiment, a host cell comprising such a nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., has been transformed by (1) or (2)) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL and an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, such as a Chinese Hamster Ovary (CHO) cell or a lymphocytic cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of preparing an anti-transferrin receptor antibody is provided, which comprises culturing a host cell comprising an antibody-encoding nucleic acid as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0366] For recombinant production of an anti-transferrin receptor antibody, for example, nucleic acid encoding the antibody described above is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using conventional techniques (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0367] Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, KA, In: Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, which describes the expression of antibody fragments in E. coli). After expression, the antibody can be isolated in a soluble fraction from the bacterial cell paste and can be further purified.

[0368] In addition to prokaryotes, eukaryotic microbes, such as fungi or yeast, including filamentous fungi and yeast strains in which the glycosylation pathway has been "humanized" resulting in the production of antibodies with partially or fully human glycosylation patterns, are suitable cloning or expression hosts for antibody-encoding vectors. See Gerngross, TU, Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.

[0369] Suitable host cells for the expression of glycosylated antibodies can also be obtained from multicellular organisms (invertebrates and vertebrates). Examples of invertebrates include plants and insect cells. Numerous baculovirus strains have been identified and can be used with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[0370] Plant cell cultures can also be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe the PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0371] Vertebrate cells can also be used as hosts, for example mammalian cell lines adapted to grow in suspension can be useful. Other examples of useful mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney lines (e.g., 293 or 293 cells described in Graham, FL et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, JP, Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); e.g., Mather, JP et al., Annals NY Acad. Sci. 383 (1982) Other useful mammalian host cell lines are DHFR cells, described in -Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220), and melanoma cell lines, e.g., Y0, NS0, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

[0372] D. Assay Methods The anti-transferrin receptor antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assay methods known in the art.

[0373] 1. Binding Assay Method In one embodiment, the antibodies of the invention are tested for their antigen binding activity, for example, by known methods such as ELISA, alphaLISA, Western blot, antibody, or reverse phase array.

[0374] In an exemplary ELISA or alphaLISA assay, transferrin receptor in solution (cell supernatant, cell or tissue lysate, body fluid, etc.) is bound by a capture antibody that specifically binds to a first epitope on the transferrin receptor or on the transferrin receptor in a particular conformation. A detection antibody linked to a detection entity specifically binds to a second epitope or conformation of the transferrin receptor. The readout is based on the detection entity (chemiluminescence, fluorescence, energy transfer induced luminescence, etc.).

[0375] In the case of antibody arrays, antibodies are spotted onto glass or nitrocellulose chips. The slide is blocked, incubated with a solution containing transferrin receptor, and washed to remove unbound antibodies. Bound antibodies are detected with corresponding fluorescently labeled secondary antibodies. The fluorescent signal is measured by a fluorescent slide scanner. Similarly, for reversed-phase arrays, recombinant transferrin receptor, cell supernatants, cell or tissue lysates, body fluids, etc. are spotted onto glass or nitrocellulose chips. The slide is blocked, and individual arrays are incubated with antibodies against specific epitopes on the transferrin receptor. Unbound antibodies are washed away, and bound antibodies are detected with corresponding fluorescently labeled secondary antibodies. The fluorescent signal is measured by a fluorescent slide scanner (Dernick, G., et al., J. Lipid Res. 52 (2011) 2323-2331).

[0376] E. Methods and Compositions for Diagnostics and Detection In certain embodiments, any of the anti-transferrin receptor antibodies provided herein are useful for detecting the presence of human transferrin receptor in a biological sample. As used herein, the term "detecting" includes quantitative or qualitative detection. In certain embodiments, the biological sample comprises a cell or tissue, e.g., brain tissue.

[0377] In one embodiment, an anti-transferrin receptor antibody is provided for use in a diagnostic or detection method. In a further aspect, a method is provided for detecting the presence of transferrin receptor in a biological sample. In certain embodiments, the method comprises contacting a biological sample with an anti-transferrin receptor antibody described herein under conditions that allow binding of the transferrin receptor antibody to the transferrin receptor, and detecting whether a complex is formed between the anti-transferrin receptor antibody and the transferrin receptor. Such a method can be an in vitro or in vivo method. In one embodiment, for example, where the transferrin receptor is a biomarker for selecting patients, the anti-transferrin receptor antibody is used to select subjects eligible for treatment with the anti-transferrin receptor antibody.

[0378] Exemplary disorders that can be diagnosed using the antibodies of the invention include neurodegeneration associated with brain iron accumulation type I (NBIA1), pure autonomic dysfunction, Down's syndrome, Gehrig's disease, and some Lewy body diseases, such as diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBVAD), certain forms of Gaucher disease, and Parkinson's disease dementia (PDD).

[0379] In certain embodiments, labeled anti-transferrin receptor antibodies are provided. Labels include, but are not limited to, labels or moieties that are directly detected (e.g., fluorescent, chromophore, electron dense, chemiluminescent, and radioactive labels) as well as moieties such as enzymes or ligands that are indirectly detected, for example, by enzymatic reactions or molecular interactions. Exemplary labels include radioisotopes. 32 P, 14 C. 125 I, 3 H, and 131I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, enzymes that utilize hydrogen peroxide to oxidize dye precursors such as luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), in combination with HRP, lactoperoxidase, or microperoxidase, luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, carbohydrate oxidases such as glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, biotin / avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

[0380] F. Pharmaceutical Preparations Pharmaceutical formulations of the anti-transferrin receptor antibodies described herein are prepared in lyophilized or aqueous solutions by mixing such antibodies having the desired degree of purity with any one or more pharma- ceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed, and may contain any of the following: buffers, e.g., phosphate, citric acid, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens, e.g., methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins. Examples of suitable pharmacopoeitic carriers include, but are not limited to, interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), such as human soluble PH-20 hyaluronidase glycoproteins, such as rhuPH20 (HYLENEX®, Baxter International, Inc.).Certain exemplary sHASEGPs, including rhuPH20, and methods of use are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0381] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.

[0382] The formulations herein may contain, as necessary for the particular indication being treated, two or more active ingredients, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts effective for the intended purpose.

[0383] The active ingredient can be encapsulated, for example, in microcapsules prepared by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).

[0384] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

[0385] Formulations to be used for in vivo administration are generally sterile. Sterility is readily accomplished, for example, by filtration through sterile filtration membranes.

[0386] G. Treatment Methods and Compositions Any of the anti-TfR antibodies provided herein can be used in therapeutic methods. In one aspect, an anti-TfR antibody for use as a medicament is provided. For example, the invention provides a method of transporting a therapeutic compound across the blood-brain barrier, comprising exposing an anti-TfR antibody (e.g., a multispecific antibody that binds both TfR and a brain antigen) bound to a therapeutic compound to the BBB, such that the antibody transports the therapeutic compound bound to it across the BBB. In another example, the invention provides a method of transporting a neuropathic agent across the blood-brain barrier, comprising exposing an anti-TfR antibody (e.g., a multispecific antibody that binds both TfR and a brain antigen) of the invention bound to a brain-pathic agent to the BBB, such that the antibody transports the neuropathic agent bound to it across the BBB. In one embodiment, the BBB is in a mammal (e.g., a human), such as one with a neuropathic disorder. Said neurological disorders include, but are not limited to, Alzheimer's disease (AD), stroke, dementia, muscular dystrophy (MD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), cystic fibrosis, Angelman syndrome, Liddle syndrome, Parkinson's disease, Pick's disease, Paget's disease, cancer, traumatic brain injury, etc. In one embodiment, the neurological disorder is selected from peripheral nerves, amyloidosis, cancer (e.g. involving the CNS or brain), eye disease or disorder, viral or bacterial infection, inflammation (e.g. of the CNS or brain), ischemia, neurodegenerative diseases, stroke, behavioral disorders, lysosomal storage diseases, etc. The antibodies of the present invention are particularly suitable for the treatment of such neurological disorders due to their ability to transport one or more associated active ingredients / conjugated therapeutic compounds across the BBB and into the CNS / brain where such disorders have their molecular, cellular, or viral / bacterial basis.Peripheral neuropathies are diseases or disorders of the nervous system characterized by inappropriate or uncontrolled nerve signaling or a deficit in such signaling, and include, but are not limited to, chronic pain (including nociceptive pain), pain caused by injury to body tissues, including cancer-related pain, neuropathic pain (pain caused by abnormalities in the nerves, spinal cord, or brain), and psychiatric pain (associated entirely or mostly with a psychiatric disorder), headaches, migraines, peripheral nerve pain, and the signs and symptoms associated with such peripheral neuropathies, such as dizziness or nausea.

[0387] For peripheral neuropathy, the nerve agent of choice may be an analgesic, which may include narcotic / opioid analgesics (i.e., morphine, fentanyl, hydrocodone, meperidine, methadone, oxymorphone, pentazocine, propoxyphene, tramadol, codeine, and oxycodone), nonsteroidal anti-inflammatory drugs (NSAIDs) (i.e., ibuprofen, naproxen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin, ketorolac, mefenamic acid, metronidazole, melamine, benzodiazepine, benzodiazepine, benzocaine ... anti-migraine drugs (i.e., sumatriptan, almotriptan, frovatriptan, sumatriptan, rizatriptan, eletriptan, zolmitriptan, dihydroergotamine, eletriptan, and ergotatriptan), ... acetaminophen, salicylates (i.e., aspirin, choline salicylate, magnesium salicylate, diflunisal, and salsalate), anticonvulsants (i.e., carbamazepine, clonazepam, gabapentin, lamotrigine, pregabalin, tiagabine, and topiramate), anesthetics (i.e., isoflurane, trichloroethylene, halothane, sevoflurane, benzocaine, chloroprocaine, cocaine, cyclomethicine, dimethicone, Antidote nerve agents include, but are not limited to, tocaine, propoxycaine, procaine, novocaine, proparacaine, tetracaine, articaine, bupivacaine, carticaine, cinchocaine, etidocaine, levobupivacaine, lidocaine, mepivacaine, piperocaine, prilocaine, ropivacaine, trimecaine, saxitoxin, and tetrodotoxin), and cox-2 inhibitors (i.e., celecoxib, rofecoxib, and valdecoxib). For peripheral neuropathy with dizziness, nerve agents that are antivertigo agents can be selected. Antivertigo agents include, but are not limited to, meclizine, diphenhydramine, promethazine, and diazepam. For peripheral neuropathy with nausea, nerve agents that are antiemetic agents can be selected.Such antiemetic agents include, but are not limited to, promethazine, chlorpromazine, prochlorperazine, trimethobenzamide, and metoclopramide.

[0388] Amyloidosis is a group of diseases and disorders associated with extracellular proteinaceous deposition in the CNS, including, but not limited to, secondary amyloidosis, age-related amyloidosis, Alzheimer's disease (AD), mild cognitive impairment (MCI), Lewy body disease, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type); Guam Parkinson-Dementia Syndrome, cerebral amyloid angiopathy, Huntington's disease, progressive supranuclear palsy, multiple sclerosis; Creutzfeldt-Jakob disease, Parkinson's disease, transmissible spongiform encephalopathy, HIV-associated dementia, amyotrophic lateral sclerosis (ALS), inclusion body myositis (IBM), and eye diseases associated with beta-amyloid deposition (i.e., macular degeneration, drusen-associated optic neuropathy, and cataracts).

[0389] For amyloidosis, beta-secretase, tau, presenilin, amyloid precursor protein or portions thereof, amyloid beta peptide or oligomers or fibrils thereof, death receptor 6 (DR6), receptor for advanced glycation end products (RAGE), parkin, and huntingtin; cholinesterase inhibitors (i.e., galantamine, donepezil, rivastigmine, and tacrine); NMDA receptor antagonists (i.e., memantine), monoamine depleting agents (i.e., tetrabenazine); ergoloid mesylates; anticholinergic antiparkinsonian agents (i.e., procyclidine, diphenhydramine, trihexylphenidyl, benztropine, biperiden, and trihexyphenidyl); dopaminergic antiparkinsonian agents (i.e., entacapone, selegiline, pramipexole, bromocriptine, rotigotine, serigiline, The neuroprotective agent may be selected from the group consisting of, but is not limited to, antibodies or other binding molecules (including but not limited to small molecules, peptides, aptamers, or other protein binders) that specifically bind to a target selected from: ropinirole, rasagiline, apomorphine, carbidopa, levodopa, pergolide, tolcapone, and amantadine; tetrabenazine; anti-inflammatory agents (including but not limited to nonsteroidal anti-inflammatory agents (i.e., indomethacin and the other compounds listed above)); hormones (i.e., estrogen, progesterone, and leuprolide); vitamins (i.e., folic acid and nicotinamide); dimebolins; homotaurines (i.e., 3-aminopropanesulfonic acid; 3APS); serotonin receptor activity modulators (i.e., xaliproden); interferons, and glucocorticoids.

[0390] Cancers of the CNS are characterized by abnormal proliferation of one or more CNS cells (i.e., neuronal cells) and include, but are not limited to, gliomas, glioblastoma multiforme, meningiomas, astrocytomas, acoustic neuromas, chondromas, oligodendrogliomas, medulloblastomas, gangliogliomas, schwannomas, neurofibromas, neuroblastomas, and epidural, intramedullary, or intradural tumors, or CNS metastases of peripheral tumors, e.g., CD20- or HER2-positive cancers.

[0391] For cancer, chemotherapy nerve agents may be chosen.

[0392] Examples of chemotherapeutic agents include alkylating agents, such as thiotepa and CYTOXAN® cyclophosphamide; alkylsulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylamelamines (altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine). olomelamime); acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicine; betulinic acid; camptothecins (including synthetic analogs topotecan (HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; kallistatin; CC-1 065 (including its synthetic analogues adozelesin, carzelesin, and bizelesin); podophyllotoxins; podophyllic acid; teniposide; cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (including the synthetic analogues KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictin; spongiostatins; nitrogen mustards, e.g., chlorambucil, chlornaphazine, cholophosphamid e), estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobuenbiquine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma II and calicheamicin omega II (see, e.g., Angew. Chem. Intl. Ed. Engl., 33 (1994) 183-186);Dynemicins, including dynemicin A; esperamicin; and neocarzinostatin chromophores and related chromogenic proteins, enediyne antibiotic chromophores), aclacinomycin, actinomycin, authramicin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (mol doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins, such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenitin, mex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-25 azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calsterone, propionate, dromostanolone phosphate, epithiostanol, mepitiostane, testolactone; antiadrenal drugs such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatraxate; defofamine; demecolcine; diazicon; eflornithine; elliptinium acetate; epothilone; etoglucide; gallium nitrate;Hydroxyurea; lentinan; lonidanine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitraerine; pentostatin; phenamet; pirarubicin; rosoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR; razoxane; rhizoxin; schizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veracrine A, roridin A, and anguidine); urethanes; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannommustine; mitobronitol; mitolactol; 5-pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids such as TAXOL® paclitaxel (Bristol-Myers-Squibb Oncology, Princeton, NJ), ABRAXANETM chromophore-free, albumin engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Illinois) and TAXOTERE® docetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogues, such as cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovobin; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitors RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine (XELODA®);Pharmaceutically acceptable salts, acids, or derivatives of any of the above, as well as combinations of two or more of the above, such as CHOP (an abbreviation for the combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone) and FOLFOX (an abbreviation for the treatment regimen with oxaliplatin (ELOXATIN™) combined with 5-FU and leucovorin);

[0393] This definition of chemotherapeutic agents also includes anti-hormonal agents, which act to control, reduce, block, or inhibit the action of hormones that can promote cancer growth, often in the form of systemic or whole-body treatment. Anti-hormonal agents can be hormones themselves. Examples include anti-estrogens and selective estrogen receptor modulators (SERMs) (e.g., including tamoxifen (including NOLVADEX® tamoxifen), EVISTA® raloxifene, droloxifene, 4-hydroxytamoxifen, trioxyfene, ketoxifene, LY117018, onapristone, and FARESTON® toremifene); anti-progesterones; estrogen receptor downregulators (ERDs); agents that act to suppress or shut down the ovaries, such as luteinizing hormone releasing hormone (LHRH) agonists, such as LUPRON® and ELIGA®. RD® leuprolide acetate, goserelin acetate, buserelin acetate, and tripterelin; other antiandrogens such as flutamide, nilutamide, and bicalutamide; and aromatase inhibitors which block the enzyme aromatase (aromatase controls estrogen production in the adrenal glands), such as 4(5)-imidazole, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestanie, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX® anastrozole.In addition, such definition of chemotherapeutic agent includes but is not limited to bisphosphonates, such as clodronate (e.g., BONEFOS® or OSTAC®), DIDROCAL® etidronate, NE-58095, ZOMETA® zoledronic acid / zoledronate, FOSAMAX® alendronate, AREDIA® pamidronate, 5 SKELID® tiludronate, or ACTONEL® risedronate, and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signal transduction pathways involved in abnormal cell proliferation, such as PKC-alpha, Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines, such as THERATOOPE® vaccines and gene therapy vaccines, such as ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; LURTOTECAN® topoisomerase 1 inhibitors; ABARELIX® rmRH; lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small molecule inhibitor, also known as GW572016), as well as pharmaceutically acceptable salts, acids, or derivatives of any of the above.

[0394] Another group of compounds that can be selected as a neuromodulator for the treatment or prevention of cancer are anti-cancer immunoglobulins (including, but not limited to, trastuzumab, pertuzumab, bevacizumab, alemtuzumab, cetuximab, gemtuzumab, ozogamicin, ibritumomab, tiuxetan, panitumumab, and rituximab). In some cases, antibodies or conjugates that are coupled with a toxic label can be used to target and kill desired cells (i.e., cancer cells). Such antibodies include, but are not limited to, tositumomab or trastuzumab entansine that contain a 131I radiolabel.

[0395] An ocular disease or disorder, for purposes herein, is a disease or disorder of the eye, taking into consideration CNS organs that are isolated by the BBB. Ocular diseases or disorders include disorders of the sclera, cornea, iris, and ciliary body (i.e., scleritis, keratitis, corneal ulcer, corneal abrasion, snow blindness, arc eye, Thygeson's punctate superficial keratitis, corneal neovascularization, Fuchs' dystrophy, keratoconus, keratitis sicca, iritis, and uveitis), disorders of the lens (i.e., cataracts), disorders of the choroid and retina (i.e., retinal detachment, retinoschisis, hypertensive retinopathy, diabetic retinopathy, retinopathy, retinopathy of prematurity, age-related macular degeneration, macular degeneration (dry or wet), preretinal membranes, retinitis pigmentosa, and macular edema), glaucoma, floaters, disorders of the optic nerve and visual pathway (i.e., Leber's hereditary optic neuropathy, and optic disc drusen), ocular muscle / binocular movement visual accommodation / refractive disorders (i.e., strabismus, ophthalmoplegia, progressive external ophthalmoplegia, esotropia, exotropia, hyperopia, myopia, astigmatism, anisometropia, presbyopia, and ophthalmoplegia), visual impairments and blindness (i.e., amblyopia, Leber congenital amaurosis, scotoma, color blindness, color blindness, night blindness, blindness, river blindness, and microphthalmia / ocular coloboma), red eye, Argyll-Robertson pupil, keratomycosis, xerophthalmia, and andaniridia.

[0396] For ocular diseases or disorders, antiangiogenic ophthalmic agents (i.e., bevacizumab, ranibizumab, and pegaptanib), ophthalmic glaucoma agents (i.e., carbachol, epinephrine, demecarium bromide, apraclonidine, brimonidine, brinzolamide, levobunolol, timolol, betaxolol, dorzolamide, bimatoprost, carteolol, metipranolol, dipivefrin, travoprost, and latanoprost), carbonic anhydrase inhibitors (i.e., methazolamide and acetazolamide), ophthalmic antihistamines (i.e., naphazoline, phenylephrine, and tetrahydrozoline), eye drops, ophthalmic steroids (i.e., fluorometholone, prednisolone, loteprednol, dexamethasone, difluprednate, rimexolone, fluocinolone, medrysone, and triamcinolone), ophthalmic anesthetics (i.e., lidocaine, proparacaine, and tetracaine), ophthalmic anti-infectives (i.e., levofloxacin, , gatifloxacin, ciprofloxacin, moxifloxacin, chloramphenicol, bacitracin / polymyxin B, sulfacetamide, tobramycin, azithromycin, besifloxacin, norfloxacin, sulfisoxazole, gentamicin, idoxuridine, erythromycin, natamycin, gramicidin, neomycin, ofloxacin, trifluridine, ganciclovir, vidarabine), ophthalmic anti-inflammatory agents (i.e., nepafenac, ketoconazole ... Nerve agents that are ophthalmic antihistamines or decongestants (i.e., lac, flurbiprofen, suprofen, cyclosporine, triamcinolone, diclofenac, and bromfenac) and ophthalmic antihistamines or decongestants (i.e., ketotifen, olopatadine, epinastine, naphazoline, cromolyn, tetrahydrozoline, pemirolast, bepotastine, naphazoline, phenylephrine, nedocromil, lodoxamide, phenylephrine, emedastine, and azelastine) may be selected.

[0397] Viral or microbial infections of the CNS include, but are not limited to, infections with viruses (i.e., influenza, HIV, poliovirus, rubella), bacteria (i.e., Neisseria species, Streptococcus species, Pseudomonas species, Proteus species, E. coli, S. aureus, Pneumococcus species, Meningococcus species, Haemophilus species, and Mycobacterium tuberculosis), and other microorganisms such as fungi (i.e., yeast, Cryptococcus neoformans), parasites (i.e., toxoplasma gondii) or amoebas, and result in CNS pathophysiology including, but not limited to, meningitis, encephalitis, myelitis, vasculitis, and abscesses, which may be acute or chronic.

[0398] For viral or microbial diseases, antiviral compounds (amantadine antivirals (i.e., rimantadine and amantadine), antiviral interferons (i.e., peg-interferon alpha-2b), chemokine receptor antagonists (i.e., maraviroc), integrase strand transfer inhibitors (i.e., raltegravir), neuraminidase inhibitors (i.e., oseltamivir and zanamivir), non-nucleoside reverse transcriptase inhibitors (i.e., efavirenz, etravirine, delavirdine, and nevirapine), nucleoside reverse transcriptase inhibitors (i.e., tenofovir, abacavir, lamivudine, zidovudine, stavudine, entecavir, emtricitabine, adefovir, zalcitabine, telbivudine, and didanosine), protease inhibitors (i.e., darunavir, atazanavir, fosamprenavir, tipranavir, ritonavir, nelfinavir, amprenavir, indinavir, and saquinavir), purine nucleosides (i.e., valacyclovir, famciclovir, acyclovir, ribavirin, ganciclovir, valganciclovir, Antivirals (i.e., enfuvirtide, foscarnet, palivizumab, and fomivirsen), antibiotics (aminopenicillins (i.e., amoxicillin, ampicillin, oxacillin, nafcillin, cloxacillin, dicloxacillin, flucoxacillin, temocillin, azlocillin, carbenicillin, ticarcillin, mesothelicillin, piperacillin, and bacampicillin), cephalosporins (i.e., cefazolin, cephalexin, cephalothin, cephamadol, ceftriaxone, cefotaxime ... cephaladine, cefpodoxime, ceftazidime, cefadroxil, cephradine, loracarbef, cefotetan, cefuroxime, cefprozil, cefaclor, and cefoxitin), carbapenems / penems (i.e., imipenem, meropenem, ertapenem, faropenem, and doripenem), monobactams (i.e., aztreonam, tigemonam, norcardicin A, and tabtoxin-beta-lactam), beta-lactamase inhibitors in combination with another beta-lactam antibiotic (i.e., clavulanic acid, tazobactam, and sulbactam),Aminoglycosides (i.e., amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, and paromomycin), ansamycins (i.e., geldanamycin and herbimycin), carbacephems (i.e., loracarbef), glycopeptides (i.e., teicoplanin and vancomycin), macrolides (i.e., azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, and spectrophotaxis). nomycin), monobactams (i.e., aztreonam), quinolones (i.e., ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, and temafloxacin), sulfonamides (i.e., mafenide, sulfonamide chrysoidine, sulfacetamide, sulfadiazine, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, , trimethoprim, and sulfamethoxazole), tetracyclines (i.e., tetracycline, demeclocycline, doxycycline, minocycline, and oxytetracycline), antineoplastic or cytotoxic antibiotics (i.e., doxorubicin, mitoxantrone, bleomycin, daunorubicin, dactinomycin, epirubicin, idarubicin, plicamycin, mitomycin, pentostatin, and valrubicin), as well as various antibacterial compounds (i.e., bacitracin, colistin, and polymyxin B), antifungal agents (sulfamethoxazole, ... i.e., metronidazole, nitazoxanide, tinidazole, chloroquine, indoquinol, and paromomycin), and antiparasitic agents (quinine, chloroquine, amodiaquine, pyrimethamine, sulfadoxine, proguanil, mefloquine, atovaquone, primaquine, artemesinin, halofantrine, doxycycline, clindamycin, mebendazole, pyrantel pamoate, thiabendazole, diethylcarbamazine, ivermectin, rifampin, amphotericin B, melarsoprol, efornithine,Nerve agents may be selected, including but not limited to, benzodiazepines (including but not limited to benzodiazepines and albendazole).

[0399] Inflammation of the CNS includes, but is not limited to, inflammation caused by injury to the CNS, which may be a physical injury (i.e., due to an accident, surgery, brain trauma, spinal cord injury, concussion) or an injury due to or associated with one or more other diseases or disorders of the CNS (i.e., an abscess, cancer, viral or microbial infection).

[0400] For inflammation of the CNS, neuroprotective agents can be selected that address the inflammation itself (i.e., nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen) or that treat the underlying cause of the inflammation (i.e., antiviral or anticancer drugs).

[0401] As used herein, ischemia of the CNS refers to a group of disorders related to abnormal blood flow or vascular behavior in the brain or its causes, including, but not limited to, focal cerebral ischemia, global cerebral ischemia, stroke (i.e., subarachnoid hemorrhage and cerebral hemorrhage), and aneurysm.

[0402] For ischemia, neuroprotective agents may be selected, including, but not limited to, thrombolytic agents (i.e., urokinase, alteplase, reteplase, and tenecteplase), platelet aggregation inhibitors (i.e., aspirin, cilostazol, clopidogrel, prasugrel, and dipyridamole), statins (i.e., lovastatin, pravastatin, fluvastatin, rosuvastatin, atorvastatin, simvastatin, cerivastatin, and pitavastatin), and compounds that improve blood flow or vascular compliance, including, for example, blood pressure medications.

[0403] Neurodegenerative diseases are a group of diseases or disorders associated with loss of function or death of nerve cells in the CNS, including, but not limited to, adrenoleukodystrophy, Alexander disease, Alpers disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten disease, Cockayne's syndrome, corticobasal degeneration, degeneration caused by or associated with amyloidosis, Friedreich's ataxia, frontotemporal lobar degeneration, Kennedy's disease, multiple system atrophy, multiple sclerosis, primary lateral sclerosis, progressive supranuclear palsy, spinal muscular atrophy, transverse myelitis, Refsum's disease, and spinocerebellar ataxia.

[0404] For neurodegenerative diseases, a neuroagent that is a growth hormone or neurotrophic factor can be selected. Examples include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-4 / 5, fibroblast growth factor (FGF)-2 and other FGFs, neurotrophin (NT)-3, erythropoietin (EPO), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, TGF-beta, vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL-1ra), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor. These include, but are not limited to, glial cell lineage-derived neurotrophic factor (GFR), granulocyte colony-stimulating factor (CSF), granulocyte-macrophage-CSF, netrin, cardiotrophin-1, hedgehog, leukemia inhibitory factor (LIF), midkine, pleiotrophin, bone morphogenetic protein (BMP), netrin, saposin, semaphorin, and stem cell factor (SCF).

[0405] Seizure disorders and disorders of the CNS are associated with inappropriate and / or abnormal electrical conduction in the CNS and include epilepsy (i.e., absence seizures, atonic seizures, benign rolandic epilepsy, childhood absence epilepsy, clonic seizures, complex partial seizures, frontal lobe epilepsy, febrile convulsions, infantile spasms, juvenile myoclonic epilepsy, juvenile absence epilepsy, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, Dravet syndrome, Ohtahara syndrome, West syndrome, myoclonic seizures, mitochondrial disorders, progressive myoclonic epilepsy, psychogenic seizures, reflex seizures, etc.). The seizure disorders include, but are not limited to, epilepsy, Rasmussen's syndrome, simple partial seizures, secondary generalized seizures, temporal lobe epilepsy, tonic-clonic seizures, tonic seizures, psychomotor seizures, limbic epilepsy, partial onset seizures, generalized onset seizures, status epilepticus, abdominal epilepsy, akinetic seizures, autonomic seizures, widespread bilateral myoclonus, catamenial epilepsy, astatic seizures, affective seizures, focal seizures, galvanic seizures, Jackson's march, Lafora's disease, motor seizures, multifocal seizures, nocturnal seizures, photosensitive seizures, pseudoseizures, sensory seizures, petit mal seizures, Sylvan seizures, withdrawal seizures, and visual reflex seizures. For seizure disorders, neurological agents that are anticonvulsants or antiepileptic agents can be selected.The anticonvulsant or antiepileptic agent may be any of the following: barbiturates (i.e., primidone, metharbital, mephobarbital, allobarbital, amobarbital, aprobarbital, alphenal, barbital, bralobarbital, and phenobarbital), benzodiazepines (i.e., diazepam, clonazepam, and lorazepam), carbamates (i.e., felbamate), carbonic anhydrase inhibitors (i.e., acetazolamide, topiramate, and zonisamide), dibenzazepines (i.e., rufinamide, carbamazepine, and oxcarbazepine), fatty acid derivatives (i.e., divalproex and valproic acid), gamma aminobutyric acid analogs (i.e., pregabalin, gabapentin, and valproic acid), and the like. These include, but are not limited to, anticonvulsants such as phenytoin, ethotoin, fosphenytoin, and mephenytoin, miscellaneous anticonvulsants (i.e., lacosamide and magnesium sulfate), progestins (i.e., progesterone), oxazolidinedione anticonvulsants (i.e., paramethadione and trimethadione), pyrrolidine anticonvulsants (i.e., levetiracetam), succinimide anticonvulsants (i.e., ethosuximide and methsuximide), triazine anticonvulsants (i.e., lamotrigine), and urea anticonvulsants (i.e., phenacemide and feneturide).

[0406] Behavioral disorders are disorders of the CNS characterized by abnormal behavior on the part of the affected subject, including, but not limited to, sleep disorders (i.e., insomnia, parasomnias, night terrors, circadian rhythm sleep disorders, and narcolepsy), mood disorders (i.e., depression, suicidal depression, anxiety, chronic affective disorders, phobias, panic attacks, obsessive-compulsive disorder, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), chronic fatigue syndrome, agoraphobia, post-traumatic stress disorder, bipolar disorder), eating disorders (i.e., anorexia or bulimia), chronic hallucinatory psychoses, developmental behavioral disorders (i.e., autism, Rett syndrome, Asperger's syndrome), personality disorders, and psychotic disorders (i.e., schizophrenia, delusional disorder, etc.).

[0407] For behavioral disorders, the neuromodifier can be selected from behavior-modifying compounds, including atypical antipsychotics (i.e., risperidone, olanzapine, apripiprazole, quetiapine, paliperidone, asenapine, clozapine, iloperidone, and ziprasidone), phenothiazine antipsychotics (i.e., prochlorperazine, chlorpromazine, fluphenazine, perphenazine, trifluoperazine, thioridazine, and mesoridazine), thioxanthenes (i.e., thiothixene), miscellaneous antipsychotics (i.e., pimozide, lithium, molindone, haloperidol, and loxapine), and select Selective serotonin reuptake inhibitors (i.e., citalopram, escitalopram, paroxetine, fluoxetine, and sertraline), serotonin-norepinephrine reuptake inhibitors (i.e., duloxetine, venlafaxine, desvenlafaxine), tricyclic antidepressants (i.e., doxepin, clomipramine, amoxapine, nortriptyline, amitriptyline, trimipramine, imipramine, protriptyline, and desipramine), tetracyclic antidepressants (i.e., mirtazapine and maprotiline), phenylpiperazine antidepressants (i.e., phenylpiperazine antidepressants), Depressants (i.e., trazodone and nefazodone), monoamine oxidase inhibitors (i.e., isocarboxazid, phenelzine, selegiline, and tranylcypromine), benzodiazepines (i.e., alprazolam, estazolam, flurazepam, clonazepam, lorazepam, and diazepam), norepinephrine-dopamine reuptake inhibitors (i.e., bupropion), CNS stimulants (i.e., phentermine, diethylpropion, methamphetamine, dextroamphetamine, amphetamine, methylphenidate, , dexmethylphenidate, lisdexamfetamine, modafinil, pemoline, phendimetrazine, benzphetamine, phendimetrazine, armodafinil, diethylpropion, caffeine, atomoxetine, doxapram, and mazindol), anxiolytic / sedative / hypnotic agents (barbiturates (i.e., secobarbital, phenobarbital, and mephobarbital), benzodiazepines (as above), and various anxiolytic / sedative / hypnotic agents (i.e., diphenhydramine, sodium oxyvert, zaleplon,Examples of suitable antidepressants include, but are not limited to, hydroxyzine, chloral hydrate, aorpidem, buspirone, doxepin, eszopiclone, ramelteon, meprobamate, and ethchlorvynol), secretin (see, e.g., Ratliff-Schaub et al. Autism 9 (2005) 256-265), opioid peptides (see, e.g., Cowen et al. J. Neurochem. 89 (2004) 273-285), and neuropeptides (see, e.g., Hethwa et al. Am. J. Physiol. 289 (2005) E301-305).

[0408] Lysosomal storage diseases are metabolic disorders that in some cases involve the CNS and have CNS-specific manifestations, including, but not limited to, Tay-Sachs disease, Gaucher disease, Fabry disease, mucopolysaccharidoses (types I, II, III, IV, V, VI, and VII), glycogen storage diseases, GM1-gangliosidosis, metachromatic leukodystrophy, Farber disease, Canavan leukodystrophy, and neuronal ceroid lipofuscinosis types 1 and 2, Niemann-Pick disease, Pompe disease, and Krabbe disease.

[0409] For lysosomal storage diseases, one may choose a neuromodulator that is either the enzyme itself that is impaired in the disease or that in some way mimics the activity of the enzyme. Exemplary recombinant enzymes for the treatment of lysosomal storage diseases include, but are not limited to, those described, for example, in U.S. Patent Application Publication No. 2005 / 0142141 (i.e., alpha-L20 iduronidase, iduronate-2-sulfatase, N-sulfatase, alpha-N-acetylglucosaminidase, N-acetylgalactosamine-6-sulfatase, beta-galactosidase, arylsulfatase B, beta-glucuronidase, acid alpha glucosidase, glucocerebrosidase, alpha-galactosidase A, hexosaminidase A, acid sphingomyelinase, beta-galactocerebrosidase, beta-galactosidase, arylsulfatase A, acid ceramidase, aspartoacylase, palmitoyl-protein thioesterase 1, and tripeptidyl aminopeptidase 1).

[0410] In one embodiment, the antibodies of the invention are used to detect neuropathy before the onset of symptoms and / or to assess the severity or course of a disease or disorder. In one embodiment, the antibodies allow for detection and / or imaging of neuropathy, including imaging by radiography, tomography, or magnetic resonance imaging (MRI).

[0411] In one aspect, a low affinity anti-TfR antibody of the invention is provided for use as a medicament. In a further aspect, a low affinity anti-TfR antibody is provided for use in treating a neurological disease or disorder (e.g., Alzheimer's disease) without depleting red blood cells (i.e., reticulocytes). In a particular embodiment, a modified low affinity anti-TfR antibody is provided for use in a treatment method described herein. In a particular embodiment, the invention provides a modified low affinity anti-TfR antibody for use in a method of treating an individual with a neurological disease or disorder, comprising administering to the individual an effective amount of an anti-TfR antibody (optionally linked to a neuropathic agent). In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. In a further embodiment, the invention provides a modified anti-TfR antibody for use in reducing or inhibiting amyloid plaque formation in a patient at risk for or suffering from a neurological disease or disorder (e.g., Alzheimer's disease). The "individual" in any of the above embodiments may be a human. In certain aspects, the anti-TfR antibodies of the invention for use in the methods of the invention improve uptake of a neuropathic agent conjugated thereto.

[0412] In a further aspect, the invention provides the use of a low affinity anti-TfR antibody of the invention in the manufacture or preparation of a medicament. In one embodiment, the medicament is for the treatment of a neurological disease or disorder. In a further embodiment, the medicament is for use in a method of treating a neurological disease or disorder, comprising administering to an individual having a neurological disease or disorder an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one further therapeutic agent.

[0413] In a further aspect, the invention provides a method for treating Alzheimer's disease. In one embodiment, the method comprises administering to an individual having Alzheimer's disease an effective amount of a multispecific antibody of the invention that binds to both BACE1 and TfR or to both Abeta and TfR. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. The "individual" in any of the above embodiments can be a human.

[0414] The anti-TfR antibodies of the invention can be used alone or in combination with other agents in therapy. For example, the anti-TfR antibodies of the invention can be co-administered with at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent is a therapeutic agent effective against the same or a different neurological disorder that the anti-TfR antibody is used to treat. Exemplary additional therapeutic agents include, but are not limited to, the various neuroprotective agents described above, cholinesterase inhibitors (e.g., donepezil, galantamine, lovastigmine, and tacrine), NMDA receptor antagonists (e.g., memantine), amyloid beta peptide aggregation inhibitors, antioxidants, gamma-secretase modulators, nerve growth factor (NGF) mimetics or NGF gene therapy, PPARγ agonists, HMS-CoA reductase inhibitors (statins), ampakines, calcium channel blockers, GABA receptor antagonists, glycogen synthase kinase inhibitors, intraneuronal immunoglobulins, muscarinic receptor agonists, nicotinic receptor modulators, active or passive amyloid beta peptide immunization, phosphodiesterase inhibitors, serotonin receptor antagonists, and anti-amyloid beta peptide antibodies. In certain embodiments, the at least one additional therapeutic agent is selected for its ability to ameliorate one or more side effects of the nerve agent.

[0415] In certain other such embodiments, at least one additional therapeutic agent is selected for its ability to inhibit or prevent activation of the complement pathway upon administration of the anti-TfR antibody. Examples of such therapeutic agents include, but are not limited to, agents that do not interfere with the ability of the anti-TfR antibody to bind to or activate the complement pathway, and agents that inhibit one or more molecular interactions within the complement pathway. Such agents are generally described in Mollnes and Kirschfink (Molec. Immunol. 43 (2006) 107-121), the contents of which are expressly incorporated herein by reference.

[0416] Such combination treatments as described above and herein include combined administration (where two or more therapeutic agents are included in the same or separate formulations) and separate administration. In this case, administration of the antibody of the invention can occur before, simultaneously with, and / or after administration of the additional therapeutic agent and / or adjunct agent. In one embodiment, administration of the anti-TfR antibody and administration of the additional therapeutic agent occur within about one month or within about one, two, or three weeks, or within about one, two, three, four, five, or six days of each other. The antibody of the invention can also be used in combination with other intervening therapies, such as, but not limited to, radiation therapy, behavioral therapy, or other therapies known in the art and appropriate for the neurological disorder being treated or prevented.

[0417] The anti-TfR antibodies (and any additional therapeutic agents) of the present invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if necessary for localized treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Administration can be by any suitable route, for example, by infusion, such as intravenous or subcutaneous infusion, depending, in part, on whether administration is brief or chronic. Various dosing regimens include, but are not limited to, single or multiple administrations over various time periods, bolus administration. Pulse infusions are contemplated herein.

[0418] The antibodies of the invention will be formulated, formulated, and administered in a manner consistent with good medical practice. Factors to consider in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the administration schedule, and other factors known to medical practitioners.

[0419] The antibody is optionally, but not necessarily, formulated with one or more agents currently used to prevent or treat the disorder of interest, or to prevent, reduce, or ameliorate one or more side effects of antibody administration. The effective amount of such other agents will depend on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These will generally be used in the same dosages and by the routes of administration described herein, and at about 1-99% of the dosages described herein, or at any dosage and by any route determined empirically / clinically appropriate.

[0420] For the prevention or treatment of disease, the appropriate dose of the antibody of the invention (alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease being treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for prophylactic or therapeutic purposes, previous treatments, the patient's medical history, and response to the antibody, as well as the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 10 mg / kg) of the antibody can be the initial candidate dose for administration to the patient, whether, for example, by one or more separate administrations or by continuous infusion. One typical daily dose can range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administration over several days or more, depending on the symptoms, the treatment will generally be sustained until the desired suppression of disease symptoms occurs. One exemplary dose of the antibody would be in the range of about 0.05 mg / kg to about 40 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg, 5.0 mg / kg, 7.5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, or 40 mg / kg (or any combination thereof) can be administered to the patient. Such doses can be administered intermittently, for example, every week or every three weeks (e.g., whereby the patient receives about 2 to about 20 or, for example, about 6 doses of the antibody). An initial larger loading dose, followed by one or more smaller doses, can be administered. However, other dosing regimens can be useful. One way to reduce the effect of administration of anti-TfR antibodies on the reticulocyte population is to alter the amount or timing of administration so that overall there is less circulating antibody in the bloodstream that interacts with reticulocytes. In one non-limiting example, a lower dose of anti-TfR antibody can be administered more frequently than a higher dose would be administered.The dose used can be balanced between the amount of antibody needed to be delivered to the CNS (which itself is related to the affinity of the CNS antigen-specific portion of the antibody), the affinity of that antibody for the TfR, and whether it protects red blood cells (i.e., reticulocytes). Compounds that stimulate proliferation and development or inhibit the complement pathway are administered simultaneously with the antibody or sequentially. The progress of this therapy is easily monitored by conventional techniques and assays as described herein and known in the art.

[0421] It is understood that any of the above formulations or treatment methods can be carried out using an immunoconjugate of the invention in place of, or in addition to, an anti-TfR antibody.

[0422] III.Product In another aspect of the invention, an article of manufacture is provided that contains materials useful for the treatment, prevention, and / or diagnosis of the disorders described above. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The container can be formed from a variety of materials, for example, glass or plastic. The container holds the composition, either by itself or in combination with another composition effective for treating, preventing, and / or diagnosing a condition, and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used to treat a selected condition. Additionally, the article of manufacture includes (a) a first container that contains a composition contained in the article of manufacture, the composition comprising an antibody of the invention, and (b) a second container that contains a composition contained in the article of manufacture, the composition comprising an additional cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further include a package insert indicating that the composition can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further include a second (or third) container containing a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0423] It is understood that any of the above products can contain an immunoconjugate of the invention in place of, or in addition to, an anti-transferrin receptor antibody. EXAMPLES

[0424] IV. Working Examples The following are illustrative of the methods and compositions of the present invention. It is understood that various other embodiments can be practiced and the above provided general description is provided.

[0425] Materials and Methods Recombinant DNA Technology Standard methods were used to manipulate DNA as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions.

[0426] Gene and Oligonucleotide Synthesis The desired gene segments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or by PCR. The individual oligonucleotides were prepared by metabion GmbH (Planegg-Martinsried, Germany).

[0427] reagent Unless otherwise noted, all commercially available chemicals, antibodies, and kits were used as provided and according to the manufacturer's protocols.

[0428] Example 1 Immunization of rabbits and mice Immunization of mice NMRI mice were genetically immunized with plasmid expression vectors encoding the full-length human or cynomolgus TfR by intradermal application of 100 μg vector DNA followed by electroporation (2 square waves of 1000 V / cm for 0.1 ms, spaced 0.125 s apart, followed by 4 square waves of 287.5 V / cm for 10 ms, spaced 0.125 s apart). Mice received either 6 or 7 consecutive immunizations on days 0, 14, 28, 42, 56, 70, and 84. The 4th and 6th immunizations were with a vector encoding the cynomolgus TfR. A vector encoding the human TfR was used for all other immunizations. Blood was collected on days 36, 78, and 92 and serum was prepared. The same serum was used for titer determination by ELISA (see below). The animal with the highest titer was selected for immunization on day 96 with 10 6 The antibodies were selected for boosting by intravenous injection of either 50 μg human TF-1 cells or 50 μg recombinant human soluble TfR lacking the helical domain (the extracellular domain of human TfR beginning at Leu122 and ending at Asn608, expressed in HEK293F cells as an N-terminal fusion to the human Fc region and purified by protein A affinity and size exclusion chromatography). Monoclonal antibodies were isolated by hybridoma technology based on their ability to bind to human and cynomolgus transferrin receptors expressed on the surface of stably transfected CHO-K1 cells (see Example 3).

[0429] Immunization of rabbits New Zealand White rabbits or transgenic rabbits expressing a humanized antibody repertoire were genetically immunized with plasmid expression vectors encoding the full-length human or cynomolgus monkey TfR by intradermal application of 400 μg vector DNA followed by electroporation (5 square waves of 750 V / cm for 10 ms, 1 s interval). Rabbits received six consecutive immunizations on days 0, 14, 28, 56, 84, and 112. The fourth and sixth immunizations were performed with a vector encoding the cynomolgus monkey TfR. A vector encoding the human TfR was used for all other immunizations. Blood (10% of the estimated total blood volume) was collected on days 35, 63, 91, and 119, and serum was prepared. The serum was used for titration by ELISA (see below). Peripheral mononuclear cells were isolated and used as a source of antigen-specific B cells in a B cell cloning method (see Example 2).

[0430] Measurement of serum titers (ELISA) Human recombinant soluble TfR (R&D Systems Cat. No. 2474-TR) was immobilized to 96-well NUNC Maxisorb plates at 3 μg / mL in PBS, 100 μL / well, followed by blocking of the plates with 200 μL / well of 2% Crotein C in PBS and adding serial dilutions of antisera in duplicate with 100 μL / well of 0.5% Crotein C in PBS: (1) HRP-conjugated goat anti-mouse antibody (Jackson Immunoresearch / Dianova 115-036-071; 1 / 16000) for all mouse sera, (2) HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch / Dianova 115-036-071; 1 / 16000) for all rabbit sera, and (3) HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch / Dianova 115-036-071; 1 / 16000) for all rabbit sera. 711-036-152; 1 / 16000), (3) for transgenic rabbit serum only, rabbit anti-human IgG antibody (Pierce / Thermo Scientific 31423; 1 / 5000), (4) for transgenic rabbit serum only, biotinylated goat anti-human kappa antibody (Southern Biotech / Biozol 2063-08, 1 / 5000) and streptavidin-HRP were detected with 0.5% CroteinC in PBS, 100 μL / well. For all steps, plates were incubated at 37° C. for 1 h. Between all steps, plates were washed 3 times with 0.05% Tween 20 in PBS. Signal was developed by adding BM Blue POD Substrate soluble (Roche) at 100 μL / well and stopped by adding 1 M HCl at 100 μL / well. Absorbance was read at 450 nm against 690 nm as reference. Titers were defined as the dilution of antiserum that gave half-maximal signal.

[0431] Example 2 B cell cloning from rabbits Isolation of rabbit peripheral blood mononuclear cells (PBMCs) Briefly, blood samples were collected from six animals (two wild type (wt) and four transgenic (tg) rabbits). The rabbits were obtained from two immunization campaigns: a first campaign with two wt and two tg rabbits and a second campaign with two tg rabbits (see also Example "Immunization of rabbits"). EDTA-containing whole blood was used for lympholyte mammals (Cedarlane Laboratories, Burlington, Ontario, Canada) and was diluted two-fold with 1x PBS (PAA, Pasching, Austria) before density centrifugation according to the manufacturer's specifications. PBMCs were washed twice with 1x PBS.

[0432] EL-4 B5 medium RPMI 1640 (Pan Biotech, Aidenbach, Germany) was supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2 mM glutamine, 1% penicillin / streptomycin solution (PAA, Pasching, Austria), 2 mM sodium pyruvate, 10 mM HEPES (PAN Biotech, Aidenbach, Germany), and 0.05 mM β-mercaptoethanol (Gibco, Paisley, Scotland).

[0433] Cell depletion First immunization campaign: Sterile 6-well plates (cell culture grade) covered with a confluent monolayer of CHO cells were used to deplete non-specifically adherent macrophages / monocytes and non-specifically binding lymphocytes.

[0434] Second immunization campaign: The depletion step using wells coated with CHO cells was omitted because it could not be excluded that antibody-producing B cells cross-reactive to hamster transferrin receptor antibodies would be depleted. Therefore, blank sterile 6-well plates (cell culture grade) were used to deplete macrophages and monocytes by non-specific adhesion, so that B lymphocytes that may produce hamster cross-reactive (and possibly mouse cross-reactive) surface antibodies could reach the next step in the workflow.

[0435] For each immunization campaign, each well was filled with up to 4 mL medium and 6 × 10 6 The cells were then plated with up to 100 PBMCs and allowed to bind for 1 hour in an incubator at 37° C. The cells in the supernatant (peripheral blood lymphocytes (PBLs)) were used for the antigen panning step.

[0436] B cell enrichment with human transferrin receptor 6 × 10 cells per 4 mL medium were added to a 6-well tissue culture plate covered with a monolayer of human transferrin receptor-positive CHO cells. 6 Up to 100 PBLs were seeded and allowed to attach for 1 h at 37°C in an incubator. Non-adherent cells were removed by carefully washing the wells 1-2 times with 1x PBS. Remaining attached cells were detached with trypsin for 10 min at 37°C in an incubator. Trypsinization was stopped with EL-4 B5 medium. Cells were kept on ice until immunofluorescence staining.

[0437] Immunofluorescence staining and flow cytometry Anti-IgG FITC (AbD Serotec, Dusseldorf, Germany) was used for single cell sorting. For surface staining, cells from the depletion and enrichment steps were incubated with anti-IgG FITC antibody in PBS and incubated for 45 min at 4°C in the dark. After staining, PBMCs were washed twice with ice-cold PBS. Finally, PBMCs were resuspended in ice-cold PBS and immediately subjected to FACS analysis. Propidium iodide (BD Pharmingen, San Diego, CA, USA) was added at a concentration of 5 μg / mL before FACS analysis to discriminate between dead and live cells.

[0438] A Becton Dickinson FACSAria equipped computer and FACSDiva software (BD Biosciences, USA) was used for single cell sorting.

[0439] B cell culture Rabbit B cell cultures were prepared in a manner similar to that described by Zubler et al. (1985). Briefly, single-sorted rabbit B cells were cultured in 200 μL / well Pansorbin Cells (1:100000) (Calbiochem (Merck), Darmstadt, Germany), 5% rabbit thymocyte supernatant (charged TSN-M13 (10242), MicroCoat, Bernried, Germany), and gamma-irradiated mouse EL-4-B5 thymocytes (2.5 × 10 4 The cells were cultured in 96-well plates containing EL-4 B5 medium containing 100 ng / well of IgG1 and IgG2-positive cells for 7 days at 37° C. in an incubator with 5% CO2. B cell culture supernatants were removed for screening, and the remaining cells were immediately harvested and frozen at −80° C. in 100 μL of RLT buffer (Qiagen, Hilden, Germany).

[0440] Example 3 Identification of human and cynomolgus monkey TfR-binding antibodies by cell-based ELISA To screen rabbit B cell or mouse hybridoma supernatants for antibodies recognizing human and cynomolgus monkey TfR, a cell ELISA using stably transfected CHO-K1 cells was utilized. Stable transformants were obtained by transfecting CHO-K1 cells with expression plasmids containing expression cassettes for human or cynomolgus monkey TfR and neomycin-phosphotransferase. After transfection, cells were diluted in growth medium containing 500 μg / mL G418 (Life Technologies). After clones were expanded, cells were detached and stained with MEM-75 (Abcam) or 13E4 (Life Technologies) and PE-labeled secondary antibodies for human or cynomolgus monkey TfR. Highly fluorescent cells were sorted as single cells within wells of 96-well plates (FACS Aria). After 7 days of expansion, clones were again checked for TfR expression. The best expressing clones were selected for cell ELISA experiments.

[0441] Briefly, 15,000 cells were seeded per well of a 384-well plate and incubated for 18 h at 37° C., 5% CO2. The supernatant was removed using an automated washer (BIOTEK). 30 μL of antibody-containing supernatant was added to each well, followed by 24 μL of growth medium. After 2 h of incubation, the wells were emptied and 30 μL of 0.05% glutaraldehyde in PBS was added for 45 min at RT. After three washes with PBS / 0.025% Tween 20 (PBST), 30 μL of anti-rabbit-HRP or anti-mouse-HRP (Southern Biotech), diluted 1:5000 in blocking buffer, was added. The plates were incubated for 1 h at RT. Wells were washed six times with PBST, signals were developed using 30 μL of TMB per well and absorbance was measured at 450 nm.

[0442] Example 4 Cloning and expression of anti-TfR antibodies Recombinant DNA Technology DNA was manipulated using standard methods as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions.

[0443] Gene and Oligonucleotide Synthesis The desired gene segments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or by PCR. The individual oligonucleotides were prepared by metabion GmbH (Planegg-Martinsried, Germany).

[0444] PCR amplification of V domains Total RNA was prepared from B cell lysates (resuspended in RLT buffer - Qiagen - Cat. No 79216) using NucleoSpin 8 / 96 RNA kit (Macherey&Nagel; 740709.4, 740698) according to the manufacturer's protocol. RNA was eluted with 60 μL RNAse-free water. 6 μL RNA was used to generate cDNA by reverse transcriptase reaction using Superscript III First-Strand Synthesis SuperMix (Invitrogen 18080-400) and oligo-dT-primer according to the manufacturer's instructions. All steps were performed in a Hamilton ML Star system. Using 4 μL of cDNA, immunoglobulin heavy and light chain variable regions (VH and VL) were amplified with AccuPrime SuperMix (Invitrogen 12344-040) using primers rbHC.up and rbHC.do for the heavy chain, rbLC.up and rbLC.do for the light chain from wild-type rabbit B cells, and BcPCR_FHLC_leader.fw and BcPCR_huCkappa.rev for the light chain from transgenic rabbit B cells in a final volume of 50 μL (see table below). All forward primers were specific for the signal peptide (VH and VL, respectively), while the reverse primers were specific for the constant region (VH and VL, respectively). The PCR conditions for RbVH+RbVL were as follows: Hot start at 94° C. for 5 min; 35 cycles of 94° C. for 20 sec, 70° C. for 20 sec, 68° C. for 45 sec, and a final extension at 68° C. for 7 min. PCR conditions for HuVL were as follows: Hot start at 94° C. for 5 min; 40 cycles of 94° C. for 20 sec, 52° C. for 20 sec, 68° C. for 45 sec, and a final extension at 68° C. for 7 min. [Table 7]

[0445] Of the 50 μL PCR solution, 8 μL was loaded onto a 48 E-gel 2% (Invitrogen G8008-02). Positive PCR reactions were washed and eluted in 50 μL elution buffer using the NucleoSpin Extract II kit (Macherey&Nagel; 740609250) according to the manufacturer's protocol. All washing steps were performed on a Hamilton ML Starlet system.

[0446] Recombinant expression of rabbit monoclonal bivalent antibodies For recombinant expression of rabbit monoclonal bivalent antibodies, PCR products encoding VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (RS Haun et al., BioTechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256). The expression vectors contained an expression cassette consisting of a 5'CMV promoter with intron A and a 3'BGH polyadenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication for plasmid amplification in E. coli and a beta-lactamase gene conferring ampicillin resistance. Three variants of the basic plasmid were used. One plasmid contains a rabbit IgG constant region designed to accept the VH region, while two additional plasmids contain rabbit or human kappa LC constant regions to accept the VL region.

[0447] Linearized expression plasmids encoding the kappa or gamma constant regions and the VL / VH inserts were amplified by PCR using overlapping primers.

[0448] The purified PCR products were incubated with T4 DNA polymerase to generate single-stranded overhangs, and the reaction was stopped by the addition of dCTP.

[0449] In the next step, the plasmid and insert were combined and incubated with recA to induce site-specific recombination. The recombinant plasmid was transformed into E. coli. The following day, grown colonies were selected and tested for correctly recombined plasmids by plasmid preparation, excision analysis, and DNA sequencing.

[0450] For antibody expression, the isolated HC and LC plasmids were transiently transfected into HEK293 cells and supernatants were harvested after one week.

[0451] Generation of vectors for expression of rabbit monoclonal monovalent antibodies For recombinant expression of the selected candidates as monoclonal monovalent antibodies, the rabbit constant regions of all VH chains were converted to human constant regions encapsulating knob mutations in the CH3 segment. For the VL chains derived from rabbit wild-type B cells, the rabbit C kappa constant region was converted to human. Using 4 μL of cDNA of the selected candidates, the variable regions of immunoglobulin heavy and light chains were amplified in a final volume of 50 μL with AccuPrime SuperMix (Invitrogen 12344-040) using a forward primer specific for the signal peptide and a reverse primer specific for the CDR3-J region with an overlapping sequence (20 bp) homologous to the human constant region (at the 3' end) (VH and VL, respectively). The PCR conditions for the amplification of VH and VL chains were as follows: High temperature start at 94°C for 5 min; 35 cycles of 20 s at 94°C, 20 s at 68°C, 45 s at 68°C, and a final extension at 68°C for 7 min.

[0452] PCR products encoding VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (RS Haun et al., BioTechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256). The expression vectors contained an expression cassette consisting of a 5'CMV promoter with intron A and a 3'BGH polyadenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication for plasmid amplification in E. coli and a beta-lactamase gene conferring ampicillin resistance. Two variants of the basic plasmid were used. One plasmid contains a human IgG constant region designed to accept the newly amplified VH chain. The second plasmid contains a human kappa LC constant region to accept the VL chain.

[0453] Linearized expression plasmids encoding the kappa or gamma constant regions and the VL / VH inserts were amplified by PCR using overlapping primers.

[0454] The purified PCR products were incubated with T4 DNA polymerase to generate single-stranded overhangs, and the reaction was stopped by the addition of dCTP.

[0455] In the next step, the plasmid and insert were combined and incubated with recA to induce site-specific recombination. The recombinant plasmid was transformed into E. coli. The following day, grown colonies were selected and tested for correctly recombined plasmids by plasmid preparation, excision analysis, and DNA sequencing.

[0456] Example 5 Transient expression of monovalent anti-TfR antibodies Antibodies were produced in vivo in transiently transfected HEK293 cells (derived from human embryonic kidney cell line 293) cultured in F17 medium (Invitrogen Corp.). For transfection, "293-Free" transfection reagent (Novagen) was used. The antibodies and antibody-based modified molecules described above were expressed from individual expression plasmids. Transfection was performed as specified in the manufacturer's instructions. Culture supernatants of cells containing recombinant proteins were harvested 3-7 days after transfection. Supernatants were stored at low temperature (e.g., -80°C) until purification.

[0457] For example, general information regarding recombinant expression of human immunoglobulins in HEK293 cells is provided in Meissner, P. et al., Biotechnol. Bioeng. 75 (2001) 197-203.

[0458] Example 6 High-throughput purification of single-arm transferrin receptor antibodies 50 mL of the washed supernatant containing the single-armed antibody in a 96-deep well plate was loaded onto a 200 μL MabSelectSuRe column. After a washing step with PBS at pH 7.4, the protein was eluted with 2.5 mM HCl using a Tecan / Atoll system to obtain 0.5 mL of eluate. The eluate was neutralized with 2M Tris pH 8. The purified protein was quantified using a Nanodrop spectrometer and analyzed by CE-SDS and analytical SEC under denaturing and reducing conditions. To obtain a protein of high purity (>95%), most antibodies must be further purified in size exclusion chromatography to separate them from half antibodies, knob-knob antibodies, and higher aggregates. Then, 500 μL of the sample was injected into a Superdex200 10 / 300GL using a Dionex UltiMate 3000 in 20 mM histidine containing 140 mM NaCl pH 6.0. This method allows for the refinement of a large number of screening hits in a single-arm format, as 25-30 samples can be fractionated per day. Fractions were pooled and reanalyzed as described above.

[0459] Example 7 hCMEC / D3 cell culture for transcytosis assay Culture medium and supplements for hCMEC / D3 (Weksler, BB et al., FASEB J. 19 (2005), 1872-1874) were obtained from Lonza. hCMEC / D3 cells (passages 26-29) were cultured to confluence on collagen-coated coverslips (microscope) or flasks in EBM2 medium containing 2.5% FBS, 1 / 4 of the added growth factors, and fully complemented with added hydrocortisone, gentamicin, and ascorbic acid.

[0460] For all transcytosis assays, high density pores (1 × 10 8 Holes / cm 2) PET membrane filter inserts (0.4 μm, 12 mm diameter) were used in 12-well cell culture plates. The optimal medium volumes were calculated to be 400 μL and 1600 μL for the apical and basolateral chambers, respectively. The apical chamber of the filter insert was filled with rat tail collagen I (7.5 μg / cm 2 ), followed by fibronectin (5 μg / cm 2 Each incubation lasted for 1 h at RT. hCMEC / D3 cells were grown in EMB2 medium to form a confluent monolayer (approximately 2 × 10 5 pieces / cm 2 ) and grown for 10 to 12 days.

[0461] Example 8 Monovalent antibody transcytosis assay The entire assay was performed in serum-free EBM2 medium reconstituted in an alternative manner as described in Example 1. Filter inserts containing cells were incubated with monovalent antibody (concentration: 2.67 μg / mL) on the apical side for 1 h at 37°C. Subsequently, the entire apical and basolateral media was collected. From these values, the paracellular flux was calculated. The monolayers were washed 3 times at RT for 3-5 min each on the apical side (400 μL) and basolateral side (1600 μL) in serum-free medium. All washes were collected to monitor the efficiency of removal of unbound antibody. Pre-warmed medium was added to the apical chamber and the filters were transferred to a new 12-well plate containing 1600 μL of pre-warmed medium (blocked overnight with PBS containing 1% BSA). At this point, the cells on the filters were lysed in 500 μL of RIPA buffer to determine specific antibody uptake. The remaining filters were incubated at 37° C. and samples were collected at various time points to determine apical and / or basolateral release of antibodies. Antibody content in the samples was quantified using a highly sensitive IgG ELISA (see Example 3). At each time point, data were generated from three filter-cell cultures.

[0462] Example 9 Highly sensitive IgG ELISA following transcytosis assay The entire procedure was performed at RT using an automated washer for the washing steps. 384-well plates were coated with 1 μg / mL Fcγ-specific anti-human / mouse IgG in PBS at 30 μL / well for 2 h, followed by incubation for 1 h in PBS blocking buffer containing 1% BSA or 1% Crotein C for human and mouse IgG assays, respectively. Serially diluted samples from the transcytosis assay and standard concentrations of antibodies used in the transcytosis assay were added to the plate and incubated for 2 h. After 4 washes, 50 ng / mL anti-human / mouse-F(ab)2-biotin in blocking buffer was added at 30 μL / well and incubated for another 2 h. After six washes, 50ng / mL (huIgG assay) or 100ng / mL (mIgG assay) poly-HRP40-streptavidin (Fitzgerald; in PBS containing 1% BSA and 0.05% Tween-20) was added at 30μL / well and incubated for 30 minutes. After four washes, immune complexes were detected by adding BM chemiluminescent substrate (Roche) at 30μL / well. Luminescent signals were measured using a luminescence plate reader and concentrations were calculated using a fitted standard curve. The sensitivity of the assay ranged from 10pg / mL to 10ng / mL.

[0463] Example 10 Epitope mapping by cell ELISA in CHO cells transfected with hTfR mutants To be able to determine epitope regions on the human transferrin receptor (hTfR), following the rationale that despite the considerable homology between human and mouse TfR (77% identity), no antibodies against the extracellular portion are known that show good cross-reactivity between both orthologues, mutations were introduced into the hTfR sequence at positions where clusters of surface exposed amino acids have different amino acids in the aligned mouse TfR sequence (see table below). The cloning of the plasmids carrying the corresponding mutations has been described above. To map the binding of human TfR binders to their epitopes, CHO-K1 cells were transiently transfected with the described plasmids. Antibody binding was measured by cell ELISA. Briefly, 10 mAbs were transfected per well of a 96-well plate the day before the experiment in normal growth medium (RPMI / 10% FCS). 4 Cells were seeded. On another day, the medium was changed to OPTI-MEM serum reduced medium (Gibco) and 10 μL of a mixture of 1200 μL OPTI-MEM, 12 μg plasmid DNA, and 12 μL XtremeGENE transfection reagent (Roche) was added to the wells after 30 min of preincubation. The cells were incubated at 37°C / 7.5% CO2 for 2 days. The medium was then removed and TfR antibodies were added in growth medium at concentrations between 1 nM and 100 nM, followed by incubation at 4°C for 2 h. The antibody solution was then replaced by 0.05% glutaraldehyde in PBS. The cells were fixed for 15 min at RT, then washed twice with PBS and incubated with HRP-conjugated anti-human Fc secondary antibody (BioRad; 1:2000 in ELISA blocking reagent (Roche)) for 1.5 h at RT. Signals were developed using 50 μL of TMB per well after washing three times with PBS and absorbance was measured at 450 nm. [Table 8]

[0464] Example 11 Surface plasmon resonance-based binding assay for human TfR-antibody interactions Binding experiments were performed on a BIAcore B 4000 (GE Healthcare) equipped with a C1 sensor chip (GE Healthcare, cat. no. BR1005-35) pretreated with an anti-human Fab antibody (GE Healthcare, cat. no 28-9583-25) using standard amino coupling chemistry according to the supplier's manual.

[0465] For kinetic measurements, sample antibodies were immobilized in phosphate buffered saline pH 7.4, 0.05% Tween 20 at 25° C. applying a contact time of 60 s and a flow rate of 10 μL / min. Recombinant His6-tagged human transferrin receptor (R&D systems, cat.no 2474-TR-050) was added in increasing concentrations and the signal was monitored over time. An average period of association time of 150 s and dissociation time of 600 s at a flow rate of 30 μL / min was recorded. Data were fitted using a 1:1 binding model (Langmuir isotherm).

[0466] Example 12 Humanization of the VH and VL domains of mouse and rabbit anti-transferrin receptor antibodies A non-human anti-transferrin receptor antibody was humanized as follows: Based on characterization of the coding and amino acid sequences including the VH and VL domains of a non-human anti-transferrin receptor antibody of the IgG1 class with a kappa light chain, a corresponding humanized anti-transferrin receptor antibody was generated by CDR grafting backward / forward mutations based on the combination of human germline frameworks VH4_3 and VK1_10 for clone 299.

[0467] Example 13 Methods for determining human / cynomolgus TfR receptor affinity In this example, a method for determining human transferrin receptor affinity for comparison of dissociation behavior is outlined.

[0468] For all analyses, the Biotin CAPture kit from GE Healthcare (Instruction 28-9242-34 AB) was used. First, the chip was rehydrated by connecting it to a BIAcore T200 instrument. Then, the chip was left overnight in running buffer. For surface preparation, Biotin CAPture reagent was diluted 1:100 in running buffer (1x PBS with 0.25M NaCl). This solution was injected into flow cells 1-4 at a flow rate of 2 μL / min for 360 seconds. Next, the sensor surface was primed with three 1-min injections of regeneration solution provided in the Biotin CAPture kit. This should be done during the connection procedure or during the first time or after storage. A solution of 100 nM human or cynomolgus monkey monobiotinylated transferrin receptor, respectively, should be injected into flow cell 2 at a flow rate of 10 μL / min for 30 seconds. For affinity determination, injections at six concentrations (500, 250, 125, 62.5, 31.25, 15.625, and 0 nM) were applied. These were injected into the "hu-TfR flow cell (e.g. flow cell 2 prepared as outlined above)" with a flow rate of 10 μL / min and an injection time of 180 s (association). After a dissociation period of 600 s, the surface was regenerated with the regeneration solution provided in the BiotinCAPture kit according to the manufacturer's instructions. The following cycles were performed:

[0469] The kinetic data were evaluated using the BIAcore T200 evaluation software. In particular, the dissociation rate constants of the various human transferrin receptor binders were taken into account after application of a 1:1 Langmuir binding model.

[0470] Example 14 B4000 relative ranking of human / cynomolgus transferrin receptor dissociation CAP sensor chips (provided in Biotin CAPture kit, series S #28-9202-34 GE) were loaded into a BIAcore B4000 system, normalized, and addressed in a hydrodynamic manner according to the manufacturer's instructions. In the first cycle, CAP reagents (provided in the kit) were addressed to spots 1, 2, 4, and 5 at a flow rate of 10 μL / min for 300 seconds. Capture of human transferrin receptor was performed at spot 1 (human transferrin receptor-biotinylated) and spot 5 (cynomolgus transferrin receptor-biotinylated) at a flow rate of 10 μL / min and a contact time of 30 seconds. Receptors were diluted to a concentration of 50 nM in running buffer (1×PBS #28995084, GE Healthcare, supplemented with 0.25 M NaCl). Antibodies were injected in all flow cells at a concentration series of 100 nM, 50 nM, 25 nM, and 0 nM for 180 s at a flow rate of 30 μL / min. The dissociation time was set to 300 s. Regeneration of the entire complex from the CAP chip was performed using the regeneration solution provided in the Biotin CAPture kit (120 s at a flow rate of 10 μL / min). To adjust the active protein concentration, a second cycle was performed in spot 5 using biotinylated protein A (#P2165-2MG, Sigma) at a flow rate of 10 μL / min and a contact time of 30 s. Spot 1 was left empty in this control cycle. Antibodies and regeneration were treated the same as in cycle 1. The relevant kinetic data were calculated using the BIAcore B4000 evaluation software. Dissociation from the human transferrin receptor was determined by applying a 1:1 dissociation fit.

Claims

1. A humanized antibody that specifically binds to a human transferrin receptor, In the heavy chain variable domain, the HVRs of SEQ ID NOs: 66, 68, and 72; In the light chain variable domain, the HVRs of SEQ ID NOs: 75, 76, and 78; Humanized antibodies.

2. The humanized antibody of claim 1, comprising a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:

37.

3. The humanized antibody of claim 1 or 2, wherein the humanized antibody is effector function silent.

4. The humanized antibody according to any one of claims 1 to 3, which specifically binds to a human transferrin receptor and a cynomolgus monkey transferrin receptor.

5. The humanized antibody of any one of claims 1 to 4, wherein the humanized antibody is a multispecific antibody having at least one binding specificity for the human transferrin receptor and at least one binding specificity for a therapeutic target.

6. 6. The humanized antibody of claim 5, wherein the humanized antibody comprises a first antigen-binding site that binds to a human transferrin receptor and a second antigen-binding site that binds to a brain antigen.

7. 7. The humanized antibody of claim 6, wherein the brain antigen is selected from the group consisting of Abeta, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), alpha-synuclein, CD20, amyloid precursor protein (APP), and glucocerebrosidase.

8. The multispecific antibody i) both the human transferrin receptor and Abeta, or ii) both the human transferrin receptor and CD20, or iii) both the human transferrin receptor and alpha-synuclein, or iv) both human transferrin receptor and phosphorylated tau, or v) Both the human transferrin receptor and glucocerebrosidase The humanized antibody of any one of claims 5 to 7, which binds to

9. The humanized antibody is i) a first binding site comprising a heavy chain variable domain of SEQ ID NO:24 and a light chain variable domain of SEQ ID NO:37; ii) a second binding site, a) a heavy chain variable domain of SEQ ID NO: 81 and a light chain variable domain of SEQ ID NO: 82, or b) a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 84, or c) a heavy chain variable domain of SEQ ID NO: 85 and a light chain variable domain of SEQ ID NO: 86, or d) a heavy chain variable domain of SEQ ID NO: 87 and a light chain variable domain of SEQ ID NO: 88, or e) a heavy chain variable domain of SEQ ID NO: 91 and a light chain variable domain of SEQ ID NO: 92, or f) a heavy chain variable domain of SEQ ID NO:89 and a light chain variable domain of SEQ ID NO:90; or g) a heavy chain variable domain of SEQ ID NO:93 and a light chain variable domain of SEQ ID NO:94, or h) a heavy chain variable domain of SEQ ID NO:79 and a light chain variable domain of SEQ ID NO:80 and a second binding site selected from the group consisting of:

10. The humanized antibody is a) a full-length antibody of human subclass IgG1, or b) a full-length antibody of human subclass IgG4, or c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) A full-length antibody of human subclass IgG4 having the mutations S228P, L235E, and optionally P329G; e) a full-length antibody of human subclass IgG1 having the mutations L234A, L235A, and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain; or f) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and optionally P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain. The humanized antibody according to any one of claims 1 to 9,

11. The humanized antibody is i) optionally a homodimeric Fc region of the human IgG1 subclass having the mutations P329G, L234A, and L235A; or ii) optionally a homodimeric Fc region of the human IgG4 subclass having the mutations P329G, S228P, and L235E; or iii) a heterodimeric Fc region, a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, in which one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C; or iv) a heterodimeric Fc region of the human IgG4 subclass, wherein both Fc region polypeptides comprise the mutations P329G, L234A, and L235A; and a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, in which one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C; or v) a heterodimeric Fc region of the human IgG4 subclass, wherein both Fc region polypeptides contain the mutations P329G, S228P, and L235E; and a) one Fc-region polypeptide comprises the mutation T366W and the other Fc-region polypeptide comprises the mutations T366S, L368A, and Y407V, or b) one Fc region polypeptide comprises the mutations T366W and Y349C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or c) a heterodimeric Fc region, wherein one Fc region polypeptide comprises the mutations T366W and S354C and the other Fc region polypeptide comprises the mutations T366S, L368A, Y407V, and Y349C. The humanized antibody of any one of claims 1 to 9, comprising:

12. i) a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 52, 53, 54, 55, 56, 57, and 58, and a light chain variable domain selected from the group consisting of SEQ ID NOs: 60, 61, 62, and 63, or ii) a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25, and a light chain variable domain selected from the group consisting of SEQ ID NOs: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47. Including, Humanized anti-transferrin receptor antibody.

13. A humanized antibody according to any one of claims 1 to 12, comprising a pharma- ceutically acceptable carrier. Pharmaceutical preparations.

14. The humanized antibody according to any one of claims 1 to 12 for use as a medicament.

15. Use of a humanized antibody according to any one of claims 1 to 12 in the manufacture of a medicament for treating a neurological disorder.

16. 16. The use according to claim 15, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative diseases, cancer, eye diseases, seizure disorders, lysosomal storage diseases, amyloidosis, viral or microbial diseases, ischemia, behavioral disorders, and CNS inflammation.

17. Use of an antibody according to any one of claims 1 to 12 in the manufacture of a medicament for the transport of one or more compounds across the BBB.

18. The humanized antibody according to any one of claims 1 to 12 for use in the treatment of a neurological disorder.

19. 19. The humanized antibody of claim 18, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy, neurodegenerative diseases, cancer, eye diseases, seizure disorders, lysosomal storage diseases, amyloidosis, viral or microbial diseases, ischemia, behavioral disorders, and CNS inflammation.

20. Use of a humanized antibody according to any one of claims 1 to 12 in the manufacture of a medicament.

21. 21. The use according to claim 20, wherein the medicament is for the treatment of a neurological disorder selected from the group consisting of peripheral neuropathy, neurodegenerative diseases, cancer, eye diseases, seizure disorders, lysosomal storage diseases, amyloidosis, viral or microbial diseases, ischemia, behavioral disorders, and CNS inflammation.

22. Administering the humanized antibody of any one of claims 1 to 12 to treat a neurological disorder. Treatment method.

23. 23. The method of claim 22, wherein the neuropathy is selected from the group consisting of peripheral neuropathy, neurodegenerative diseases, cancer, eye diseases, seizure disorders, lysosomal storage diseases, amyloidosis, viral or microbial diseases, ischemia, behavioral disorders, and CNS inflammation.

Citation Information

Patent Citations

  • Low-affinity blood-brain barrier receptor antibodies and their use

    JP2014500886A

  • Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates

    WO1993010819A1

  • Methods for improving safety of blood-brain barrier transport

    WO2013177062A2

  • Anti-transferrin receptor antibodies and methods of use

    WO2014189973A2